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Abstract
Quantum mechanical (QM) methods are becoming popular in computational drug design
and development mainly because high accuracy is required to estimate (relative) binding
affinities. For low- to medium-throughput in silico screening, (e.g., scoring and prioritizing a
series of inhibitors sharing the same molecular scaffold) efficient approximations have been
developed in the past decade, like linear scaling QM in which the computation time scales
almost linearly with the number of basis functions. The first chapter of this thesis is a review
of QM methods for drug design.
In the second chapter, LIECE, which is short for linear interaction energy model with con-
tinuum electrostatic solvation, is further improved by using a linear scaling semiempirical
QM method. The new method is termed QMLIECE. Then QMLIECE is tested on three enzy-
me/inhibitor systems: the West Nile virus NS3 protease (a serine protease), the HIV-1 protease
(an aspartic protease), and the human cyclindependent kinase 2. After that the necessity of
QM method for predicting binding free energy is discussed.
In the third chapter, the QM probe method is suggested as a filter in high throughput virtual
screening. To speed up the calculation, the QM probe method approximates the ATP-binding
site of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor
B4 (EphB4) by 6 types of small molecules (probes) with particular orientations, and uses a
semi-empirical QM Hamiltonian to calculate interaction energies between a compound and
probes. These interaction energies are further used for filtering multimillion poses generated
by high throughput docking. A single-digit micromolar inhibitor of EphB4 with a relatively
good selectivity profile is identified upon experimental tests of only 23 molecules.
To elucidate the technology of high throughput docking used in the third chapter, in the forth
chapter, a distributed virtual screening data management system (DVSDMS) is introduced, in
which the data handling and the distribution of jobs are realized by the open-source structured
query language database software MySQL. In DVSDMS, the data management is separated
from docking and ranking process. In both benchmark and production, DVSDMS performed
efficiently with a limited effort of programming and a trivial investment of software and
hardware.
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In the last chapter, the original ultrafast shape recognition (USR) method is complemented
with an optical isomerism descriptor (USR:OptIso). Then the USR:OptIso is tested on discri-
minating mirror images of three kinase inhibitors and 15 types of isomers, some of which can
not be distinguished by the original USR, which uses only the atomic distances. Finally, both
similarity scores calculated by the original USR and USR:OptIso are extensively compared
with ROCS shape Tanimoto, which is based on Gaussian molecular volume overlap.
Zusammenfassung
Quantenmechanische (QM) Methoden erfreuen sich im computergestützen Wirkstoffdesign
und der Entwicklung wachsender Beliebtheit, da eine hohe Genauigkeit für die Berechnung
von Bindungsaffinitäten notwendig ist. Für das Screening einer kleinen und mittleren Anzahl
an Molekülen wurden im letzten Jahrzehnt effiziente Näherungen entwickelt.
In dieser Arbeit wird LIECE, was kurz ist für lineares Interaktions-Energiemodell mit kon-
tinuierlicher elektrostatischer Solvatation, weiterentwickelt durch Verwendung einer linear
skalierenden, semiempirischen QM Methode. Das neue Verfahren wird QMLIECE genannt.
QMLIECE wird an drei Enzym/Inhibitor-Komplexen getestet. Anschliessend wird die Not-
wendigkeit der QM Methode für die Vorhersage der freien Bindungsenergien diskutiert.
Im nächsten Abschnitt der Arbeit wird die QM Probemethode als Filter für virtuelles
Hochdurchsatz-Screening vorgeschlagen, für das ein neues virtuelles Screening-Datenverarbeitungs-
system angewendet wird. Ein einstellig mikromolarer Inhibitor von EphB4 mit relativ gutem
Selektivitätsprofil wird identifiziert durch experimentelle Untersuchung von nur 23 Molekü-
len.
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Chapter 1
Quantum Mechanical Methods for Drug
Design
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Introduction
Accurate models for computing the binding free energy between small molecules and proteins are
needed for drug discovery and design.[1] The increasing popularity of quantum mechanical methods
in computer-aided drug design (CADD) is not just a consequence of ever growing computing power
but is also due to the first principle nature of QM, which should provide the highest accuracy.[2, 3]
Because of their first principle nature, both the time-consuming ab initio methods[4] and fast
semi-empirical approaches[5, 6] do not suffer from the limitation inherent to the ball and spring
description and the fixed-charge approximation used in the force fields (FFs). In a recent review,
it has been suggested that the application of QM methods in all phases of CADD is likely to
become reality.[3] At the same time, interest for QM in CADD has spurred further methodological
development of QM methods and in particular QM approaches for docking, scoring, improvement of
known lead compounds, and unraveling the reaction mechanism. As an example, QM calculations
were performed to investigate significant differences in binding affinities upon modification of a
−CH2− linker into a carbonyl.[7]
In the following sections, we will classify the QM methods into two broad classes according to
their functionalities: the first class includes the methods used for quantifying energies and optimizing
structures, while the second contains the techniques employed for calculating molecular properties.
The methods in the first class are the conventional and straightforward applications of QM. They
can be directly exploited for interpreting the reactivities of biologically active molecules, which are
always accompanied by the transfer of energy and transformation of molecular structures. However,
the currently available computating power is not enough for the direct ab initio QM calculations of
macromolecules with accuracy similar to that of in vitro experiments. Therefore this section will
unavoidably give the prominence to the acceleration of QM methods for macromolecules, including
linear scaling algorithms and hybrid quantum-mechanics/molecular-mechanics (QM/MM). Apart
from the methods for calculating the energies and optimizing structures of biomolecules, we also
illustrate two typical applications of QM relevant to structure-based drug design: the analysis of the
protonation states of titratable side chains[8, 9] and the evaluation, with high structural and energetic
2
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accuracy, of cation-π and π-π interactions that are beyond the limits of classical FF methods. The
methods in the second class are mainly used for calculating specific properties of molecules, such
as partial charges, bond strength, and torsion angles which can be applied in the parameterization of
FFs, and other descriptors that can be used in building quantitative structure-activity relationship
(QSAR) models or quantitative structure-property relationship (QSPR) models. We also discuss
recent advances in two emerging topics: molecular quantum similarity and variational particle
number approach for molecular design.
Using QM to calculate energies and optimize structures
QM is preferable to classical FF based methods for accurate energies and electronic structure
calculations,[2, 3] and even for examining the potential energy hypersurface of small molecules.[10]
Recently, Butler and coworkers used QM-based methods to describe both the internal energy of
the ligand and the solvation effect.[11] Their analysis indicates that two thirds of the bioactive
conformations of small-molecule inhibitors lie within 0.5 kcal·mol−1 of a local minimum, and
conformations with penalties above 2.0 kcal·mol−1 are generally attributable to inaccuracies in
structure determination. However QM can only be applied to molecular systems of limited size, so
that QM has to be simplified to adapt to the available computational power, e.g., apply pure QM to a
small subset of atoms and polarizable continuum model to emulate the protein and the solvent,[12]
or use accelerated techniques which will be mentioned in the following sections.
Linear scaling QM methods
The computational time of QM ranges from N3 (semi-empirical) to N5 (second order Møller-Plesset
perturbation theory (MP2) and other post-Hartree-Fock (HF) methods), where N is the number
of basis functions.[13] Linear scaling quantum mechanics (LSQM) has been applied extensively
for the evaluation of binding enthalpy between small molecules and proteins.[2, 3] In LSQM, the
computing time scales with N2 or even N if the local character of chemical interactions is fully
3
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exploited.[14–18] In the divide-and-conquer (D&C) approach, one of the typical LSQM techniques,
a large system is decomposed into many subsystems, and the density matrix of each subsystem is
determined separately. Finally contributions of individual subsystems are summed to obtain the total
density matrix and energy of the system (1).[15–17, 19] Raha and Merz developed a semi-empirical
D&C-based scoring function[18] and studied the ion-mediated ligand binding process. Their study
shows that QM is needed for metal-containing system, because the atom types and parameters of
metal atoms in most classical FFs are not accurate enough to describe the nature of the interactions
between a small molecule and a metal ion in the active site.[20]
We have suggested the use of a semi-empirical D&C strategy as an improvement of the linear
interaction energy model with continuum electrostatic solvation (LIECE).[21] The new method
QMLIECE was compared to LIECE by application to three enzymes belonging to different classes:
the West Nile virus NS3 serine protease (WNV PR) , the aspartic protease of human immunodefi-
ciency virus (HIV-1 PR), and the human cyclin-dependent protein kinase 2 (CDK2).[19] Our results
indicate that QMLIECE is superior to LIECE when the inhibitor/protein complexes have highly
variable charge–charge interactions, as in the case of 44 peptidic inhibitors of WNV PR, because of
the variable polarization effects (2) which are captured only by QMLIECE (3).
Localized molecular orbital (LMO) theory is an LSQM approach in which occupied-virtual
interactions involving distant LMOs are neglected, i.e., only density matrix and energies of LMOs
that belong to a limited number of atoms need to be calculated.[28] Used as a scoring function in
virtual screening, however, LMO theory is still not fast enough for evaluating all poses of small
molecules generated by docking. Therefore, Vasilyev and Bliznyuk, performed QM implemented in
MOZYME[28] based on LMOs only for the 10 – 100 top binders predicted by simplified scoring
functions.[29] By comparing the results with and without solvation they pointed out that although
QM was able to provide more accurate enthalpy values, the solvation model needed to be improved.
Anikin and coworker developed another linear-scaling semi-empirical algorithm based on LMOs
named LocalSCF.[30] The method resolves the SCF task through the finite atomic expansion of
weakly nonorthogonal localized molecular orbitals. The inverse overlap matrix arising from the
4
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Figure 1: D&C protocol[15] for calculation of QM interaction energy between a protein and a
small molecule (ligand). The interaction energy between a protein with m residues and the ligand is
decomposed into
Eligand-protein = Eligand-A1C1 +Eligand-N2A2C2 + . . .+Eligand-Nm−1Am−1Cm−1 +Eligand-NmAm
−Eligand-N2C1 −Eligand-N3C2 − . . .−Eligand-NmCm−1
where Ni and Ci are N terminal and C terminal cap, respectively, of residue Ai. The fragments with
blue names are protein residues with conjugate caps,[17] while the ones with red names are pure
“caps” that have to be subtracted to remove the duplication in energy calculation.[19] This figure is
reprinted from Ref.19 with permission of ACS.
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Figure 2: Polarization of protein atoms due to inhibitor binding: WNV PR, whose carbons are
in green, in complex with a peptidic inhibitor, whose carbons are in cyan. The polarized charges
were calculated by subtracting self-consistent field (SCF) atomic charges before binding from
that after binding, using the D&C protocol (see 1).[15] The protein surface was rendered with the
blue-white-red spectrum according to polarized charges of atoms. The blue color on the surface
denotes atomic partial charges that become more positive upon binding, while red color means
more negative atomic charges upon binding, and white color indicates atomic charges which do not
change upon binding.
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Figure 3: Comparison of the calculated (QMLIECE filled symbols, LIECE empty symbols) versus
experimental binding free energies for 44 WNV PR[22–24] (top left), 24 HIV-1 PR[25] (top right),
and 73 CDK2[26, 27] (bottom) inhibitors. The experimental data are fitted with two-parameter
models for WNV PR, three-parameter models for HIV-1 PR, and two-parameter models for CDK2.
Digit in parentheses is the total charge of the inhibitor. This figure is reprinted from Ref.19 with
permission of ACS.
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nonorthogonality of the localized orbitals is approximated by preserving the first-order perturbation
term and applying the second-order correction by means of a penalty function. Furthermore, for
very large systems (> 104 atoms) the performance of LocalSCF is more efficient in CPU time and
memory consumption than MOZYME with the help of the fast multipole method.[31]
QM/MM
The computational procedures based on QM/MM (see also the review article by J. Gascon at page
nnn) combine the strengths of both QM (accuracy) and molecular mechanics (MM) (efficiency)
methods, and are widely employed to model chemical reactions and other electronic processes in
biomolecular systems.[32–42] QM/MM can be used for preparing the structures of small molecules
and proteins, such as optimizing the binding poses obtained from docking,[43] and refining the
geometries of enzyme active sites obtained from a harmonically restrained minimization with
MM,[44] or X-ray structures.[45] It has been suggested that within the drug discovery process
QM/MM is valuable for (1) helping the interpretation of poorly resolved electron density,[45] (2)
probing the details of the interactions within enzymes active sites,[46] and (3) investigating the
effects of different substituents on the binding mode or in the assessment of alternate scaffolds.[47]
QM/MM is also very useful in describing the process of charge polarization and electron
transfer, which is not possible by classical FF methods. Anisimov and coworkers used a QM/MM
docking approach based on variational finite localized molecular orbital approximation to speed up
conventional QM,[30, 31] which took explicitly into account the effects of charge polarization and
intermolecular charge transfer.[48] Gentilucci et al. carried out QM/MM calculation to investigate
the binding mode into the M-opioid receptor and the electronic properties of an atypical agonist,
the cyclic peptide c[YpwFG] which contains aromatic side chains.[43] In their research the highly
favorable dipole-dipole interaction between the protein and the peptide agonist indicates that ligand
polarization induced by the protein environment contribute noteworthily to the overall binding
energy. Gao and coworkers used docking, molecular dynamics (MD), and QM/MM methods to
study the reaction dynamics between pyrimidine nucleoside phosphorylase and a substrate.[49]
8
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Their results show that catalysis involved residues stabilize the uridine in a high-energy conformation
by electrostatic interactions and the activation of phosphorolytic catalysis stems from polarization
effects. As mentioned above, QM is also appropriate to describe electron transfer. Blumberger
and coworkers applied QM/MM to calculate the free energy profile for peptide bond cleavage.[50]
Zheng and coworkers developed a QM/MM based approach for in silico screening of transition
states of the enzymatic reaction and calculated the activation energy.[51] By this approach they
designed a human butyrylcholinesterase mutant with a 2000-fold improved catalytic efficiency
for therapeutic use as an exogenous enzyme in humans to treat cocaine overdose and addiction.
Wallrapp and coworkers presented docking and QM/MM studies for the electron transfer pathway
between cytochrome P-450 camphor and putidaredoxin.[52]
QM/MM is a powerful instrument of parameterization of FFs for the system containing structural
motifs not adequately described by empirical FFs, such as diverse drug-like molecules,[53] and
metal-containing system.[54] QM/MM can also be used for incorporating polarization effects into a
FF, which enables the qualitative improvement in constructing patterns of hydrogen bonds of the
docked ligand, water structures and dynamics.[55]
QM Simulation
QM simulation is a useful tool for unraveling the mechanism of reactions.[56] In the drug design
field which involves biological macromolecules, QM simulation is often working with the classical
MD simulation.[40, 57] To explain the catalytic pathway of metalloenzyme farnesyltransferase
(FTase), Ho and coworkers exploited the Car-Parrinello MD[58] version of QM(B3LYP density
functional theory (DFT))/MM(Amber FF[59]) dynamics. Their results might be helpful in designing
selective inhibitors of FTase, given the proposed mechanism of the FTase reaction and the inhibition
by fluorine substituents of farnesyl diphosphate substrate.[60]
QM combined with classical MD is also useful for improving accuracy of interaction energy and
sampling of conformational space. Feenstra and coworkers used semi-empirical QM to calculate
activation energy barriers, and compare substrate activation barriers at different locations from MD
9
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simulations in the enzyme.[61] Alves and coworkers explained the viral resistance of diketo acids
(DKAs) to the integrase of human immunodeficiency virus (HIV-1 IN) N155S mutant by QM/MM
MD simulation.[62] Their decomposition analysis of energy terms shows that there is a strong
interaction between the Lys159, Lys156, Asn155, and Mg2+ cation and the DKA inhibitor with
complex electrostatic interactions. QM/MM can be used in free energy perturbation (FEP) method.
QM/MM FEP was applied to calculate the relative solvation free energies for a diverse set of small
molecules (root mean square deviation (RMSD)) from experimental data < 1.02 kJ·mol−1).[53]
Using the same method, the > 2000-fold decrease in the affinity for fructose-1,6-bisphosphatase of
an adenosine monophosphate (AMP) analogue (phosphonate 4) compared with AMP was explained
by the absence of hydrogen bonds and the loss of the electrostatic interactions,[63] which were
well described by the QM method.[64] Similarly Khandelwal and coworkers reported that QM/MM
calculated energies for the time averaged structures from MD simulations were able to distinguish
subtle differences in binding affinities of only one order of magnitude (4).[65, 66] These methods,
however, are very time-consuming, and therefore are not applicable for in silico high throughput
screening at present.
Protonation states
The rapid growth of the number of protein structures determined by X-ray crystallography calls
for robust methods for determining hydrogen positions, in particular for active site residues in
enzymes.[35, 36, 67] Explicit hydrogen atoms are required for most of the structure based drug
design methods,[68] e.g., all-atom MM, MD, docking, and electrostatic calculations. A recent
study reaffirms that the protonation state in the active site influences the ability of scoring methods
to determine the native binding pose.[69] Although other classical methods, e.g., MD[67] and
MM/Poisson-Boltzmann (PB) surface area,[70] can be used for determining the position of hydrogen
atoms, the prediction of protonation states should be more robust by means of QM because
protonation is related to the formation of the covalent bond between the hydrogen and heavy atom.
There are several studies on the determination of protonation states of protease, e.g., β -secretase
10
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Figure 4: Correlations between experimental and calculated inhibition potencies of hydroxamates
vs MMP-9 as obtained by FlexX docking with the zinc-binding-based selection of modes (green),
QM/MM minimization (blue), MD simulation with constrained zinc bonds (red), and by QM/MM
energy calculations for the time-averaged structures from MD simulation (black).[65, 66] This
figure is reprinted from Ref.65 with permission of ACS.
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(BACE),[71–74] plasmepsin,[67] and HIV-1 PR.[69, 75] Which of the two aspartates in the catalytic
dyad of BACE (Asp32 or Asp228) is protonated is likely to depend on the presence and type of
inhibitor.[71, 72, 76] Rajamani and coworkers used a LSQM method and the finite-difference PB
method to determine the protonation state and proton location in the presence and absence of an
inhibitor.[72] They performed structural optimization in the region surrounding the catalytic dyad.
Their calculation favors the monoprotonated state of Asp228 in presence of the hydroxyethylene
based inhibitor and di-deprotonated state for the apo enzyme. Yu and coworkers applied the
QM/MM to further refine the X-ray structure of BACE, and observed an energetically favored
monoprotonated configuration of Asp32 by fitting eight refined structures of BACE and an inhibitor
to the observed electron density.[74]
Determination of protonation states of metal-binding sites poses challenges on classical methods.[77,
78] Lin and Lim used a combination of QM and continuum dielectric methods to compute the free
energies for deprotonating a Zn-bound imidazole/water in various zinc complexes.[79] They found
that the protonation state of the His in the Zn-binding site depends on the solvent accessibility of
metal-binding site and Lewis acid ability of the zinc atom. They also suggested that it is critical for
the QM region to include not only the metal’s first-shell interactions, but also the second shell in
QM/MM modeling of metal-binding sites of metalloproteins.[79, 80] A comprehensive review of
Kamerlin and coworkers summarizes the progresses in ab initio QM/MM free-energy simulations
of electrostatic energies in proteins.[40] Their accelerated QM/MM method, which uses an updated
mean charge distribution and a classical reference potential, was benchmarked on the pKa of titrat-
able side chains. For Asp3 in the bovine pancreatic trypsin inhibitor they obtained the deviation
of ∼ 1 pKa unit (1 kcal·mol−1). For Lys102 in T4-lysozyme mutant the deviation was 2.4 pKa unit
(∼ 3 kcal·mol−1). The protonation state of Lys102 may affect the conformation of the protein, since
it is deeply buried in the hydrophobic surface. Therefore there is much larger likelihood to attain
significant errors in calculation of pKa of its side chain.[81] Compared to the 7 kcal·mol−1 energy
difference required for catalysis, an error of 3 kcal·mol−1 may be acceptable to determine the main
energetic contribution to the reaction.
12
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Cation-π and π-π interactions
Cation-π and π-π stacking interactions play a fundamental role in chemical and biological recognition.[82]
Classical FFs sometimes fail to describe these interactions because of the lack of charge delocal-
ization in fixed-charge models or the particular FF parameters. Even HF methods have limitations
in capturing π-interactions because of incompleteness of electronic correlation.[83, 84] Villar and
coworkers analyzed whether ligand-protein binding enthalpies evaluated by semi-empirical Austin
Model 1 (AM1) are sufficient for use in the rational design of new drugs by comparing with B3LYP
DFT, and MP2 method.[85] They pointed out that with the exception of cation-π interactions the
enthalpies calculated by AM1 correlated well with that by counterpoise-corrected MP2/6-31G(d).
However, the structures calculated by AM1 and DFT do not correlated with that calculated by MP2
consistently. Wu and McMahon applied DFT and MP2 to optimize the structures of the most stable
isomers of protonated Tyr and ammonia or methylamine and to calculate the enhancement of binding
energies due to cation-π interactions. Møller-Plesset perturbation and coupled-cluster methods show
that dispersive forces and electrostatic and exchange-repulsion forces play the primary stabilizing
role in π-stacked complexes.[84, 86, 87] High-level ab initio calculations, including extrapolation
to the MP2 basis set limit and inclusion of a CCSD(T) correction, show that T-shaped and parallel-
displaced configurations are virtually isoenergetic in gas phase, with binding energies of −11.46
and −11.63 kJ·mol−1 respectively, whereas the sandwich structure is less stable at −7.57 kJ·mol−1
(5),[84] and substituted benzene dimers bind more strongly than unsubstituted benzene.[88] Hobza
and coworkers suggested to model the π-π stacking interactions by MP2 with a medium-sized
basis set with a more diffuse polarization function, i.e., MP2/6 31G*(0.25) where exponents of d
polarization functions are changed into more diffuse 0.25 from 0.8 used in the standard 6-31G*
basis.[89–92] Because of its computational efficiency, DFT has been used by several groups to
describe π-stacking interactions.[93–97] To attain predicting power similar to high-level ab initio
methods, some researchers have combined HF theory and DFT, and using modest basis sets have
reproduced the potential energy surface of higher level calculations for a number of instances of
π-stacking.[98–100]
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(a) (b)
(c)
Figure 5: (a) Sandwich, (b) T-shaped, and (c) parallel-displaced configurations of the benzene
dimer.[84, 88]
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Using QM to calculate molecular properties
It has long been recognized that if one could accurately evaluate the standard free energy change
of complexation of biologically active molecules, it would be possible both to gain a deeper
understanding of molecular recognition in biology, and to shed light onto the first principles design
of pharmaceuticals and other compounds.[101] The currently available computer power does not
allow highly accurate QM calculations of free energies, particularly for proteins and ligands in
solution. Moreover, usage of QM methods in high-throughput docking is prohibitive. Therefore QM
is more suitable to derive models for prediction rather than for the direct evaluation of binding free
energies. Classical FFs and QSAR are examples of compromises between accuracy and efficiency.
QM derived FFs
Due to the large chemical space of molecules, FFs do not include all the parameters required
for describing drug-like molecules.[102] QM is being used routinely in optimizing geometries,
fitting the torsion parameters, and deriving atomic charges for proteins,[103] DNA,[104] and in
particular small molecules.[105–108] Spiegel and coworkers developed a new set of FF parameters
of platinated moiety via a force matching procedure of the classical forces to ab initio forces obtained
from QM/MM trajectories, and extended the classical MD simulation to describe slow converging
rearrangement of dinuclear Pt compounds and DNA duplex.[109] Sugiyama and coworkers used
DFT calculated partial charges and FF parameters for the atoms near the active site, which are
usually significantly polarized, and metal atoms for which FF parameters are not available.[110]
Multipole expansion (ME) is often used in the representation of the molecular electrostatic
potential.[30, 111–113] To account for the effects of charge penetration, the point charges, dipoles,
quadrupoles, and octupoles in ME model need to be damped. The damping strategies are particular
crucial for short-range energies. For example, damping strategies have to be used when ME is
applied on calculation of electrostatic potentials or electric fields on van der Waals (vdW) or solvent
accessible surface of a molecule.[114] Werneck and coworkers suggested a general methodology
15
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to optimize the damping functions with the ab initio (HF/6-31G** and 6-31G**+) electrostatic
potential.[115]
QM-derived partial charges
In the molecular simulations with fixed charge models, the method used to derive partial charges
influences the computed physical properties and subsequent docking and scoring significantly.[116,
117] Mobley and coworker compared the hydration free energies of small molecules, whose partial
charges are assigned according to different levels of QM, including AM1, HF, DFT, and MP2, by
explicit water MD simulations.[118] They found that AM1 bond charge correction method[119] for
computing charges works almost as well as any of the more computationally expensive ab initio
method. Fischer et al. compared FF-based scoring functions with QM-based scoring functions
by computing binding free energies of eleven ligands to the human estrogen receptor subtype
α (ERα) and four ligands to the human retinoic acid receptor of isotype γ .[120] They found
that the improvement for the complexes with the ERα receptor stemmed from applying classical
electrostatic models partial charges derived by fragment molecular orbital (FMO).[121] Illingworth
and coworkers implemented QM/MM derived induced charges into a classical framework, redocked
12 difficult protein-ligand complexes with AutoDock,[122] and found that there was no significant
improvement in RMSD of the lowest energy structure against the crystal structure but an increment
of the largest cluster size.[123] Pasquini and coworkers explained different binding affinities of
similar compounds to HIV-1 IN by calculating the partial charges of these compounds and attributed
the difference to a poor interaction of the molecules with the divalent metal ions of the active site
due to the electron-withdrawing effect.[7] Instead of using fixed and point-charge model, Wang and
coworkers calculated solvation free energies of 31 small neutral molecules from QM charge density
and continuum dielectric theory (finite-difference PB equation).[124] The QM and PB equations
were solved self-consistently until both the charge and reaction field converged. The calculations
took into account polarized electronic wave function asymmetric distortion, and spreading out of the
electron cloud. In particular, when the solute is treated by QM, part of its electron density penetrates
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into the solvent. The experimentally measured solvation free energies of these molecules spanned a
range of 25 kcal·mol−1. The authors reported root mean square error of only 1.3 kcal·mol−1 upon
tuning a single parameter to shift the calculated values.
QM descriptors in QSAR/QSPR models
The information provided by QM is more accurate than FFs, therefore more robust QSAR models
and/or QSPR models are expected with QM descriptors.[125] Partial charges are the most common
descriptors in QSAR/QSPR models due to their simplicity and informative content. Occhiato and
coworkers employed atomic partial charges derived from DFT electrostatic potential in a CoMFA
model, with which they designed new 5α-reductase 1 inhibitors.[126] Lepp and Chuman applied
LocalSCF calculated atomic charges to build a QSAR model to predict Michaelis-Menten constants,
and attained better correlation than classical QSAR descriptors.[127] Wan et al. found that the net
charge of the atoms and polarizability correlate with biological activity.[128] Furthermore, they
reported that the predictive power of QSAR models derived from DFT charges is higher than from
semi-empirical PM3 charges. Besides partial charges, other QM descriptors are commonly used to
build QSAR/QSPR models. Yamagami and coworkers used various quantum chemical descriptors,
e.g., frontier energy and frontier electron density, which are powerful for describing chemical
reactivity.[129] Their CoMFA method shows that the antimutagenic activities are increased by
electron-withdrawing substituents and also by hydrogen-bonding between 2-hydroxy group and the
receptor. Singh and coworkers developed a QSAR model of derivatives of testosterone with several
QM parameters, e.g., absolute hardness and electronegativity.[130] Pasha and coworkers derived
QSAR models utilizing various QM descriptors to analyze the factors affecting inhibitory potency
for a series of analogues of the MK886 inhibitor of microsomal prostaglandin E2 synthase-1.[131]
These QM models indicate that the steric properties, as well as electrostatic and hydrophobic
interactions are relevant to the inhibitory potency.
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Molecular quantum similarity
Molecular similarity measures have been used in CADD since more than 15 years.[132] Malde
and coworkers have investigated boron analogs of natural peptides by QM to find the secondary
structural preferences and the impact on stability of different substitutions on boron.[133–135]
Recently they have shown that the B(OH)−NH isostere is an interesting surrogate for the pep-
tide bond because of the similar geometry and barrier for rotation around the backbone dihedral
angle ω , as well as stability to proteolytic enzymes.[136] Carbó et al. measured the similarity
of electron density calculated by QM, and developed a novel QSAR descriptor named molecular
quantum similarity measures (MQSM).[137–144] The MQSM relies on the first order electronic
density function as molecular descriptor. Before comparing the similarities of electronic density
functions, approximated functions[145, 146] and a maximization algorithm are needed to obtain
optimal molecular superposition.[147] The MQSM was then used to predict the toxicity[148, 149]
and to describe the substituent effect in an aromatic series traditionally described by empirical
Hammett equation.[144, 150] MQSM also can be applied for classification of molecules using
dendrograms.[151] A further development of MQSM is quantum topological molecular similarity
(QTMS),[152] which is based on the definition of distances between molecules in bond critical point
space.[153, 154] QTMS is very useful to describe pKa of molecules as QSAR descriptors.[155, 156]
Singh et al. suggested the connection between QTMS and relative bond dissociation enthalpies, and
attained good QSAR.[157] Hemmateenejad and Mohajeri used QTMS indices for describing the
quantitative effects of molecular electronic environments on the O-methylation kinetic of substituted
phenols.[158] Their results revealed that the rate constant of esterification of phenols is highly
influenced by the electronic properties of the C2−C1−O−H fragment of the parent molecule, which
can be considered as frontier bonds in the O-methylation reaction. As shown in these examples, the
effects of substitutions are related to the electron density of the bond connecting the scaffolds and
the substituents, such that molecular quantum similarity is suitable for studying substitutive effects.
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Variational particle number approach for molecular design
Chemical space is the high-dimensional molecular space spanned by the astronomical number of
accessible chemical structures. How to sample the chemical space efficiently is always a difficult
problem in de novo drug design. In general terms, compound design efforts usually attempt a
mapping of a given molecular system to the observable of interest. However in structure-based
drug design, the inverse question applies, i.e., which modification of a given compound will result
in a desired molecular property. Two independent research groups have recently addressed this
question. Lilienfeld and coworkers developed an approach that can explore chemical space in
a less heuristic manner by extending the conceptual DFT by the chemical potential for nuclei
(alchemical potential).[159] With their approach, they modified a peptidic inhibitor of an anticancer
target (human X-chromosome linked inhibitor-of-apoptosis-proteins) into a nonpeptidic inhibitor
by optimizing the interaction energy between the inhibitor and the target. Almost at the same
time, Wang and coworkers optimized molecular polarizability and hyperpolarizability using a
similar method. The main idea of these methods is mapping the discrete chemical structures onto a
continuous hypersurface (6). In this case, enumerating the astronomical number of discrete chemical
structures can be avoided by a systematic optimization of parameters introduced in the mapping
procedure. Up to now, these methods are merely applied for optimizing several molecular properties
e.g., polarizability and hyperpolarizability, which can be calculated by QM straightforwardly.[160–
166] QSAR/QSPR models may bridge the gap between the properties calculated directly by QM
and those that are useful for drug discovery, e.g., high binding affinity and selectivity to the target,
good pharmacokinetics and pharmacodynamics, and low toxicity, so that the variational particle
number approach might become a routine of structure-based drug design.
Conclusion and outlook
Several QM-based methods already play an important role in many phases of CADD, and will have
a stronger impact in the future because of the ever growing computing power and development
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Figure 6: Schematic representation of optimization of molecular properties by a linear combination
of atomic potentials. Bar heights represent electronic polarizabilities for candidate structures. The
optimization of the property is performed on the smooth (hyper)surface (only two degrees of
freedom are denoted). Establishing a well behaved property surface that interpolates among the
realizable molecules is a key aspect of the variational particle number approach.[167] This figure is
reprinted from Ref.167 with permission of ACS.
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of efficient algorithms. The compromise between accuracy and efficiency is a perpetual issue in
the applications of QM methods. It is important to select the most appropriate technique at each
phase of drug development, and QM methods should be selected only if there is a real advantage
with respect to the classical approaches. The initial phase of CADD, e.g., high-throughput docking,
which is useful to identify hit compounds,[168] requires full sampling of conformations of the small
molecules within the protein binding site. Such extensive sampling calls for approximated energy
functions and predicted properties thereof, which are usually calculated by classical FF methods
or fast semi-empirical QM methods. In the subsequent phase, hits have to be optimized to leads
which does not require extensive sampling but high accuracy because of the small differences in
the binding free energy. Therefore QM methods should be applied on the hits to shed light on the
energetics of binding. The QM methods are particularly important to capture charge transfer and
polarization effects, which are usually pronounced in systems containing metal atoms or charged
groups, and/or dispersion forces which play a significant role in the interactions of conjugated π
systems. Importantly, before starting CADD it is necessary to evaluate the status of the project,
which in turn dictates the number and diversity of molecules to be evaluated and the demand of
accuracy, and to select the most appropriate approach accordingly.
Acknowledgement
This work was supported by a grant of the Swiss National Science Foundation to A.C.
References
[1] Jorgensen, W. L. The many roles of computation in drug discovery. Science 2004, 303,
1813–1818.
[2] Cavalli, A.; Carloni, P.; Recanatini, M. Target-related applications of first principles quantum
chemical methods in drug design. Chem. Rev. 2006, 106, 3497–3519.
[3] Raha, K.; Peters, M. B.; Wang, B.; Yu, N.; WollaCott, A. M.; Westerhoff, L. M.; Merz, K. M.
21
25
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
The role of quantum mechanics in structure-based drug design. Drug Discov. Today 2007,
12, 725–731.
[4] Peters, M. B.; Raha, K.; Merz, K. M. Quantum mechanics in structure-based drug design.
Curr. Opin. Drug Discovery Dev. 2006, 9, 370–379.
[5] Rocha, G. B.; Freire, R. O.; Simas, A. M.; Stewart, J. J. P. RMI: A reparameterization of
AM1 for H, C, N, O, P, S, F, Cl, Br, and I. J. Comput. Chem. 2006, 27, 1101–1111.
[6] Stewart, J. J. P. Optimization of parameters for semiempirical methods V: Modification of
NDDO approximations and application to 70 elements. J. Mol. Model. 2007, 13, 1173–1213.
[7] Pasquini, S.; Mugnaini, C.; Tintori, C.; Botta, M.; Trejos, A.; Arvela, R. K.; Larhed, M.;
Witvrouw, M.; Michiels, M.; Christ, F.; Debyser, Z.; Corelli, F. Investigations on the 4-
quinolone-3-carboxylic acid motif. 1. Synthesis-activity relationship of a class of human
immunodeficiency virus type 1 integrase inhibitors. J. Med. Chem. 2008, 51, 5125–5129.
[8] Vorobjev, Y. N.; Scheraga, H. A.; Honig, B. Theoretical modeling of electrostatic effects of
titratable side-chain groups on protein conformation in a polar ionic solution. 2. pH-induced
helix-coil transition of poly-(L-lysine) in water and methanol ionic solutions. J. Phys. Chem.
1995, 99, 7180–7187.
[9] Vorobjev, Y. N.; Scheraga, H. A.; Hitz, B.; Honig, B. Theoretical modeling of electrostatic
effects of titratable side-chain groups on protein conformation in a polar ionic solution. 1.
Potential of mean force between charged lysine residues and titration of poly-(L-lysine) in
95% methanol solution. J. Phys. Chem. 1994, 98, 10940–10948.
[10] Bombasaro, J. A.; Masman, M. F.; Santagata, L. N.; Freile, M. L.; Rodriguez, A. M.;
Enriz, R. D. A comprehensive conformational analysis of bullacin B, a potent inhibitor of
complex I. Molecular dynamics simulations and ab initio calculations. J. Phys. Chem. A
2008, 112, 7426–7438.
22
26
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[11] Butler, K. T.; Luque, F. J.; Barril, X. Toward accurate relative energy predictions of the
bioactive conformation of drugs. J. Comput. Chem. 2009, 30, 601–610.
[12] Buback, V.; Mladenovic, M.; Engels, B.; Schirmeister, T. Rational design of improved
aziridine-based inhibitors of cysteine proteases. J. Phys. Chem. B 2009, 113, 5282–5289.
[13] Van der Vaart, A.; Gogonea, V.; Dixon, S. L.; Merz, K. M. Linear scaling molecular orbital
calculations of biological systems using the semiempirical divide and conquer method. J.
Comput. Chem. 2000, 21, 1494–1504.
[14] Gadre, S. R.; Shirsat, R. N.; Limaye, A. C. Molecular tailoring approach for simulation of
electrostatic properties. J. Phys. Chem. 1994, 98, 9165–9169.
[15] Dixon, S. L.; Merz, K. M. Semiempirical molecular orbital calculations with linear system
size scaling. J. Chem. Phys. 1996, 104, 6643–6649.
[16] Lee, T. S.; Lewis, J. P.; Yang, W. T. Linear-scaling quantum mechanical calculations of
biological molecules: The divide-and-conquer approach. Comp. Mat. Sci. 1998, 12, 259–277.
[17] Zhang, D. W.; Zhang, J. Z. H. Molecular fractionation with conjugate caps for full quantum
mechanical calculation of protein-molecule interaction energy. J. Chem. Phys. 2003, 119,
3599–3605.
[18] Raha, K.; Merz, K. M. Large-scale validation of a quantum mechanics based scoring function:
Predicting the binding affinity and the binding mode of a diverse set of protein–ligand
complexes. J. Med. Chem. 2005, 48, 4558–4575.
[19] Zhou, T.; Huang, D.; Caflisch, A. Is quantum mechanics necessary for predicting binding
free energy? J. Med. Chem. 2008, 51, 4280–4288.
[20] Raha, K.; Merz, K. M. A quantum mechanics-based scoring function: Study of zinc ion-
mediated ligand binding. J. Am. Chem. Soc. 2004, 126, 1020–1021.
23
27
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[21] Huang, D.; Caflisch, A. Efficient evaluation of binding free energy using continuum electro-
statics solvation. J. Med. Chem. 2004, 47, 5791–5797.
[22] Knox, J. E.; Ma, N. L.; Yin, Z.; Patel, S. J.; Wang, W. L.; Chan, W. L.; Rao, K. R. R.;
Wang, G.; Ngew, X.; Patel, V.; Beer, D.; Lim, S. P.; Vasudevan, S. G.; Keller, T. H. Peptide
inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J. Med.
Chem. 2006, 49, 6585–6590.
[23] Yin, Z.; Patel, S. J.; Wang, W. L.; Chan, W. L.; Rao, K. R. R.; Wang, G.; Ngew, X.; Patel, V.;
Beer, D.; Knox, J. E.; Ma, N. L.; Ehrhardt, C.; Lim, S. P.; Vasudevan, S. G.; Keller, T. H.
Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde
inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 40–43.
[24] Yin, Z.; Patel, S. J.; Wang, W. L.; Wang, G.; Chan, W. L.; Rao, K. R. R.; Alam, J.; Je-
yaraj, D. A.; Ngew, X.; Patel, V.; Beer, D.; Lim, S. P.; Vasudevan, S. G.; Keller, T. H. Peptide
inhibitors of dengue virus NS3 protease. Part 1: Warhead. Bioorg. Med. Chem. Lett. 2006,
16, 36–39.
[25] Dreyer, G. B.; Lambert, D. M.; Meek, T. D.; Carr, T. J.; Tomaszek, T. A.; Fernandez, A. V.;
Bartus, H.; Cacciavillani, E.; Hassell, A. M.; Minnich, M.; Petteway, S. R.; Metcalf, B. W.;
Lewis, M. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease
- structure activity analysis using enzyme-kinetics, X-ray crystallography, and infected T-cell
assays. Biochemistry (Mosc.) 1992, 31, 6646–6659.
[26] Bramson, H. N. et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2):
Design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem.
2001, 44, 4339–4358.
[27] Gibson, A. E. et al. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1
and 2 with O6 substituted guanine derivatives. J. Med. Chem. 2002, 45, 3381–3393.
24
28
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[28] Stewart, J. J. P. Application of localized molecular orbitals to the solution of semiempirical
self-consistent field equations. Int. J. Quantum Chem. 1996, 58, 133–146.
[29] Vasilyev, V.; Bliznyuk, A. Application of semiempirical quantum chemical methods as a
scoring function in docking. Theor. Chem. Acc. 2004, 112, 313–317.
[30] Anikin, N. A.; Anisimov, V. M.; Bugaenko, V. L.; Bobrikov, V. V.; Andreyev, A. M. LocalSCF
method for semiempirical quantum-chemical calculation of ultralarge biomolecules. J. Chem.
Phys. 2004, 121, 1266–1270.
[31] Anisimov, V. M.; Bugaenko, V. L.; Bobrikov, V. V. Validation of linear scaling semiempirical
LocalSCF method. J. Chem. Theory Comput. 2006, 2, 1685–1692.
[32] Gao, J. L.; Truhlar, D. G. Quantum mechanical methods for enzyme kinetics. Annu. Rev.
Phys. Chem. 2002, 53, 467–505.
[33] Gao, J. L.; Ma, S. H.; Major, D. T.; Nam, K.; Pu, J. Z.; Truhlar, D. G. Mechanisms and free
energies of enzymatic reactions. Chem. Rev. 2006, 106, 3188–3209.
[34] Cheng, Y. H.; Cheng, X. L.; Radic, Z.; McCammon, J. A. Acetylcholinesterase: Mechanisms
of covalent inhibition of H447I mutant determined by computational analyses. Chem. Biol.
Interact. 2008, 175, 196–199.
[35] Hu, H.; Boone, A.; Yang, W. T. Mechanism of OMP decarboxylation in orotidine 5 ’-
monophosphate decarboxylase. J. Am. Chem. Soc. 2008, 130, 14493–14503.
[36] Lameira, J.; Alves, C. N.; Moliner, V.; Marti, S.; Kanaan, N.; Tunon, I. A quantum mechan-
ics/molecular mechanics study of the protein–ligand interaction of two potent inhibitors of
human O-GlcNAcase: PUGNAc and NAG-thiazoline. J. Phys. Chem. B 2008, 112, 14260–
14266.
[37] Mladenovic, M.; Junold, K.; Fink, R. F.; Thiel, W.; Schirmeister, T.; Engels, B. Atomistic
insights into the inhibition of cysteine proteases: First QM/MM calculations clarifying the
25
29
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
regiospecificity and the inhibition potency of epoxide- and aziridine-based inhibitors. J. Phys.
Chem. B 2008, 112, 5458–5469.
[38] Suresh, C. H.; Vargheese, A. M.; Vijayalakshmi, K. P.; Mohan, N.; Koga, N. Role of structural
water molecule in HIV protease-inhibitor complexes: A QM/MM study. J. Comput. Chem.
2008, 29, 1840–1849.
[39] Wu, R. B.; Cao, Z. X. QM/MM study of catalytic methyl transfer by the N-5-Glutamine
SAM-dependent methyltransferase and its inhibition by the nitrogen analogue of coenzyme.
J. Comput. Chem. 2008, 29, 350–357.
[40] Kamerlin, S. C. L.; Haranczyk, M.; Warshel, A. Progress in ab initio QM/MM free-energy
simulations of electrostatic energies in proteins: accelerated QM/MM studies of pKa, redox
reactions and solvation free energies. J. Phys. Chem. B 2009, 113, 1253–1272.
[41] Lodola, A.; Mor, M.; Sirirak, J.; Mulholland, A. J. Insights into the mechanism and inhibition
of fatty acid amide hydrolase from quantum mechanics/molecular mechanics (QM/MM)
modelling. Biochem. Soc. Trans. 2009, 37, 363–367.
[42] Senn, H. M.; Thiel, W. QM/MM methods for biomolecular systems. Angew. Chem., Int. Ed.
2009, 48, 1198–1229.
[43] Gentilucci, L.; Squassabia, F.; Demarco, R.; Artali, R.; Cardillo, G.; Tolomelli, A.; Spamp-
inato, S.; Bedini, A. Investigation of the interaction between the atypical agonist c[YpwFG]
and MOR. FEBS J. 2008, 275, 2315–2337.
[44] Mukherjee, P.; Desai, P. V.; Srivastava, A.; Tekwani, B. L.; Avery, M. A. Probing the
structures of leishmanial farnesyl pyrophosphate synthases: homology modeling and docking
studies. J. Chem. Inf. Model. 2008, 48, 1026–1040.
[45] Fanfrlik, J.; Brynda, J.; Rezac, J.; Hobza, P.; Lepsik, M. Interpretation of protein/ligand
26
30
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
crystal structure using QM/MM calculations: case of HIV-1 protease/metallacarborane
complex. J. Phys. Chem. B 2008, 112, 15094–15102.
[46] Mladenovic, M.; Arnone, M.; Fink, R. F.; Engels, B. Environmental effects on charge densi-
ties of biologically active molecules: Do molecule crystal environments indeed approximate
protein surroundings? J. Phys. Chem. B 2009, 113, 5072–5082.
[47] Gleeson, M. P.; Gleeson, D. QM/MM calculations in drug discovery: A useful method for
studying binding phenomena? J. Chem. Inf. Model. 2009, 49, 670–677.
[48] Anisimov, V. M.; Bugaenko, V. L. QM/MM docking method based on the variational finite
localized molecular orbital approximation. J. Comput. Chem. 2009, 30, 784–798.
[49] Gao, X.; Huang, X.; Sun, C. Role of each residue in catalysis in the active site of pyrimidine
nucleoside phosphorylase from Bacillus subtilis: A hybrid QM/MM study. J. Struct. Biol.
2006, 154, 20–26.
[50] Blumberger, J.; Lamoureux, G.; Klein, M. L. Peptide hydrolysis in thermolysin: Ab initio
QM/MM investigation of the Glu143-assisted water addition mechanism. J. Chem. Theory
Comput. 2007, 3, 1837–1850.
[51] Zheng, F.; Yang, W.; Ko, M.; Liu, J.; Cho, H.; Gao, D.; Tong, M.; Tai, H.; Woods, J. H.;
Zhan, C. Most efficient cocaine hydrolase designed by virtual screening of transition states. J.
Am. Chem. Soc. 2008, 130, 12148–12155.
[52] Wallrapp, F.; Masone, D.; Guallar, V. Electron transfer in the P450cam/PDX complex. The
QM/MM e-pathway. J. Phys. Chem. A 2008, 112, 12989–12994.
[53] Reddy, M. R.; Singh, U. C.; Erion, M. D. Ab initio quantum mechanics-based free energy
perturbation method for calculating relative solvation free energies. J. Comput. Chem. 2007,
28, 491–494.
27
31
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[54] Magistrato, A.; Ruggerone, P.; Spiegel, K.; Carloni, P.; Reedijk, J. Binding of novel azole-
bridged dinuclear Platinum(II) anticancer drugs to DNA: Insights from hybrid QM/MM
Molecular Dynamics simulations. J. Phys. Chem. B 2006, 110, 3604–3613.
[55] Friesner, R. A. Modeling polarization in proteins and protein–ligand complexes: Methods
and preliminary results. Adv. Protein Chem. 2006, 72, 79–104.
[56] Trout, B. L.; Parrinello, M. The dissociation mechanism of H2O in water studied by first-
principles molecular dynamics. Chem. Phys. Lett. 1998, 343–347.
[57] Ridder, L.; Mulholland, A. J. Modeling biotransformation reactions by combined quantum
mechanical/molecular mechanical approaches: from structure to activity. Curr. Top. Med.
Chem. 2003, 3, 1241–1256.
[58] Car,; Parrinello, Unified approach for molecular dynamics and density-functional theory.
Phys. Rev. Lett. 1985, 55, 2471–2474.
[59] Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.;
Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field
for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995,
117, 5179–5197.
[60] Ho, M.; Vivo, M. D.; Peraro, M. D.; Klein, M. L. Unraveling the catalytic pathway of
metalloenzyme farnesyltransferase through QM/MM computation. J. Chem. Theory Comput.
2009, 5, 1657–1666.
[61] Feenstra, K. A.; Starikov, E. B.; Urlacher, V. B.; Commandeur, J. N. M.; Vermeulen, N.
P. E. Combining substrate dynamics, binding statistics, and energy barriers to rationalize
regioselective hydroxylation of octane and lauric acid by CYP102A1 and mutants. Protein
Sci. 2007, 16, 420–431.
28
32
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[62] Alves, C. N.; Marti, S.; Castillo, R.; Andres, J.; Moliner, V.; Tunon, I.; Silla, E. A quantum
mechanic/molecular mechanic study of the wild-type and N155S mutant HIV-1 integrase
complexed with diketo acid. Biophys. J. 2008, 94, 2443–2451.
[63] Reddy, M. R.; Erion, M. D. Relative binding affinities of fructose-1,6-bisphosphatase in-
hibitors calculated using a quantum mechanics-based free energy perturbation method. J. Am.
Chem. Soc. 2007, 129, 9296–9297.
[64] Sponer, J.; Leszczynski, J.; Hobza, P. Electronic properties, hydrogen bonding, stacking, and
cation binding of DNA and RNA bases. Biopolymers 2001, 61, 3–31.
[65] Khandelwal, A.; Lukacova, V.; Comez, D.; Kroll, D. M.; Raha, S.; Balaz, S. A combina-
tion of docking, QM/MM methods, and MD simulation for binding affinity estimation of
metalloprotein ligands. J. Med. Chem. 2005, 48, 5437–5447.
[66] Khandelwal, A.; Balaz, S. QM/MM linear response method distinguishes ligand affinities for
closely related metalloproteins. Proteins 2007, 69, 326–339.
[67] Friedman, R.; Caflisch, A. The protonation state of the catalytic aspartates in plasmepsin II.
FEBS Lett. 2007, 581, 4120–4124.
[68] Klein, C. D. P.; Schiffmann, R.; Folkers, G.; Piana, S.; Rothlisberger, U. Protonation states of
methionine aminopeptidase and their relevance for inhibitor binding and catalytic activity. J.
Biol. Chem. 2003, 278, 47862–47867.
[69] Fong, P.; McNamara, J. P.; Hillier, I. H.; Bryce, R. A. Assessment of QM/MM scoring
functions for molecular docking to HIV-1 protease. J. Chem. Inf. Model. 2009, 49, 913–924.
[70] Wittayanarakul, K.; Hannongbua, S.; Feig, M. Accurate prediction of protonation state as a
prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease
inhibitors. J. Comput. Chem. 2008, 29, 673–685.
29
33
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[71] Park, H.; Lee, S. Determination of the active site protonation state of β -secretase from
molecular dynamics simulation and docking experiment: Implications for structure-based
inhibitor design. J. Am. Chem. Soc. 2003, 125, 16416–16422.
[72] Rajamani, R.; Reynolds, C. H. Modeling the protonation states of the catalytic aspartates in
β -secretase. J. Med. Chem. 2004, 47, 5159–5166.
[73] Polgar, T.; Keseru, G. M. Virtual screening for β -secretase (BACE1) inhibitors reveals the
importance of protonation states at Asp32 and Asp228. J. Med. Chem. 2005, 48, 3749–3755.
[74] Yu, N.; Hayik, S. A.; Wang, B.; Liao, N.; Reynolds, C. H.; Merz, K. M. Assigning the proto-
nation states of the key aspartates in β -secretase using QM/MM X-ray structure refinement.
J. Chem. Theory Comput. 2006, 2, 1057–1069.
[75] Piana, S.; Sebastiani, D.; Carloni, P.; Parrinello, M. Ab initio molecular dynamics-based
assignment of the protonation state of pepstatin A/HIV-1 protease cleavage site. J. Am. Chem.
Soc. 2001, 123, 8730–8737.
[76] Gorfe, A. A.; Caflisch, A. Functional plasticity in the substrate binding site of β -secretase.
Structure 2005, 13, 1487–1498.
[77] Dudev, T.; Lim, C. Metal binding affinity and selectivity in metalloproteins: Insights from
computational studies. Annu. Rev. Biophys. 2008, 37, 97–116.
[78] Seebeck, B.; Reulecke, I.; Kamper, A.; Rarey, M. Modeling of metal interaction geometries
for protein–ligand docking. Proteins 2008, 71, 1237–1254.
[79] Lin, Y. L.; Lim, C. Factors governing the protonation state of Zn-bound histidine in proteins:
A DFT/CDM study. J. Am. Chem. Soc. 2004, 126, 2602–2612.
[80] Dudev, T.; Lim, C. Principles governing Mg, Ca, and Zn binding and selectivity in proteins.
Chem. Rev. 2003, 103, 773–787.
30
34
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[81] Riccardi, D.; Schaefer, P.; Cui, Q. pKa calculations in solution and proteins with QM/MM
free energy perturbation simulations: a quantitative test of QM/MM protocols. J. Phys. Chem.
B 2005, 109, 17715–17733.
[82] Meyer, E. A.; Castellano, R. K.; Diederich, F. Interactions with aromatic rings in chemical
and biological recognition. Angew. Chem., Int. Ed. 2003, 42, 1210–1250.
[83] Hobza, P.; Selzle, H. L.; Schlag, E. W. Potential energy surface for the benzene dimer. Results
of ab initio CCSD(T) calculations show two nearly isoenergetic structures: T-shaped and
parallel-displaced. J. Phys. Chem. 1996, 100, 18790–18794.
[84] Sinnokrot, M. O.; Valeev, E. F.; Sherrill, C. D. Estimates of the ab initio limit for π–π
interactions: The benzene dimer. J. Am. Chem. Soc. 2002, 124, 10887–10893.
[85] Villar, R.; Gil, M. J.; Garcia, J. I.; Martinez-Merino, V. Are AM1 ligand-protein binding
enthalpies good enough for use in the rational design of new drugs? J. Comput. Chem. 2005,
26, 1347–1358.
[86] Kim, K. S.; Tarakeshwar, P.; Lee, J. Y. Molecular clusters of π-systems: Theoretical studies
of structures, spectra, and origin of interaction energies. Chem. Rev. 2000, 100, 4145–4185.
[87] Wu, R. H.; McMahon, T. B. Investigation of cation–π interactions in biological systems. J.
Am. Chem. Soc. 2008, 130, 12554–12555.
[88] Sinnokrot, M. O.; Sherrill, C. D. Substituent effects in π–π interactions: Sandwich and
T-shaped configurations. J. Am. Chem. Soc. 2004, 126, 7690–7697.
[89] Sponer, J.; Gabb, H. A.; Leszczynski, J.; Hobza, P. Base-base and deoxyribose-base stacking
interactions in B-DNA and Z-DNA: A quantum-chemical study. Biophys. J. 1997, 73, 76–87.
[90] Hobza, P.; Sponer, J. Significant structural deformation of nucleic acid bases in stacked base
pairs: an ab initio study beyond Hartree-Fock. Chem. Phys. Lett. 1998, 288, 7–14.
31
35
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[91] Reha, D.; Kabelac, M.; Ryjacek, F.; Sponer, J.; Sponer, J. E.; Elstner, M.; Suhai, S.; Hobza, P.
Intercalators. 1. Nature of stacking interactions between intercalators (ethidium, daunomycin,
ellipticine, and 4 ’,6-diaminide-2-phenylindole) and DNA base pairs. Ab initio quantum
chemical, density functional theory, and empirical potential study. J. Am. Chem. Soc. 2002,
124, 3366–3376.
[92] Jurecka, P.; Hobza, P. True stabilization energies for the optimal planar hydrogen-bonded
and stacked structures of guanine center dot center dot center dot cytosine, adenine center
dot center dot center dot thymine, and their 9-and 1-methyl derivatives: Complete basis set
calculations at the MP2 and CCSD(T) levels and comparison with experiment. J. Am. Chem.
Soc. 2003, 125, 15608–15613.
[93] Meijer, E. J.; Sprik, M. A density-functional study of the intermolecular interactions of
benzene. J. Chem. Phys. 1996, 105, 8684–8689.
[94] Ye, X. Y.; Li, Z. H.; Wang, W. N.; Fan, K. N.; Xu, W.; Hua, Z. Y. The parallel π–π stacking:
a model study with MP2 and DFT methods. Chem. Phys. Lett. 2004, 397, 56–61.
[95] Xu, X.; Goddard, W. A. The X3LYP extended density functional for accurate descriptions of
nonbond interactions, spin states, and thermochemical properties. Proc. Natl. Acad. Sci. U. S.
A. 2004, 101, 2673–2677.
[96] Johnson, E. R.; Wolkow, R. A.; DiLabio, G. A. Application of 25 density functionals to
dispersion-bound homomolecular dimers. Chem. Phys. Lett. 2004, 394, 334–338.
[97] Cerny, J.; Hobza, P. The X3LYP extended density functional accurately describes H-bonding
but fails completely for stacking. Phys. Chem. Chem. Phys. 2005, 7, 1624–1626.
[98] Perez-Jorda, J. M.; San-Fabian, E.; Perez-Jimenez, A. J. Density-functional study of van
der Waals forces on rare-gas diatomics: Hartree-Fock exchange. J. Chem. Phys. 1999, 110,
1916–1920.
32
36
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[99] Walsh, T. R. Exact exchange and Wilson-Levy correlation: a pragmatic device for studying
complex weakly-bonded systems. Phys. Chem. Chem. Phys. 2005, 7, 443–451.
[100] Waller, M. P.; Robertazzi, A.; Platts, J. A.; Hibbs, D. E.; Williams, P. A. Hybrid density
functional theory for pi-stacking interactions: Application to benzenes, pyridines, and DNA
bases. J. Comput. Chem. 2006, 27, 491–504.
[101] McCammon, J. A. Free energy calculations in rational drug design. Abstracts of Papers of
the American Chemical Society 2004, 227, U896–U896.
[102] Curioni, A.; Mordasini, T.; Andreoni, W. Enhancing the accuracy of virtual screening:
molecular dynamics with quantum-refined force fields. J. Comput. Aided Mol. Des. 2004, 18,
773–784.
[103] Ponder, J. W.; Case, D. A. Force fields for protein simulations. Protein Simulations 2003, 66,
27–85.
[104] Ryjacek, F.; Kubar, T.; Hobza, P. New parameterization of the Cornell et al. empirical force
field covering amino group nonplanarity in nucleic acid bases. J. Comput. Chem. 2003, 24,
1891–1901.
[105] Maple, J. R.; Dinur, U.; Hagler, A. T. Derivation of force fields for molecular mechanics and
dynamics from ab initio energy surfaces. Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 5350–5354.
[106] Palmo, K.; Mannfors, B.; Mirkin, N. G.; Krimm, S. Potential energy functions: From
consistent force fields to spectroscopically determined polarizable force fields. Biopolymers
2003, 68, 383–394.
[107] Maurer, P.; Laio, A.; Hugosson, H. W.; Colombo, M. C.; Rothlisberger, U. Automated
parametrization of biomolecular force fields from quantum mechanics/molecular mechanics
(QM/MM) simulations through force matching. J. Chem. Theory Comput. 2007, 3, 628–639.
33
37
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[108] Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; Darian, E.;
Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A. D. CHARMM general force field:
A force field for drug-like molecules compatible with the CHARMM all-atom additive
biological force fields. J. Comput. Chem. 2009, in press.
[109] Spiegel, K.; Magistrato, A.; Maurer, P.; Ruggerone, P.; Rothlisberger, U.; Carloni, P.; Reed-
ijk, J.; Klein, M. L. Parameterization of azole-bridged dinuclear platinum anticancer drugs
via a QM/MM force matching procedure. J. Comput. Chem. 2007, 29, 38–49.
[110] Sugiyama, A.; Takamatsu, Y.; Nishikawa, K.; Nagao, H.; Nishikawa, K. Docking stability
and electronic structure of azurin-cytochrome c551 complex system. Int. J. Quantum Chem.
2006, 106, 3071–3078.
[111] Dykstra, C. E. Electrostatic interaction potentials in molecular-force fields. Chem. Rev. 1993,
93, 2339–2353.
[112] Narayszabo, G.; Ferenczy, G. G. Molecular electrostatics. Chem. Rev. 1995, 95, 829–847.
[113] Engkvist, O.; Astrand, P. O.; Karlstrom, G. Accurate intermolecular potentials obtained from
molecular wave functions: Bridging the gap between quantum chemistry and molecular
simulations. Chem. Rev. 2000, 100, 4087–4108.
[114] Dardenne, L. E.; Werneck, A. S.; Neto, M. D.; Bisch, P. M. Electrostatic properties in the
catalytic site of papain: A possible regulatory mechanism for the reactivity of the ion pair.
Proteins 2003, 52, 236–253.
[115] Werneck, A. S.; Filho, T. M. R.; Dardenne, L. E. General methodology to optimize damp-
ing functions to account for charge penetration effects in electrostatic calculations using
multicentered multipolar expansions. J. Phys. Chem. A 2008, 112, 268–280.
[116] Cho, A. E.; Guallar, V.; Berne, B. J.; Friesner, R. Importance of accurate charges in molecular
34
38
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
docking: Quantum mechanical/molecular mechanical (QM/MM) approach. J. Comput. Chem.
2005, 26, 915–931.
[117] Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J. M.; DuHadaway, J. B.; Malachowski, W. P.;
Prendergast, G. C.; Muller, A. J. Structure based development of phenylimidazole-derived
inhibitors of indoleamine 2,3-dioxygenase. J. Med. Chem. 2008, 51, 4968–4977.
[118] Mobley, D. L.; Dumont, E.; Chodera, J. D.; Dill, K. A. Comparison of charge models for
fixed-charge force fields: Small-molecule hydration free energies in explicit solvent. J. Phys.
Chem. B 2007, 111, 2242–2254.
[119] Jakalian, A.; Bush, B. L.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality
atomic Charges. AM1-BCC model: I. Method. J. Comput. Chem. 2000, 21, 132–146.
[120] Fischer, B.; Fukuzawa, K.; Wenzel, W. Receptor-specific scoring functions derived from
quantum chemical models improve affinity estimates for in-silico drug discovery. Proteins
2008, 70, 1264–1273.
[121] Kitaura, K.; Ikeo, E.; Asada, T.; Nakano, T.; Uebayasi, M. Fragment molecular orbital
method: an approximate computational method for large molecules. Chem. Phys. Lett. 1999,
313, 701–706.
[122] Goodsell, D. S.; Olson, A. J. Automated docking of substrates to proteins by simulated
annealing. Proteins 1990, 8, 195–202.
[123] Illingworth, C. J. R.; Morris, G. M.; Parkes, K. E. B.; Snell, C. R.; Reynolds, C. A. Assessing
the role of polarization in docking. J. Phys. Chem. A 2008, 112, 12157–12163.
[124] Wang, M. L.; Wong, C. F. Calculation of solvation free energy from quantum mechanical
charge density and continuum dielectric theory. J. Phys. Chem. A 2006, 110, 4873–4879.
[125] Gacche, R.; Khsirsagar, M.; Kamble, S.; Bandgar, B.; Dhole, N.; Shisode, K.; Chaudhari, A.
Antioxidant and anti-inflammatory related activities of selected synthetic chalcones: structure-
35
39
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
activity relationship studies using computational tools. Chem. Pharm. Bull. (Tokyo) 2008, 56,
897–901.
[126] Occhiato, E. G.; Ferrali, A.; Menchi, G.; Guarna, A.; Danza, G.; Comerci, A.; Mancina, R.;
Serio, M.; Garotta, G.; Cavalli, A.; De Vivo, M.; Recanatini, M. Synthesis, biological
activity, and three-dimensional quantitative structure-activity relationship model for a series
of benzo[c]quinolizin-3-ones, nonsteroidal inhibitors of human steroid 5 α-reductase 1. J.
Med. Chem. 2004, 47, 3546–3560.
[127] Lepp, Z.; Chuman, H. Connecting traditional QSAR and molecular simulations of papain
hydrolysis - importance of charge transfer. Bioorg. Med. Chem. 2005, 13, 3093–3105.
[128] Wan, J.; Zhang, L.; Yang, G. F.; Zhan, C. G. Quantitative structure-activity relationship
for cyclic imide derivatives of protoporphyrinogen oxidase inhibitors: A study of quantum
chemical descriptors from density functional theory. J. Chem. Inf. Comput. Sci. 2004, 44,
2099–2105.
[129] Yamagami, C.; Motohashi, N.; Akamatsu, M. Quantum chemical- and 3-D-QSAR (CoMFA)
studies of benzalacetones and 1,1,1-trifluoro-4-phenyl-3-buten-2-ones. Bioorg. Med. Chem.
Lett. 2002, 12, 2281–2285.
[130] Singh, P. P.; Srivastava, H. K.; Pasha, F. A. DFT-based QSAR study of testosterone and its
derivatives. Bioorg. Med. Chem. 2004, 12, 171–177.
[131] Pasha, F. A.; Muddassar, M.; Jung, H.; Yang, B.; Lee, C.; Oh, J. S.; Cho, S. J.; Cho, H. QM
and pharmacophore based 3D-QSAR of MK886 analogues against mPGES-1. Bull. Korean
Chem. Soc. 2008, 29, 647–655.
[132] Good, A. C.; So, S. S.; Richards, W. G. Structure-activity-relationships from molecular
similarity-matrices. J. Med. Chem. 1993, 36, 433–438.
36
40
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[133] Malde, A.; Khedkar, S.; Coutinho, E.; Saran, A. Geometry, transition states, and vibrational
spectra of boron isostere of N-methylacetamide by ab initio calculations. Int. J. Quantum
Chem. 2005, 102, 734–742.
[134] Malde, A. K.; Khedkar, S. A.; Coutinho, E. C. Stationary points on the PES of N-methoxy
peptides and their boron isosteres: An ab initio study. J. Chem. Theory Comput. 2006, 2,
1664–1674.
[135] Malde, A. K.; Khedkar, S. A.; Coutinho, E. C. Isosteres of peptides: boron analogs as dipolar
forms of alpha-amino acids - a theoretical study. J. Phys. Org. Chem. 2007, 20, 151–160.
[136] Malde, A. K.; Khedkar, S. A.; Coutinho, E. C. The B(OH)–NH analog is a surrogate for the
amide bond (CO–NH) in peptides: An ab initio study. J. Chem. Theory Comput. 2007, 3,
619–627.
[137] Carbó, R.; Besalu, E.; Amat, L.; Fradera, X. Quantum molecular similarity measures (QMSM)
as a natural way leading towards a theoretical foundation of quantitative structure-properties
relationships (QSPR). J. Math. Chem. 1995, 18, 237–246.
[138] Fradera, X.; Amat, L.; Besalu, E.; Carbó-Dorca, R. Application of molecular quantum
similarity to QSAR. Quantitative Structure-Activity Relationships 1997, 16, 25–32.
[139] Lobato, M.; Amat, L.; Besalu, E.; Carbó-Dorca, R. Structure-activity relationships of a
steroid family using quantum similarity measures and topological quantum similarity indices.
Quantitative Structure-Activity Relationships 1997, 16, 465–472.
[140] Amat, L.; Robert, D.; Besalu, E.; Carbó-Dorca, R. Molecular quantum similarity measures
tuned 3D QSAR: An antitumoral family validation study. J. Chem. Inf. Comput. Sci. 1998,
38, 624–631.
[141] Besalu, E.; Girones, X.; Amat, L.; Carbó-Dorca, R. Molecular quantum similarity and the
fundamentals of QSAR. Acc. Chem. Res. 2002, 35, 289–295.
37
41
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[142] Bultinck, P.; Carbó-Dorca, R.; Van Alsenoy, C. Quality of approximate electron densities
and internal consistency of molecular alignment algorithms in molecular quantum similarity.
J. Chem. Inf. Comput. Sci. 2003, 43, 1208–1217.
[143] Bultinck, P.; Kuppens, T.; Girone, X.; Carbó-Dorca, R. Quantum similarity superposition
algorithm (QSSA): A consistent scheme for molecular alignment and molecular similarity
based on quantum chemistry. J. Chem. Inf. Comput. Sci. 2003, 43, 1143–1150.
[144] Girones, X.; Carbó-Dorca, R.; Ponec, R. Molecular basis of LFER. Modeling of the electronic
substituent effect using fragment quantum self-similarity measures. J. Chem. Inf. Comput.
Sci. 2003, 43, 2033–2038.
[145] Constans, P.; Carbó, R. Atomic shell approximation - electron-density fitting algorithm
restricting coefficients to positive values. J. Chem. Inf. Comput. Sci. 1995, 35, 1046–1053.
[146] Amat, L.; Carbó-Dorca, R. Quantum similarity measures under atomic shell approximation:
First order density fitting using elementary Jacobi rotations. J. Comput. Chem. 1997, 18,
2023–2039.
[147] Constans, P.; Amat, L.; Carbó-Dorca, R. Toward a global maximization of the molecular
similarity function: Superposition of two molecules. J. Comput. Chem. 1997, 18, 826–846.
[148] Gallegos, A.; Robert, D.; Girones, X.; Carbó-Dorca, R. Structure-toxicity relationships of
polycyclic aromatic hydrocarbons using molecular quantum similarity. J. Comput. Aided
Mol. Des. 2001, 15, 67–80.
[149] Girones, X.; Carbó-Dorca, R. Modelling toxicity using molecular quantum similarity mea-
sures. QSAR Comb. Sci. 2006, 25, 579–589.
[150] Girones, X.; Ponec, R. Molecular quantum similarity measures from Fermi hole densities:
Modeling Hammett sigma constants. J. Chem. Inf. Model. 2006, 46, 1388–1393.
38
42
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[151] Bultinck, P.; Carbó-Dorca, R. Molecular quantum similarity matrix based clustering of
molecules using dendrograms. J. Chem. Inf. Comput. Sci. 2003, 43, 170–177.
[152] O’Brien, S. E.; Popelier, P. L. A. Quantum molecular similarity. 3. QTMS descriptors. J.
Chem. Inf. Comput. Sci. 2001, 41, 764–775.
[153] Popelier, P. L. A. Quantum molecular similarity. 1. BCP space. J. Phys. Chem. A 1999, 103,
2883–2890.
[154] O’Brien, S. E.; Popelier, P. L. A. Quantum molecular similarity. Part 2: The relation between
properties in BCP space and bond length. Canadian Journal of Chemistry-Revue Canadienne
De Chimie 1999, 77, 28–36.
[155] Chaudry, U. A.; Popelier, P. L. A. Estimation of pK(a) using quantum topological molecular
similarity descriptors: Application to carboxylic acids, anilines and phenols. J. Org. Chem.
2004, 69, 233–241.
[156] Esteki, M.; Hemmateenejad, B.; Khayamian, T.; Mohajeri, A. Multi-way analysis of quantum
topological molecular similarity descriptors for modeling acidity constant of some phenolic
compounds. Chem. Biol. Drug Des. 2007, 70, 413–423.
[157] Singh, N.; Loader, R. J.; O’Malley, P. J.; Popelier, P. L. A. Computation of relative bond
dissociation enthalpies (Delta BDE) of phenolic antioxidants from quantum topological
molecular similarity (QTMS). J. Phys. Chem. A 2006, 110, 6498–6503.
[158] Hemmateenejad, B.; Mohajeri, A. Application of quantum topological molecular similarity
descriptors in QSPR study of the O-methylation of substituted phenols. J. Comput. Chem.
2008, 29, 266–274.
[159] von Lilienfeld, O. A.; Lins, R. D.; Rothlisberger, U. Variational particle number approach for
rational compound design. Phys. Rev. Lett. 2005, 95, Doi 10.1103.
39
43
Current Topics in Medicinal Chemistry Volume 10, Number 1, January 2010 , pp. 33–45
[160] von Lilienfeld, O. A.; Tuckerman, M. E. Molecular grand-canonical ensemble density
functional theory and exploration of chemical space. J. Chem. Phys. 2006, 125, 154104–
154113.
[161] Keinan, S.; Hu, X. Q.; Beratan, D. N.; Yang, W. T. Designing molecules with optimal proper-
ties using the linear combination of atomic potentials approach in an AM1 semiempirical
framework. J. Phys. Chem. A 2007, 111, 176–181.
[162] von Lilienfeld, O. A.; Tuckerman, M. E. Alchemical variations of intermolecular energies
according to molecular grand-canonical ensemble density functional theory. J. Chem. Theory
Comput. 2007, 3, 1083–1090.
[163] Balamurugan, D.; Yang, W. T.; Beratan, D. N. Exploring chemical space with discrete,
gradient, and hybrid optimization methods. J. Chem. Phys. 2008, 129, 174105–174113.
[164] Hu, X. Q.; Beratan, D. N.; Yang, W. T. A gradient-directed Monte Carlo approach to
molecular design. J. Chem. Phys. 2008, 129, 64102–64110.
[165] Keinan, S.; Paquette, W. D.; Skoko, J. J.; Beratan, D. N.; Yang, W. T.; Shinde, S.; John-
ston, P. A.; Lazo, J. S.; Wipf, P. Computational design, synthesis and biological evaluation
of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase
Cdc25B. Org. Biomol. Chem. 2008, 6, 3256–3263.
[166] Keinan, S.; Therien, M. J.; Beratan, D. N.; Yang, W. T. Molecular design of porphyrin-based
nonlinear optical materials. J. Phys. Chem. A 2008, 112, 12203–12207.
[167] Wang, M. L.; Hu, X. Q.; Beratan, D. N.; Yang, W. T. Designing molecules by optimizing
potentials. J. Am. Chem. Soc. 2006, 128, 3228–3232.
[168] Huang, D.; Caflisch, A. Library screening by fragment-based docking. J. Molec. Recogn.
2009, in press.
40
44
Chapter 2
Is Quantum Mechanics Necessary for
Predicting Binding Free Energy?
Zhou, T.; Huang, D.; Caflisch A. J. Med. Chem. 2008, 51 (14), 4280–4288
45
Is Quantum Mechanics Necessary for Predicting Binding Free Energy?
Ting Zhou, Danzhi Huang,* and Amedeo Caflisch*
Department of Biochemistry, UniVersity of Zu¨rich, Winterthurerstrasse 190, CH-8057 Zu¨rich, Switzerland
ReceiVed March 6, 2008
To take into account polarization effects, the linear interaction energy model with continuum electrostatic
solvation (LIECE) is supplemented by the linear-scaling semiempirical quantum mechanical calculation of
the intermolecular electrostatic energy (QMLIECE). QMLIECE and LIECE are compared on three enzymes
belonging to different classes: the West Nile virus NS3 serine protease (WNV PR), the aspartic protease of
the human immunodeficiency virus (HIV-1 PR), and the human cyclin-dependent kinase 2 (CDK2).
QMLIECE is superior for 44 peptidic inhibitors of WNV PR because of the different amount of polarization
due to the broad range of formal charges of the inhibitors (from 0 to 3). On the other hand, QMLIECE and
LIECE show similar accuracy for 24 peptidic inhibitors of HIV-1 PR (20 neutral and 4 with one formal
charge) and for 73 CDK2 inhibitors (all neutral). These results indicate that quantum mechanics is essential
when the inhibitor/protein complexes have highly variable charge-charge interactions.
1. Introduction
Accurate methods for computing the binding affinity between
small molecules and proteins are needed for drug discovery and
design.1 Approaches based on ab initio quantum mechanics (QM)
are rigorous but slow for the studies of macromolecules of
biological interest. In order to accelerate QM calculations the hybrid
QM/molecular mechanics method2,3 has been developed for the
study of enzyme catalysis.4–7 In addition linear-scaling QM
approaches8–11 have also been applied extensively for the evaluation
of binding affinity between small molecules and proteins.12,13
Because of their first principle nature, both the time-consuming
ab initio methods14 and fast semiempirical methods15,16 do not
suffer of the approximation inherent to the ball-spring description
and the fix-charge approach used in the force field method. Raha
and Merz17 developed a semiempirical/linearly scaling QM-based
scoring function and studied the ion-mediated ligand binding
processes. They pointed out that QM is needed for metal-containing
system because the ill-defined atom types of metal atoms in most
of the force field parameters cannot describe the nature of the
interactions between a small molecule and a metal ion in the active
site. Nevertheless, even with the fast semiempirical/linearly scaling
methods, QM approaches are still time-consuming compared with
force field based methods especially for high throughput docking.18,19
Moreover, most of the QM methods significantly underestimate
the weak London dispersion forces which require highly correlated
theoretical levels and large basis sets.20 These weak forces,
however, play a major role in the hydrophobic effect, molecular
recognition, and ligand binding.21–23 Therefore, it is important to
find an optimal compromise between accuracy and efficiency in
binding affinity calculation for high-throughput docking campaigns
of multimillion library of compounds.
Recently, the linear interaction energy model with continuum
electrostatic solvation (LIECEa)24 has been successfully applied
in high-throughput docking resulting in the discovery of
inhibitors of proteases25,26 and kinases.27 LIECE is about 2
orders of magnitude faster than the original LIE28–30 method
because molecular dynamics (MD) sampling is replaced by a
simple energy minimization. In this paper, LIECE is further
improved by using a linearly scaling semiempirical QM method9
to calculate the electrostatic interaction energy between the
ligand and the protein, and the new approach is termed
* To whom correspondence should be addressed. (D.H.) Phone: (+41
44) 635 55 21. Fax: (+41 44) 635 68 62. E-mail: huang@bioc.uzh.ch. (A.C.)
Phone: (+41 44) 635 55 21. Fax: (+41 44) 635 68 62. E-mail:
caflisch@bioc.uzh.ch.
a Abbreviations: LIECE, linear interaction energy model with continuum
electrostatic solvation; QMLIECE, quantum mechanical linear interaction
energy model with continuum electrostatic solvation; CDK2, cyclin-
dependent kinase 2; HIV-1 PR, human immunodeficiency virus protease;
WNV PR, West Nile virus NS3 serine protease.
Figure 1. Divide and conquer protocol9 for calculation of quantum
mechanical interaction energy between a protein and a small molecule
(ligand). The interaction energy between a protein with m residues and
the ligand is decomposed into
where Ni and Ci are N-terminal and C-terminal cap, respectively, of
residue Ai. The fragments with blue names are protein residues with
conjugate caps,10 while the ones with red names are pure “caps” that
have to be subtracted to remove the duplication in energy calculation.
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QMLIECE. The LIECE and QMLIECE models are tested on
three enzyme/inhibitor systems: the West Nile virus NS3
protease (WNV PR, a serine protease), the HIV-1 protease
(HIV-1 PR, an aspartic protease), and the human cyclin-
dependent kinase 2 (CDK2). Because of the large variability
of charge-charge interactions in the complexes of WNV PR
with the 44 peptidic inhibitors (having between 0 and 3
positively charged side chains), the use of QM is necessary to
capture polarization effects,31,32 which are neglected in fixed-
charge approximation of force field based methods. On the other
hand, QM and force field methods show similar accuracy for
the binding affinity evaluation of mainly neutral inhibitors of
HIV-1 PR and CDK2.
2. Method
Preparation of WNV NS3-NS2B Protease. The coordinates
of WNV PR in complex with the substrate-based inhibitor
benzoyl-norleucine-lysine-arginine-arginine-aldehyde (Bz-Nle-
Lys-Arg-Arg-H) were downloaded from the PDB database (PDB
entry 2FP7).33 All water molecules were removed. The spurious
termini at the segments missing in the X-ray structure (residues
28-32 in chain B) were neutralized by a -COCH3 and a
-NHCH3 group at the N-terminus and C-terminus, respectively.
The 44 peptidic inhibitors of WNV PR used in this study include
Bz-Nle-Lys-Arg-Arg-H (IC50 ) 4.1 μM) and a series of 43
related inhibitors with an aldehyde warhead (IC50 values ranging
from 0.4 to 463 μM) synthesized in the same laboratory and
tested all with the same enzymatic assay (Table 1).34–36 The
initial binding conformations were modeled manually according
to the binding mode of Bz-Nle-Lys-Arg-Arg-H because all
inhibitors have similar backbone structure and are covalently
bound to the Ser135 side chain by an ester linkage.
For interaction energy calculation, the ester bond between
protein and inhibitor and the adjacent -OH group of Ser135
and -C(H)OH group of inhibitor were removed to avoid the
artificial crash. The resulting empty valencies on both protein
and inhibitors were filled with hydrogen atoms.
Preparation of HIV-1 PR and CDK2. The coordinates of
the 24 complexes of HIV-1 PR (PDB code 1AAQ) with the
inhibitors tested by Dreyer and co-workers37 were available from
a previous study.24 The coordinates of the 73 complexes of
Table 1. 44 Peptidic Inhibitors of WNV PR Tested at the Novartis
Institute for Tropical Diseases34–36,a
ID structure
no. of
formal
charges
IC50
(μm)
ΔG
(kcal/mol)
1 Bz-Nle-Lys-Arg-Arg-H 3 4.1 -7.39
2 Bz-Nle-Lys-Lys(Z)-Arg-H 2 99.5 -5.49
3 Bz-Nle-Lys-Gln-Arg-H 2 1.7 -7.90
4 Bz-Nle-Lys-Lys-Arg-H 3 1.9 -7.86
5 Ac-Lys-Lys-Arg-H 3 0.4 -8.84
6 Bz-Lys-Arg-Arg-H 3 1.5 -7.99
7 Bz-Lys-Lys(Tos)-Arg-H 2 117.9 -5.39
8 Ac-Lys-Lys(Tos)-Arg-H 2 463.4 -4.58
9 Ac-Lys-Lys(Bz)-Arg-H 2 116.5 -5.40
10 Bz-Lys-(p-Me)Phe-Arg-H 2 194.3 -5.09
11 Bz-Lys-Lys(Bz)-Arg-H 2 68.1 -5.72
12 indole-Lys-Arg-Arg-H 3 2.4 -7.72
13 Bz-Lys-Asn-Arg-H 2 71.8 -5.69
14 Bz-Nle-Ala-Arg-Arg-H 2 3.8 -7.44
15 Bz-Ala-Lys-Arg-Arg-H 3 0.7 -8.45
16 Bz-Nle-Lys-Arg-Phe-H 2 109.8 -5.43
17 Bz-Nle-Lys-Phe-Arg-H 2 108.0 -5.44
18 Bz-Nle-Phe-Arg-Arg-H 2 4.2 -7.38
19 Bz-Phe-Lys-Arg-Arg-H 3 1.2 -8.14
20 Bz-Lys-Arg-Tyr-H 2 14.6 -6.64
21 Ac-KRR-H 3 0.5 -8.60
22 pyridine-KRR-H 3 0.8 -8.40
23 isoquinoline-KRR-H 3 0.6 -8.56
24 pyrazine-Lys-Arg-Arg-H 3 1.1 -8.18
25 3-pyridyl-KRR-H 3 1.0 -8.24
26 Bzl-Nle-Lys-Arg-(4-CN)-Phe-H 2 62.0 -5.77
27 Bzl-Nle-Lys-Arg-Trp-H 2 10.0 -6.86
28 Bz-Nle-Lys-Arg-Lys-H 3 57.7 -5.82
29 BZ-Nle-Lys-Arg-
(4-guanidinyl)-Phe-H
3 11.8 -6.76
30 Bz-Nle-Lys-Arg-His-H 2 43.1 -5.99
31 Bz-Nle-Lys-Arg-Phg-H 2 90.9 -5.55
32 Bz-Arg-Arg-H 2 3.9 -7.42
33 Bz-Lys(Z)-Arg-H 1 436.3 -4.61
34 Bz-Lys-Arg-H 2 1.4 -8.03
35 Bz-Arg-Lys-H 2 57.5 -5.82
36 Bz-Lys(Z)-(2-napthyl)Ala-H 0 15.9 -6.59
37 Bz-Lys(Z)-Tyr(Bn)-H 0 17.2 -6.54
38 Bz-Tyr(Bn)-(p-Me)Ph-H 0 12.7 -6.72
39 Bz-Lys(Z)-(p-NH-1-
isoquinoline)Phe-H
0 18.0 -6.51
40 Bz-Lys(Z)-(p-NH-1-indole)Phe-H 0 38.2 -6.06
41 Bz-Lys-Lys(Z)-(p-Me)Phe-H 1 43.3 -5.99
42 Bz-Lys-Arg-Phe-H 2 71.1 -5.69
43 Bz-Lys-Arg-(P-Me)Phe-H 2 17.7 -6.52
44 Bz-Lys-Arg-Tyr(Bn)-H 2 11.8 -6.76
a Weakest and strongest affinities are in bold.
Table 2. Energy Components for WNV PR Peptidic Inhibitors34–36,a
ID ΔEvdW ΔEelec,coul ΔEQM ΔGsolvation no. of formal charges
1 -45.2 -898.0 -856.8 846.9 3
2 -53.2 -603.1 -511.1 608.9 2
3 -41.1 -601.1 -516.6 566.1 2
4 -40.9 -880.5 -874.2 840.1 3
5 -38.4 -926.0 -950.3 883.2 3
6 -41.2 -899.4 -860.7 842.0 3
7 -46.3 -621.8 -530.3 616.5 2
8 -45.8 -617.6 -530.2 616.0 2
9 -48.3 -593.8 -513.1 601.3 2
10 -43.7 -583.8 -511.5 558.0 2
11 -47.2 -596.7 -503.7 595.3 2
12 -36.9 -881.8 -874.0 839.0 3
13 -35.7 -589.4 -506.0 556.0 2
14 -46.3 -620.5 -530.6 565.0 2
15 -44.9 -898.5 -862.2 845.9 3
16 -54.2 -654.5 -565.1 621.2 2
17 -43.5 -580.6 -510.4 556.6 2
18 -53.9 -623.6 -531.1 568.3 2
19 -45.9 -898.1 -860.2 846.0 3
20 -52.8 -657.1 -565.0 616.9 2
21 -39.3 -898.7 -869.7 847.2 3
22 -40.9 -905.7 -870.4 847.6 3
23 -41.0 -904.3 -868.3 847.8 3
24 -40.4 -900.4 -862.9 842.5 3
25 -40.9 -901.8 -866.5 845.4 3
26 -52.3 -661.8 -573.2 623.1 2
27 -56.4 -650.8 -559.7 619.0 2
28 -45.8 -950.8 -870.4 906.6 3
29 -47.7 -903.9 -851.7 867.8 3
30 -50.3 -656.0 -554.7 619.3 2
31 -52.6 -660.0 -556.5 629.5 2
32 -41.7 -628.0 -539.2 565.0 2
33 -49.7 -362.3 -269.2 357.1 1
34 -36.1 -649.8 -566.5 595.6 2
35 -37.3 -672.9 -566.3 615.7 2
36 -52.9 -111.5 -34.2 116.3 0
37 -59.6 -113.0 -35.4 121.3 0
38 -54.0 -70.9 -11.6 81.1 0
39 -58.0 -124.5 -44.2 136.4 0
40 -58.8 -121.4 -43.4 124.4 0
41 -60.1 -350.5 -260.1 347.3 1
42 -48.4 -654.1 -553.8 621.3 2
43 -47.1 -651.3 -552.4 616.2 2
44 -49.5 -653.5 -547.7 616.3 2
a All energy values are in kcal ·mol-1.
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CDK2 (PDB code 1KE5) with the inhibitors published by
Bramson38 and Gibson39 were also available from a previous
study.27
Minimization. Standard protonation states at neutral pH were
used for all ionizable side chains (i.e., neutral His, positively
charged Arg and Lys, and negatively charged Asp and Glu)
except for one of the two carboxy groups in the Asp catalytic
dyad of HIV-1 PR.24 The net charge of WNV PR, HIV-1 PR,
and CDK2 is -10, +7, and +5, respectively. Hydrogen atoms
were added to all structures and minimized with the program
CHARMM40 and the CHARMm22 force field41 (Accelrys Inc.).
Partial charges were assigned using the MPEOE method.42,43
The WNV PR protein/inhibitor complexes were minimized with
a two-step protocol. First, the inhibitors were minimized by 200
iterations of the steepest descent algorithm with rigid protein.
The second step consisted of 10 000 iterations of the adopted
basis Newton-Raphson algorithm to an rms of the gradient of
0.001 kcal mol-1 Å-1 with flexible protein but using harmonic
restraints on all carbon atoms of protein and inhibitor. The value
of the force constants was gradually decreased from 20 to 1
kcal mol-1 Å2. In the first minimization the electrostatic energy
term was screened by a distance-dependent dielectric function
(ε(r) ) 4r), and the default nonbonding cutoff of 14 Å was
used. In the second minimization the Coulombic energy
(constant dielectric of 1.0) was evaluated without truncation.
The distance-dependent dielectric in the first minimization and
the harmonic restraints on carbon atoms in the second minimi-
zation were applied to prevent artificial deviations due to vacuum
effects. The second step of the minimization protocol with
vacuum dielectric yields optimal QMLIECE model. Several
optimization protocols were tested, and it was found that
QMLIECE always outperforms LIECE model for WNV PR,
irrespective of the protocol (see Supporting Information). Ideally,
one should minimize the sum of van der Waals and QM energy
contributions. However, optimization using QM, even with
linear-scaling techniques, is still computationally too costly for
enzyme/ligand complexes.44 For HIV-1 PR and CDK2 com-
plexes, the inhibitors were optimized by 200 iterations of the
Table 3. Energy Components of HIV-1 PR Peptidic Inhibitors37,a
ID ΔEvdW ΔEelec,coul ΔEQM ΔGsolvation no. of formal chargesb
1 -58.4 -22.3 -14.6 58.4 0
2 -61.2 -21.2 -14.9 61.3 0
3 -66.6 -18.1 -12.3 62.2 0
4 -64.9 -19.2 -8.7 62.4 0
5 -71.0 -21.2 -15.5 66.0 0
6 -64.6 -31.4 -21.3 74.5 0
7 -67.4 -29.4 -21.5 76.8 0
8 -72.4 -26.1 -20.3 79.2 0
9 -72.1 -24.6 -17.5 81.8 0
10 -77.5 -26.9 -23.4 86.1 0
11 -73.2 -27.5 -25.1 99.2 0
12 -76.2 -24.3 -25.8 102.7 0
13 -80.7 -22.5 -23.8 103.4 0
14 -80.4 -18.8 -16.4 105.6 0
15 -81.2 -22.9 -17.1 100.3 0
16 -75.4 -14.4 -29.3 129.2 0
17 -78.5 -12.2 -30.3 133.0 0
18 -82.6 -10.4 -27.5 133.7 0
19 -82.4 -7.5 -20.2 135.5 0
20 -83.2 -11.9 -21.0 132.5 0
21 -69.1 -56.2 -38.2 69.3 1
22 -71.7 -50.5 -34.3 71.8 1
23 -76.0 -46.2 -29.0 73.7 1
24 -76.2 -60.4 -32.1 64.2 1
a All energy values are in kcal ·mol-1. b Neutral blocking group or
positive charge on unblocked N-terminal amino group of inhibitors 21-24.
The C-terminal group is neutral; it is -NH2 or -O-Me for inhibitors 1-10
or 11-24, respectively.
Table 4. Energy Components of the CDK2 Inhibitorsa
ID ΔEvdW ΔEelec,coul ΔEQM ΔGsolvation
1 -24.5 -10.1 -8.3 36.0
2 -26.5 -10.2 -9.2 30.1
3 -28.2 -9.4 -9.2 32.1
4 -24.2 -11.0 -8.7 35.0
5 -26.7 -10.9 -10.0 34.7
6 -28.5 -8.7 -7.2 34.1
7 -28.9 -9.7 -4.5 28.6
8 -28.8 -8.1 -4.5 35.1
9 -22.3 -9.2 -7.9 29.5
10 -28.3 -10.4 -10.4 39.5
11 -23.2 -10.1 -8.5 35.7
12 -26.6 -11.1 -9.0 36.1
13 -28.5 -11.3 -6.2 33.6
14 -30.6 -8.8 -8.2 39.3
15 -31.2 -13.7 -15.9 46.2
16 -29.7 -10.5 -9.2 37.0
17 -29.3 -10.3 -12.0 40.4
18 -31.2 -9.9 -7.8 37.9
19 -29.9 -10.1 -10.4 39.0
20 -31.7 -1.5 2.1 35.3
21 -34.6 -11.3 -11.1 52.3
22 -31.3 -5.8 -4.2 31.2
23 -32.9 -14.0 -15.9 59.3
24 -39.3 -27.0 -21.8 54.3
25 -43.8 -26.6 -21.0 55.3
26 -43.6 -27.1 -22.9 56.2
27 -46.2 -26.4 -22.6 59.7
28 -47.3 -25.7 -21.0 63.1
29 -46.4 -27.3 -24.1 64.4
30 -44.3 -28.0 -24.4 64.7
31 -46.5 -29.1 -25.2 69.0
32 -48.9 -18.2 -19.3 66.3
33 -51.3 -32.7 -28.9 71.8
34 -51.8 -28.6 -27.4 69.7
35 -46.0 -27.2 -19.6 60.6
36 -42.7 -26.1 -21.9 53.8
37 -38.9 -26.0 -20.3 58.2
38 -40.0 -20.5 -19.2 59.1
39 -40.7 -20.4 -18.8 61.8
40 -42.2 -20.4 -17.8 59.3
41 -40.1 -21.8 -20.7 56.9
42 -39.4 -37.7 -27.4 63.1
43 -38.8 -17.4 -12.1 53.2
44 -39.9 -33.7 -25.8 61.5
45 -38.6 -30.8 -24.5 57.8
46 -41.4 -37.4 -26.7 79.1
47 -40.9 -41.9 -33.4 81.1
48 -41.9 -28.9 -28.7 67.5
49 -45.2 -33.3 -30.8 79.3
50 -50.9 -35.3 -22.4 80.8
51 -50.9 -40.9 -26.7 85.3
52 -44.3 -20.2 -23.3 66.6
53 -39.5 -25.8 -20.7 59.4
54 -42.9 -22.7 -16.1 52.8
55 -36.8 -17.6 -22.0 64.9
56 -42.0 -18.0 -19.3 58.0
57 -41.3 -15.5 -12.0 55.9
58 -41.5 -32.4 -25.6 61.1
59 -39.5 -27.1 -20.1 53.0
60 -39.6 -22.8 -15.5 50.6
61 -36.5 -23.3 -13.5 52.5
62 -40.3 -26.4 -20.1 53.2
63 -37.8 -23.3 -13.1 61.9
64 -41.6 -46.0 -31.8 71.0
65 -40.2 -24.7 -19.4 56.8
66 -40.5 -27.9 -22.2 64.2
67 -42.0 -30.2 -23.4 72.6
68 -42.4 -27.4 -26.2 65.9
69 -44.0 -29.4 -23.4 75.0
70 -47.1 -26.6 -24.8 71.7
71 -46.9 -32.9 -28.0 78.3
72 -47.8 -30.5 -28.2 83.4
73 -43.1 -31.1 -23.9 72.4
a All 73 inhibitors are nonpeptidic and devoid of formal charges.38,39
All energy values are in kcal ·mol-1.
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steepest descent algorithm followed by 10 000 iterations of the
adopted basis Newton-Raphson algorithm to an rms of the
gradient of 0.001 kcal mol-1 Å-1 with rigid protein. Because
of the predominance of the van der Waals term, which is
identical in LIECE and QMLIECE, similar fitting results for
these two complexes are obtained by minimizing with rigid
protein or harmonically restrained protein (not shown).
Energy Calculation. All QM energy values were calculated
on CHARMM-minimized structures. The vacuum interaction
energies in QMLIECE were calculated with a divide and
conquer approach9,10 (Figure 1) using MOPAC45 and the
recently developed semiempirical Hamiltonian RM1.16 The QM
energy characterizes the nonclassical charge transfer effect,
which is omitted in the fixed-charge model but can be strong if
a cation group and an anion group are closed to each other,
e.g., the positively charged side chains of Bz-Nle-Lys-Arg-
Arg-H and negatively charged sub pockets of WNV PR.34 van
der Waals interactions are fundamentally charge-charge inter-
actions consisting of attractive and repulsive interactions orig-
inating from dispersive forces and exchange forces, respectively.
The interaction energies from semiempirical QM calculations
include the repulsive part of van der Waals interaction energy
but ignore the attractive part,17 which needs highly correlated
treatments and large basis sets.46 Ideally, “pure” electrostatic
part of QM interaction energy is needed for linear combination
with van der Waals part from molecular mechanics (MM)
calculation. However, the QM interaction energy cannot be
decomposed as in classical force fields. A linear combination
of the QM and MM energy contributions is used in QMLIECE
to partially remove the double counting of the repulsive part of
van der Waals interaction. In any case, minimized complexes
have negligible repulsive interactions.
The van der Waals energy and the MM vacuum Coulombic
energy (ε(r) ) 1, infinite cutoff) were calculated using
CHARMM40 and the CHARMm41 force field with the same
protocol as in a previous publication.24
The electrostatic solvation energy was calculated by the finite-
difference Poisson approach using the PBEQ47 module in
CHARMM40 and a focusing procedure with a final grid spacing
of 0.25 Å. The size of the initial grid was determined by
considering a layer of at least 22.5 Å around the solute. The
dielectric discontinuity interface was delimited by the molecular
surface which is spanned by the surface of a rolling probe of
1.4 Å. The ionic strength was set to zero, and the temperature
was set to 300 K. Two finite-difference Poisson calculations
were performed for each of the three systems (inhibitor, protein,
inhibitor/protein complex). The exterior dielectric constant was
set to 78.5 and 1.0 for the first and second calculation,
respectively, while the solute dielectric constant was set to 1.0,
which is consistent with QM energy and parameters of the
CHARMm22 force field.
Binding Free Energy. The equations used for the fitting are
two-parameter models
ΔGbind) ΔGelesol+ΔGtr,rot,bond for WNV PR (1)
ΔGbind)RΔEvdW+ ΔGelesol for CDK2
48 (2)
and a three-parameter model
ΔGbind)RΔEvdW+ ΔGelesol+ΔGtr,rot for HIV-1 PR
24
(3)
The electrostatic contribution to the binding energy ΔGelesol
is the sum of the ligand/protein electrostatic interaction energy
in solvent (ΔGpro/ligsol ) and the change in solvation energy of ligand
and protein upon binding:49,50
ΔGelesol )ΔGprot/lig
sol -ΔGprot
solvation-ΔGlig
solvation
)ΔGprot/lig
vacuo +ΔGprot/lig
solvation-ΔGprot
solvation-ΔGlig
solvation
)ΔGprot/lig
vacuo +ΔGsolvation
(4)
For the vacuum electrostatic interaction energyΔGprot/ligvacuo , QM
(ΔEQM in Table 2–4) and MM (ΔEelec,coul) calculations were
used in QMLIECE and LIECE, respectively. Note that ΔEQM
could be further decomposed into electrostatic and explicit
polarization energy terms,31,32 but such decomposition would
require additional fitting parameters. The finite-difference Pois-
son approach was used to calculate the solvation energy changes
upon binding (ΔGsolvation). Details are given in the Supporting
Information.
Table 5. QMLIECE and LIECE Modelsa
leave-one-out cross-valid
R  ΔGtr,rot,bond (kcal ·mol-1) rms error (kcal ·mol-1) q2 rms error on test setb (kcal ·mol-1)
WNV PR (44 Peptidic Inhibitors with 0 e Q e 3)
ΔGQM_elesol + ΔGtr,rot,bond 0.022 -7.6 0.67 0.65
standard deviation (0.003 (0.2
ΔGMM_elesol + ΔGtr,rot,bond 0.032 -5.7 0.91 0.35
standard deviation (0.006 (0.3
WNV PR (37 Peptidic Inhibitors with 2 e Q e 3)
ΔGQM_elesol + ΔGtr,rot,bond 0.024 -7.6 0.64 0.70
standard deviation (0.004 (0.2
ΔGMM_elesol + ΔGtr,rot,bond 0.048 -5.0 0.84 0.49
standard deviation (0.009 (0.4
HIV-1 PR (24 Peptidic Inhibitors)
RΔEvdW + ΔGQM_elesol+ΔGtr,rot 0.350 0.067 8.3 0.64 0.80 1.15
standard deviation (0.063 (0.025 (2.8
RΔEvdW + ΔGMM_elesol + ΔGtr,rot 0.299 0.032 7.9 0.67 0.78 1.30
standard deviation (0.048 (0.013 (2.8
CDK2 (Nonpeptidic Inhibitors)
RΔEvdW + ΔGQM_elesol 0.241 0.002c 0.99 0.79
standard deviation (0.022 (0.022c
RΔEvdW + ΔGMM_elesol 0.265 0.029 0.98 0.79
standard deviation (0.018 (0.020
a For each set of enzyme/inhibitor complexes the QMLIECE and LIECE models differ only in ΔGQM_elesol and ΔGMM_elesol, respectively (see Methods).
b The test set was not used to derive the model. It contains five HIV-1 PR inhibitors with Ki values of 0.05, 0.38, 3.2, 437, and 1100 nM. c Parameters with
leave-one-out standard deviation larger than the average value are statistically not significant and are given in italics.
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The term ΔEvdW is the ligand/protein van der Waals interac-
tion energy. Since the semiempirical QM calculation does not
take into account the attractive part of the van der Waals energy,
the van der Waals interaction energy of the force field is still
used in QMLIECE.
The constant term ΔGtr,rot,bond accounts for the loss of
translational and rotational degrees of freedom upon binding
and the energy of formation of the covalent bond for the 44
aldehyde inhibitors of WNV PR. The entropic penalty due to
loss of translational and rotational degrees of freedom (ΔGtr,rot)
is unfavorable and therefore positive, but its sum with the
covalent bond energy can also be negative.
For WNV PR (eq 1), ΔEvdW was neglected because the
statistical significance of the fitting deteriorates (see Supporting
Information). The same is observed upon addition of ΔGtr,rot in
the CDK2 models, which is consistent with the significantly
smaller flexibility of the nonpeptidic inhibitors of CDK2 than
the peptidic inhibitors of WNV PR and HIV-1 PR.
3. Results and Discussion
The energy values and the parameters obtained by least-
squares fitting are given in Tables 2–4 and Table 5, respectively,
while the correlation between LIECE/QMLIECE binding ener-
gies and experimental values is shown in Figure 2.
WNV PR. The two-parameter QMLIECE model yields a
leave-one-out rms of the error of 0.67 kcal ·mol-1 and cross-
validated q2 of 0.65. These results are significantly better than
those obtained by LIECE (rms error of 0.91 kcal ·mol-1 and
cross-validated q2 of 0.35). As an additional test, the LIECE
and QMLIECE models were applied to a nonpeptidic inhibitor,
discovered recently in our group (Ekonomiuk et al., unpublished
results), which was not used to derive the model. The LIECE
and QMLIECE binding affinity are -5.5 and -8.6 kcal ·mol-1,
respectively, while the experimentally measured binding affinity
is -7.2 kcal ·mol-1. Since this inhibitor does not bind covalently
to the protein, the calculated binding free energy should be more
favorable than the measured value because the LIECE and
Figure 2. Comparison of the calculated (QMLIECE filled symbols, LIECE empty symbols) versus experimental binding free energies for 44
WNV PR34–36 (top left), 24 HIV-1 PR37 (top right), and 73 CDK238,39 (bottom) inhibitors. The experimental data are fitted with two-parameter
models for WNV PR (eq 1), three-parameter models for HIV-1 PR (eq 3), and two-parameter models for CDK2 (eq 2). Digit in parentheses is the
total charge of the inhibitor.
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QMLIECE models for WNV PR were derived from 44 peptidic
inhibitors covalently bound to the protein. Therefore, the
QMLIECE value is more reliable than the LIECE one.
A statistical test based on the randomization of the data points
was used to analyze an eventual chance correlation between
the QMLIECE model and the data points.25,51 The binding free
energies of the 44 peptidic inhibitors34–36 were randomly chosen
from uniformly distributed values in the same range as the
experimental values (i.e., from -8.84 to -4.58 kcal ·mol-1),
and the multiplicative parameters of ΔGelesol and ΔGtr,rot,bond
constant term were determined by fitting to random “data
points”. The rationale behind this test is that the statistical
significance of the real model is poor if there is a significant
correlation between the descriptors and the randomized data
points. The randomization and fitting were repeated 10 000
times, and Figure 3 shows the cross-validated q2 (obtained by
the leave-one-out procedure) plotted versus the correlation
coefficient. The QMLIECE model with the two parameters fitted
to the real data points is located at the top right corner and is
significantly separated from the models generated by the
randomization of the binding free energies. This separation
provides further evidence that the QMLIECE two-parameter
model not only fits the experimental data but also has very good
predictive ability, i.e., chance correlation is not present. To
further assess the significance of the QMLIECE model, the same
statistical test was performed on two naive models suggested
by an anonymous reviewer: a combination of LIECE and a
binary descriptor for distinguishing inhibitors with charge +2
from all others and a simple five-parameter model based only
on binary descriptors for the number of positive charges in the
inhibitors (Supporting Information). Interestingly, the risk of
chance correlation increases with increasing number of fitting
parameters and decreasing physical soundness. In other words,
for the QMLICE model only, there is a genuine correlation
between descriptors and data points.
HIV-1 PR. The three-parameter QMLIECE model yields an
rms of the error of 0.64 kcal ·mol-1 and a cross-validated q2 of
0.80. These results are similar to those obtained by LIECE (rms
error of 0.67 kcal ·mol-1 and a cross-validated q2 of 0.78). (Note
that the rms error of 0.67 kcal ·mol-1 is slightly smaller than in
ref 24, where it was 0.77 kcal ·mol-1, because of the different
minimization protocol.) The predictive ability of the LIECE and
QMLIECE approach was further tested on a set of five inhibitors
available from a previous work52 and not used to derive the
models. Their PDB identifiers and Ki values are the following:
1HVR, Ki ) 0.05 nM, Ki ) 0.38 nM; 1HTG, Ki ) 3.2 nM;
Figure 3. Statistical test to assess the predictive power of the
QMLIECE two-parameter model for WNV PR (cross) by comparison
with 10 000 models obtained by randomizing the activity values (dots).
The QMLIECE model is clearly separated, which indicates that
QMLIECE not only better fits the data than the random models but
also has a better predictive ability. In other words, the plot shows that
the QMLIECE model does not suffer from chance correlation.
Figure 4. Polarization of protein atoms due to inhibitor binding: WNV PR in complex with its inhibitor 1 (top left), HIV-1 PR in complex with
its inhibitor 21 (top right, only one monomer of the C2-symmetric structure of the HIV-1 PR homodimer is shown), and CDK2 in complex with
its inhibitor 24 (R-helical domain bottom left and -sheet domain bottom right). The polarized charges were calculated by subtracting SCF atomic
charges before binding from that after binding, using the divide and conquer protocol.9 The protein surfaces were rendered with the blue-white-red
spectrum according to polarized charges of atoms. The blue on the surface denotes atomic partial charges that become more positive upon binding,
while red means more negative atomic charges upon binding, and white indicates atomic charges that do not change upon binding.
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1HBV, Ki ) 437 nM; 1HVS, 5HVP, Ki ) 1100 nM.53–57 The
five inhibitors were minimized in the HIV-1 PR conformation
from the 1HVR complex because of its highest resolution (1.8
Å). The error rms for the five inhibitors of the test set is 1.30
and 1.15 kcal ·mol-1 for the LIECE and QMLIECE models,
respectively. This comparison indicates that for the 24 mainly
neutral inhibitors of HIV-1 PR the QMLIECE model is only
slightly more predictive than the LIECE model.
CDK2. The two-parameter model of QMLIECE yields an
rms of the error of 0.99 kcal ·mol-1 and a cross-validated q2 of
0.79. This accuracy is essentially identical to the one of the
LIECE model. Moreover, the electrostatic parameter of the
QMLIECE model is smaller than the standard deviation obtained
by the leave-one-out procedure, which indicates that the
QMLIECE model of CDK2 is not robust.
Applicability of QM. It is important to clarify under which
circumstance it is necessary to use QM for calculating electro-
static energy contribution in linear interaction energy models.
The advantage of QM compared with MM is that QM allows
the evaluation of charge-transfer effects by self-consistent field
(SCF) calculation. Upon inhibitor binding, the amount of
polarization of WNV PR is larger than HIV-1 PR and much
larger than CDK2 (Figure 4). As a matter of fact, for the
complexes of HIV-1 PR and CDK2 the charge-charge interac-
tions are relatively similar and small (Figure 4). Furthermore,
more than 90% of their atoms are not significantly polarized
(less than 0.001e) upon inhibitor binding (Figure 5). Therefore,
the absolute errors originating from polarization are small for
these two enzyme/inhibitor complexes, and can be rectified by
the regression parameters without leading to poor fitting. On
the other hand, the 44 peptidic inhibitors of WNV have between
zero and three positively charged side chains resulting in a large
variability of polarized charges; as a consequence, the energies
calculated by MM are significantly different from QM energies
because only the latter takes charge polarization effects into
account. This explains the better predictive ability of QMLIECE
than LIECE for the 44 inhibitors of WNV PR.
An additional test was performed to separate the effect of
total charge from charge variability. The inhibitors of WNV
PR with zero or one formal charge (7 of the 44 inhibitors) were
removed from the fitting data of two-parameter model of LIECE.
The variability of polarized charges, therefore, becomes smaller
for this subset, while the average value of polarized charges
becomes even larger. By application of leave-one-out cross-
validation to the reduced set of data (37 inhibitors), it is found
that QMLIECE does not change significantly whereas q2 of
LIECE improves from 0.35 to 0.49, Moreover, in the LIECE
model generated using only 37 inhibitors with 2 e Q e 3 the
parameter of ΔGMM_elesol increases from 0.032 to 0.048, and
the constant term ΔGtr,rot,bond changes from -5.7 to -5.0
kcal ·mol-1 (Table 5). These results indicate that the weight of
the electrostatic contribution in the LIECE regression model
increases by reducing the formal charge variability of inhibitors
despite the larger average total charge. In other words, the
neglect of polarization in LIECE results in acceptable predictive
ability for binding affinities of inhibitors with two or three formal
charges.
Therefore, if the charge-charge interactions between inhibi-
tors and protein are similar, even though the absolute values of
them are large, the fixed charge model in the force field method
can attain reasonable results for the evaluation of electrostatic
energies. Otherwise, QM is needed to more accurately evaluate
the variable influence of polarization effects on electrostatic
interactions.
Computational Requirements. The time for the QM cal-
culation is linearly related to the number of residues. For WNV
PR (187 residues), the QM calculation needs about 40 min on
an Opteron 252 (2.6 GHz). The total time required by QM-
LIECE is about 1 h for each inhibitor. The finite-difference
Poisson and QM calculations require about 900 and 50 MB
memory, respectively.
4. Conclusions
Previously the computationally expensive sampling by MD
in the linear interaction energy model had been substituted with
a simple energy minimization and continuum electrostatics
calculation (LIECE).24 QMLIECE is a further development of
LIECE, in which the force field based electrostatic part of the
inhibitor/protein interaction energy is replaced by the corre-
sponding contribution evaluated by a QM calculation at the
semiempirical RM116 level with a linear-scaling method. LIECE
and QMLIECE models are assessed on three classes of inhibitor/
enzyme complexes: 44 inhibitors of a flaviviral serine protease,
24 inhibitors of a retroviral aspartic protease, and 73 inhibitors
of the CDK2 serine/threonine protein kinase. Only for the 44
inhibitors of the serine protease, which have between zero and
three positive charges, did QMLIECE show a significant
improvement compared to LIECE. However, for the subset of
37 of the 44 inhibitors with two or three positive charges LIECE
Figure 5. Distribution of average (top) and standard deviation (bottom)
of individual polarized charges of proteins upon binding, calculated
over all inhibitors (44, 24, and 73 inhibitors for WNV PR, HIV-1 PR,
and CDK2, respectively). The polarized charges were calculated by
subtracting SCF atomic charges before binding from that after binding,
using the divide and conquer protocol.9
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was more predictive than for the full set of 44 inhibitors but
still not as robust as QMLIECE. Therefore, the comparison of
LIECE and QMLIECE indicates that the use of QM is necessary
when complexes with different inhibitors have significantly
diverse charge-charge interactions, i.e., a large variability of
polarized charges of protein atoms upon binding different
inhibitors.
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1 Robustnessuponchoiceofminimizationprotocol
QMLIECE a LIECE
1 1 1 0.55 0.30
2 3 1 0.59 0.32
3 4 2 0.53 0.06
4 5 2 0.51 0.06
5 2 1 0.46 0.12
6 5 1 0.57 0.39
7 3 3 0.48 0.31
8 3 4 0.46 0.31
9 3 5 0.45 0.32
Leave-one-out cv q2Protocol NonbondID
Minimization
parameter ID



Nonbond ID CHARMM nonbond-specification b
1 NBONDS NBXMOD 5 GROUP  SWITCH CDIE  VDW VSWI  EXTEND
GRAD QUAD CUTNB 180  WMIN 1.5  EPS 1.0
2 NBONDS NBXMOD 5 ATOM SWITCH VATOM VSWITCHED CUTNB 15.0
CTONNB 11 CTOFNB 14 EPS 1.0 E14FAC 0.5 WMIN 1.5 CDIE
3 NBONDS NBXMOD 5 ATOM SWITCH VATOM VSWITCHED CUTNB 180
EPS 1.0 E14FAC 0.5 WMIN 1.5 CDIE
4 NBONDS  ATOM  FSHIFT CDIE  VDW VSHIFT  CUTNB 180  WMIN 1.5
EPS 1.0
5 NBONDS  ATOM  FSWITCH CDIE  VDW VSHIFT CUTNB 180 WMIN 1.5
EPS 1.0 




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Minimization parameter ID CHARMM minimization commands c
1
cons harm force 20 sele (type C*) end
mini sd nstep 200
cons harm force 10 sele (type C*) end
mini abnr nstep 200
cons harm force 8 sele (type C*) end
mini abnr nstep 200
cons harm force 6 sele (type C*) end
mini abnr nstep 200
cons harm force 4 sele (type C*) end
mini abnr nstep 200
cons harm force 2 sele (type C*) end
mini abnr nstep 200
cons harm force 1 sele (type C*) end
mini abnr nstep 10000 tolgrd 0.01
2
cons harm force 20 sele (protein and (type C*) or (type O*) or (type N*)) end
mini sd nstep 200
cons harm force 10 sele (protein and (type C*) or (type O*) or (type N*)) end
mini abnr nstep 200
cons harm force 8 sele (protein and (type C*) or (type O*) or (type N*)) end
mini abnr nstep 200
cons harm force 6 sele (protein and (type C*) or (type O*) or (type N*)) end
mini abnr nstep 200
cons harm force 4 sele (protein and (type C*) or (type O*) or (type N*)) end
mini abnr nstep 200
cons harm force 2 sele (protein and (type C*) or (type O*) or (type N*)) end
mini abnr nstep 200
cons harm force 1 sele (protein and (type C*) or (type O*) or (type N*)) end
mini abnr nstep 10000 tolgrd 0.01
3
cons harm force 20 sele (type C*) end
mini sd nstep 200
cons harm force 10 sele (type C*) end
mini abnr nstep 200
cons harm force 8 sele (type C*) end
mini abnr nstep 200
cons harm force 6 sele (type C*) end
mini abnr nstep 200
cons harm force 4 sele (type C*) end
mini abnr nstep 200
cons harm force 2 sele (type C*) end
mini abnr nstep 200
cons harm force 1.1 sele (type C*) end
mini abnr nstep 10000 tolgrd 0.01
4
cons harm force 20 sele (type C*) end
mini sd nstep 200
cons harm force 10 sele (type C*) end
mini abnr nstep 200
cons harm force 8 sele (type C*) end
mini abnr nstep 200
cons harm force 6 sele (type C*) end
mini abnr nstep 200
cons harm force 4 sele (type C*) end
mini abnr nstep 200
cons harm force 2 sele (type C*) end
mini abnr nstep 200
cons harm force 1.2 sele (type C*) end
mini abnr nstep 10000 tolgrd 0.01
5
cons harm force 20 sele (type C*) end
mini sd nstep 200
cons harm force 10 sele (type C*) end
mini abnr nstep 200
cons harm force 8 sele (type C*) end
mini abnr nstep 200
cons harm force 6 sele (type C*) end
mini abnr nstep 200
cons harm force 4 sele (type C*) end
mini abnr nstep 200
cons harm force 2 sele (type C*) end
mini abnr nstep 200
cons harm force 1.3 sele (type C*) end
mini abnr nstep 10000 tolgrd 0.01

Table 1. Influence of minimization protocol on fitting results for 44 peptidic inhibitors of 
WNV PR. a These leave-one-out q2 of QMLIECE were calculated using semiempirical 
Hamiltonian PM3. We finally chose RM1 Hamiltonian because we found that RM1 is more 
sophisticated than PM3, and could attain higher fitting qualities. b The explanation of charmm 
nonbond-specification can be found at 
	
	
	 . c The explanation of 
charmm minimization commands can be found at 
	
	
	 . 
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2 ThreeparameterLIECEandQMLIECEmodels
Gtr,rot,bond
(kcalmol1)
rmserror
(kcalmol1)
q2
WNVPR(44peptidicinhibitors)
EvdW+GQM_elesol+Gtr,rot,bond ????? ????? ???? ???? ????
Standarddeviation ?????? ?????? ????
EvdW+GMM_elesol+Gtr,rot,bond ??????? ? ????? ???? ???? ????
Standarddeviation ?????? ?????? ????
CDK2(73nonpeptidicinhibitors)
EvdW+GQM_elesol+Gtr,rot ????? ???????? ? ??? ???? ????
Standarddeviation ?????? ?????? ????
EvdW+GMM_elesol+Gtr,rot ????? ????? ??? ???? ????
Standarddeviation ?????? ?????? ????
 
?????????????????????????

Table 2. Three-parameter LIECE and QMLIECE models. a Parameters with leave-one-out 
standard deviation larger than the average value are statistically not significant and are given in 
italics. 
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3 QMLIECEvs.simplemodels(WNVPR)
3.1 HistogramofGbindvalues
The 44 inhibitors can be separated according to number of positively charged groups as in the 
histograms enclosed. By inspection of the histograms one could speculate that the activity is 
related simply to the number of charges except for the compounds with q=2 (and q=1 which are 
only two) which seem shifted to less negative values. 
0
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4
5
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7
8
9 8.5 8 7.5 7 6.5 6 5.5 5 4.5
Co
nu
t
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3.2 Statistical tests 
In response to an anonymous reviewer we compare the probability of chance correlation of 
QMLIECE and simple models derived using the total charge. 
The QMLIECE model is the two-parameter model as in Equation (1) in the main text. 
The LIECE and binary (LB) is a three-parameter model 
 MM_elesolbind 2G =0.0318 +G 1.1307Q -6.3154  
where GMM_elesol is the electrostatic contribution of binding free energy calculated by force field 
method, and Q2 is a binary descriptor described below.. 
The binary descriptor (BD) is a five-parameter model 
 bind 0 1 2 3G =1.141Q +2.325Q +1.451Q -0.350Q -7.625  
where “Qn” is a binary descriptor, equals to one for ligands with charge of n and zero for all 
others. 
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These statistical tests evaluate the predictive power of QMLIECE and two simple models. For 
each of the three models a total of 100000 models are generated by random guessing of the 
binding affinities (see main text for details). 
The rationale behind this statistical test is that the significance of the model is low if there is a 
significant correlation between descriptors and randomized values of Gbind. In other words, the 
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distance between the actual model (cross) and random models (dots) is an indicator of predictive 
power, i.e., lack of chance correlation. Note that the QMLIECE performs better in this test than 
LB, and much better than BD. This behavior is consistent with the decreasing physical soundness 
and increasing amount of fitting parameters in going from QMLIECE to LB and BD. The 
horizontal line at q2=0.4 and the vertical line at R=0.6 are drawn to better compare the plots. 
4 Thermodynamic cycle used in (QM)LIECE to calculate the
bindingfreeenergyinsolution
solvation solvation solvation
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vacu
ol prot/lig prot/lig prot l
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Abstract: A procedure based on the semi-empirical quantum mechanical (QM) calculation
of the interaction energy is proposed for the fast screening of compound poses generated by
high-throughput docking. Small molecules (consisting of 2–10 atoms and termed “probes”) are
overlapped to polar groups in the binding site of the protein target. The interaction energy values
between each compound pose and the probes, calculated by a semi-empirical Hamiltonian, are
used as filters. The QM probe method does not require fixed partial charges, and takes into
account polarization and charge-transfer effects which are not captured by conventional force
fields. The procedure is applied to screen about 100 million poses (of 2.7 millions of commercially
available compounds) obtained by high-throughput docking in the ATP-binding site of the tyrosine
kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). Three
QM probes on the hinge region and one at the entrance pocket are employed to select for binding
affinity, while a QM probe on the side chain of the so-called gatekeeper residue (a hypervariable
residue in the kinome) is used to enforce selectivity. The poses with favorable interactions with
the five QM probes are filtered further for hydrophobic matching and low ligand strain. In this
way, a single-digit μM inhibitor of EphB4 with a relatively good selectivity profile is identified in
a multi-million compound library upon experimental tests of only 23 molecules.
1 Introduction
Fast and accurate methods for computing the binding free energy between small molecules
and proteins are required for computer-aided drug design.[1–6] The increasing popularity of QM
methods in computer-aided drug design (CADD) is not just a consequence of ever growing
computing power but is also due to the first principle nature of QM, which should provide the
highest accuracy.[7–10] However, the computational time of QM ranges from N3 (semi-empirical)
to N5 (second order Møller-Plesset perturbation theory and other post-Hartree-Fock methods),
where N is the number of basis functions.[11] Therefore, QM is used for molecular systems of
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limited size, e.g., in the hybrid quantum mechanics/molecular mechanics approach[12,13], or for a
small subset of atoms while a polarizable continuum model is employed to describe the protein
and the solvent. [14] In linear scaling QM method, the computing time scales with N2 or even
N if the local character of chemical interactions is fully exploited.[7,15–19] Using linear scaling
theory, Stewart and Anikin et al. applied the software package MOZYME[20] and LocalSCF[21],
respectively, to calculate QM energies with localized molecular orbital (LMO) theory. Recently,
we have developed the quantum mechanical linear interaction energy model with continuum
electrostatic solvation (QMLIECE), in which the electrostatic contribution to the binding energy
is evaluated by a semi-empirical QM divide-and-conquer strategy. QMLIECE is useful for highly
variable charge–charge interactions, as in the case of 44 peptidic inhibitors of a flaviviral non-
structural 3 serine protease. [22] Nevertheless, neither LMO theory nor the QMLIECE approach are
fast enough for evaluating multiple poses of small molecules generated by high-throughput virtual
screening (HTVS). Therefore, Vasilyev and Bliznyuk first used fast scoring functions for ranking
and then applied the LMO theory, as implemented in MOZYME, to only the 10–100 top ranking
poses. [23] We have applied QMLIECE to less than 10000 poses at most. [22] No application of QM
methods to millions of poses in HTVS has been reported as of today.
Here, a procedure based on semi-empirical QM is developed for the in silico screening of
millions of poses generated by high-throughput docking of large libraries of compounds. The
interaction energies (IEs) between small molecules and individual polar groups (probes) in the
binding pocket of the protein target are used to filter out poses that are not likely to bind. The
method focuses on exploiting advantages of QM in HTVS, e.g., independence of force field
parameters, and ability to capture charge transfer, polarization, and direction-specific effects
which are very important for describing hydrogen bonds (HBs).[24] Flexibility of the functional
groups of some of the side chains is taken into account by partial optimization of the structure of
the complex. As a proof of principle, the QM probe approach is applied to the receptor tyrosine
kinase EphB4, which is involved in cancer-related angiogenesis. [25–27] Docking is performed at the
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ATP-binding site, and five QM probes are used for filtering: Three probes represent the backbone
polar groups of the hinge region[28], one probe is located at the entrance pocket, and a fifth probe
is selected at the gatekeeper side chain[28–32] (Thr693 in EphB4) to bias the in silico screening
towards selective inhibitors of EphB4.
2 Methods
2.1 Design of QM probes
The QM probes are small molecular fragments (2–10 atoms) used for the efficient evaluation of
the IE between polar groups of the protein and the ligand. The QM probes are “designed” (1)
to reflect the local electronic structures in the binding pocket, (2) to be as simple as possible for
computational efficiency, and (3) to distinguish between favorable and adverse contact sensitively.
Methanol, acetate anion, methylammonium cation, and guanidinium cation probes are essentially
identical to the corresponding functional groups in the side chains of Ser/Thr/Tyr, Asp/Glu, Lys,
and Arg, respectively (Table 1).
A water molecule is used as probe for the carbonyl group in the backbone as well as in the Asn
and Gln side chains. Furthermore, the plane of the water molecule is perpendicular to the carbonyl
group to have the same orientation of the lone pairs (Table 1). [33,34] Water is more appropriate
than acetone or acetamide because the additional methyl or amino group, respectively, may be
involved in van der Waals (vdW) interactions with the ligand, and thus attenuate the energetic
difference due to the formation of HB. Formaldehyde is not as sensitive as the water molecule to
detect the formation of HB, because it has a carbon atom more than water, and the carbon atom
may also form vdW interaction with the ligand.
The hydrogen fluoride (HF) probe is used to emulate the amide group in the backbone of the
protein as well as in the Asn and Gln side chains for two reasons. First, HF is the strongest neutral
HB donor, and thus is the most sensitive as a probe molecule to detect HB acceptors. Second, HF
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Table 1: The QM probes for polar groups in proteins. The atoms in boldface are flexible during
QM minimization of complex formation enthalpy, which is carried out with rigid ligand.
Functional group Location in proteins Probe molecule Overlapping position
C O
R1
R2
backbone,
Asn, Gln H2O
N H
R1
R2
backbone,
Asn, Gln HF
H2
C
OHR1
Ser, Thr,
Tyr CH3OH —
H2
C
CR1
O-
O
Asp, Glu CH3CO
2− —
H2
C
NH3+R1
Lys CH3NH
+
3 —
NH2+
H
N
NH2
R1 Arg C(NH2)
+
3 —
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is a two-atom molecule, and has little additional vdW interaction with ligands.
The QM probe method was first assessed on cyclin-dependent kinase 2 (CDK2) (see Supp.
Mat.) and then applied to EphB4. The application to CDK2 shows that the method is able to
identify classical HBs as well as favorable polar interactions like the one between aromatic CH
and carbonyl oxygen[35].
2.2 Calculation of interaction energy
Multiple poses of the ligands are determined by automatic docking and force field minimization
(see below). Ligands are always fixed during the evaluation of the interaction energy IE =
Hligand-probe − Hligand − Hprobe, where H is the formation enthalpy calculated with MOPAC[36]
and the semi-empirical Hamiltonian PM6.[37] It has been reported that density functionals can
quantitatively reproduce the HB energy of CCSD(T) (Coupled-Cluster with Single and Double
and perturbative Triple excitations), [38–44] but considering the efficiency required for filtering
multi-million poses, rapid PM6 was selected eventually. [45] The IEs between rigid probes and the
ligand are calculated directly, while optimization of Hligand-probe is carried out for flexible probes.
In particular, the coordinates of the atoms in boldface in Table 1 are optimized to find an energy
minimum of the ligand-probe complex. The IE evaluation of rigid probes is fast (less than half
second), while about 30 seconds are required for the flexible probes. To improve efficiency, the
interactions of the ligand with the rigid probes are calculated first and can be used as filters. This
strategy was used in the application to EphB4 (see subsection 3.2).
2.3 Preparation of EphB4
Since the structure of the kinase domain of EphB4 was not available when we started this work, a
homology model was built using the structure of EphB2 (mouse, PDB entry 1JPA) as template.
The sequence identity between human EphB4 and mouse EphB2 is 88%. A detailed description
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of the homology modelling procedure has been published previously[46]. Notably, the root mean
square deviation (RMSD) between the homology model and the crystal structure of EphB4 (PDB
entry 2VWX) is only 0.28 Å for 179 of 242 Cα atoms. Moreover, the orientation of the side chains
in the ATP-binding site is essentially identical in the model and the X-ray structure, the largest
discrepancy (1.1 Å) being at the tip of the Met668 side chain in the hydrophobic pocket.
2.4 Preparation of the library and initial filtering
Of the 9.8 million compounds in the 2007 version of the ZINC library[47], about 2.7 millions
had at least one HB donor and one HB acceptor, and molecular weight (MW) smaller than
500 g · mol−1. The molecules were assigned protonation states at pH=7, and were prepared in
multiple protonation states and multiple tautomeric forms. The presence of HB donor(s) and
acceptor(s) is essential as the QM probe method focuses on the evaluation of HB patterns[35], while
the filter on MW was employed because small molecules are more appropriate as lead compounds.
The molecular properties used for filtering were calculated by DAIM.[48] The program WITNOTP
(Armin Widmer, Novartis Pharma, Basel) was used for automatic assignment of CHARMm atom
types and parameters[49], including partial charges which were determined by an iterative approach
based on the partial equalization of orbital electronegativity.[50,51]
2.5 Docking into EphB4
Version 4 of AutoDock[52] was used for flexible ligand docking of the ZINC subset of 2.7 million
compounds using a rigid protein. First, the atom-specific affinity map files were generated by
AutoGrid.[53] The numbers of points in the x, y, and z directions were 62, 52, and 42, respectively,
and the spacing between two adjacent grid points was 0.25 Å. Then AutoDock was employed
to generate multiple poses for further minimization by CHARMM[54]. Since the AutoDock
scoring function was not used for ranking, to speed up the docking procedure, AutoDock energy
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evaluations was limited to 25000 for each hybrid-genetic-local-search. The hybrid-genetic-local-
search was run 400 times with different initial seeds to obtain multiple poses for each compound.
(In preliminary docking runs of known inhibitors of EphB4, it was more likely to obtain the correct
binding mode by using a large number of hybrid-genetic-local-searches than a large number of
energy evaluations and only a few searches.) The docking was followed by energy minimization
in the rigid protein using the CHARMm force field.[49] Redundant poses were eliminated by
clustering using an all-atom RMSD cutoff 0.01 Å. For each pose, the IE values with the QM
probes as well as electrostatics and vdW efficiencies were stored in a table of DVSDMS (data
management system for distributed virtual screening). [55]
2.6 van der Waals filters
Upon energy minimization, loose vdW filters[56] were applied to all poses to eliminate those with
clashes and/or poor steric complementarity. [7] The following cutoffs of the CHARMm intermolec-
ular vdW energy were employed: EvdW < −20 kcal · mol−1 and EvdW/MW< −0.05 kcal · g−1.
Considering the efficiency and accuracy, the vdW filters are more appropriately calculated with
force field methods than with QM.[57]
3 Results and Discussion
3.1 Docking and van der Waals filters
A total of about 100 million poses of 2.7 million compounds were generated by flexible ligand
docking into the rigid ATP-binding site of EphB4. The vdW filters reduced the number of poses
to about 90 millions.
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3.2 Polar interactions: QM probe energies
Thirteen polar groups were replaced by QM probes in the ATP-binding site of EphB4 (Figure
1). According to the definitions of Traxler and Furet, [28,58] Probes 1–3 lie in the adenine binding
region, Probe 4 is located at the entrance pocket, Probes 5 and 9 lie in the ribose binding pocket,
Probe 6 is in the phosphate binding pocket, and Probes 10–12 lie in the hydrophobic pocket. The
virtual screening focuses on binding at the hinge region, therefore Probes 1–3 were selected for
filtering. Probe 4 was also taken into account for filtering as it is very close to the hinge region.
Moreover, the hydroxyl group of the gatekeeper residue (Probe 10 at Thr693) was included to bias
the search towards selective kinase inhibitors[28–32], as only 95 of the 507 human protein kinases
have Thr as a gatekeeper. [59] Whether to consider a specific probe depends on the requirement,
e.g., Probe 5 and 9 have to be taken into account if the polar interactions in the ribose binding
pocket need to be inspected. Therefore the unused probes may be employed in future studies, e.g.,
for combinatorial lead optimization or de novo design.[60]
Four known inhibitors of EphB4 were used to determine the cutoffs for filtering according
to the QM probe energy. The four inhibitors were docked into the ATP-binding site of EphB4
and minimized with the same protocols as used for the high-throughput docking. Table 2 shows
structures and probe energies of these inhibitors. The probe energy values are robust upon minor
shifts in the binding mode (see Suppl. Mat. Table S-I ).
The QM probe energies of the four known EphB4 inhibitors and about 100 compounds
(selected randomly as representative of inactive compounds) were taken into account to determine
the cutoffs for filtering. These are: Eprobe1 < −2 kcal · mol−1 (typical hydrogen bond energy
of N−H··· : O)[64] and Eprobe2, Eprobe3, Eprobe4, and Eprobe10 < 0.5 kcal · mol−1. Furthermore, the
filter based on the sum Eprobe1 + Eprobe2 < −3.8 kcal · mol−1 was employed to give more weight
to the two most buried polar groups of the hinge region. Since the methanol probe 10 at the
gatekeeper residue is flexible, its interaction was calculated only if the Eprobe1 < 0 kcal · mol−1.
The filters based on QM probes reduced the number of poses from 90 millions to 955,094 poses
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Figure 1: The 13 QM probes in the ATP-binding site of the receptor tyrosine kinase EphB4. The
probes are shown by spheres colored according to the atomic element with hydrogen in gray,
carbon in green, nitrogen in blue, oxygen in red, and fluorine in cyan. The QM probes on side
chains are labeled with the residue type and number, while those on the backbone are labeled only
by the residue number.
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Table 2: Values of QM probe energies and experimentally measured IC50 of four known inhibitors
of EphB4. The probe energies are in kcal·mol−1.
Compound Structure MW(g·mol−1)
IC50
(μM) Probe 1 Probe 2 Probe 3 Probe 4 Probe 10
ALTA2[46] N
N
N
N
HN
O
O
HO
353 1.4 −4.31 0.37 0.14 0.34 0.41
PP2[61]
N
N N
NH2N
Cl 302 0.34 −3.71 −3.18 −1.24 0.12 −2.98
ONC102[62]
Cl
NH
N
O
N
N 365 0.10 −2.46 −2.43 −1.38 −0.22 −2.32
MIYA9f[63]
NH2
NH2N
HO
OH
Cl
F
S
S 434 0.021 −3.04 −2.25 −1.16 −5.53 −3.47
of 509,101 molecules. In other words, the QM probe filtering diminished the average number of
poses per molecule from 37 to 2.
3.3 Apolar interactions: Hydrophobic matching
The QM probes do not account for hydrophobic surface matching upon binding, which is important
to evaluate the interaction at the hydrophobic pocket for kinases with small gatekeeper residue
(e.g., EphB4).[65] The atoms of the ligand were classified as polar or nonpolar according to
their QM-calculated partial charges (semi-empirical PM6 Hamiltonian and Mulliken population
analysis). By comparing the QM charges of typical polar and nonpolar atoms in small molecules,
0.22 electronic units was selected as threshold, i.e., those atoms with partial charge in the range
from −0.22 to 0.22 electronic units were considered apolar, while the remaining atoms polar.
Although this assignment requires the choice of an arbitrary threshold value, it was adopted
because of its efficiency and simplicity. The hydrophobic matching was approximated by the
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vdW interactions between the residues within the hydrophobic pocket of EphB4 (Val629, Ala645,
nonpolar part of Lys647, Met668, Ile691, and Thr693) and the nonpolar atoms of the ligand. A
hydrophobic matching of at least −5 kcal·mol−1was used to significantly reduce the number of
poses for further analysis (15,979 poses belonging to 13,823 molecules). Visual inspection of
some of the discarded poses confirmed that they do not fill the hydrophobic pocket with significant
apolar surface matching.
3.4 Ligand strain filter
To evaluate the strain of the ligand, a minimization was performed in the absence of the protein
starting from the bound conformation. The program MOPAC with a semi-empirical Hamiltonian
RM1[66] was used for the minimization. The program ROCS[67] was employed to overlap the
conformation minimized in the absence of the protein to the pose used as the starting point of the
minimization, and to calculate the shape Tanimoto. The latter is defined as OAB/(VA +VB −OAB),
where OAB is the volume overlap between conformer A and conformer B, and VA and VB is the
volume of conformer A and B, respectively.[68] A shape Tanimoto close to 1 implies that the two
conformations are essentially identical. The distribution of the shape Tanimoto of the 15,979
poses is shown in Suppl. Mat. Figure S-VII. A threshold for shape Tanimoto larger than 0.9 was
chosen to further reduce the amount of poses for visual inspection. In total, 8,461 poses belonging
to 7,536 molecules passed this filter. Finally, 23 compounds were selected for experimental
validation upon visual inspection of the first 1000 poses sorted according to QM probe energies
and CHARMm intermolecular energy (See Suppl. Mat. Table S-IV). Sortings were simply carried
out according to the sum of CHARMm intermolecular non-bonding energy terms, and the five
probe energies (Probe 1–4 and Probe 10) separately. The top ∼ 166 poses of each ranking were
selected. The main criteria used to filter out poses during visual inspection were the involvement of
highly flexible functional groups, e.g., −(CH2)n−OH (n ≥ 1), in HBs with the hinge region, and
the desolvation of polar groups in the ATP-binding site that were not involved in intermolecular
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HBs. The former was required as the QM probe filters do not take into account the conformational
entropy loss upon binding. Visual inspection, although subjective, is an unavoidable procedure
for discarding poses with unfavorable interactions and/or unlikely conformations[69]. Filtered by
the QMprobe and vdW energies, the remaining poses are inspected very efficiently, as key polar
and apolar interactions have already been verified.
3.5 Computational requirements
The docking approach requires about 10 minutes per compound on a single Opteron CPU 244
(2.4GHz). The energy minimization requires about 10 minutes for an average of 50 poses for each
compound. The CPU time for calculating an IE with a rigid QM probe is less than 0.5 second
mainly for the program input/output process, while about 30 seconds are needed for calculating
the IE with a flexible probe. Despite the large amount of molecules and poses, distributing docking
and minimization jobs to hundreds of CPUs in two Beowulf clusters, selecting specific molecules
and poses, and applying filters was efficiently managed by the database management system
DVSDMS.[55]
3.6 Experimental validation
The 23 compounds selected for validation were tested in two different enzymatic assays with the
kinase catalytic domain of EphB4 in solution. One assay is based on fluorescence-resonance en-
ergy transfer (FRET) between coumarin and fluorescein (Omnia® Tyr recombinant kit KNZ4051,
BioSource™[70]), while the other measures the amount of radioisotope labeled phosphate trans-
ferred from ATP to the substrate upon phosphorylation by EphB4.[71] Three of the 23 compounds
tested share a 2-formamido-4-phenylthiophene-3-carboxamide scaffold. Two of these three thio-
phene derivatives have an inhibitor concentration for half-maximal activity (IC50) smaller than
10 μM in both assays, while the third one has IC50 values of 9 μM and 17 μM (Table 3).
75
Table 3: Experimental validation of EphB4 inhibitors identified by high-throughput docking and
the QM probe approach.
Compound Structure MW(g·mol−1)
IC50 a
(μM)
IC50 b
(μM)
1
O
-O
O HN
S
O
NH2
373 8.4, 7.6 2
2
O
-O
O HN
S
O
NH2
360 7.1, 4.6 2
3
O
-O
O H
N
S
O
NH2
388 17.5, 16.7 9
a FRET-based enzymatic assay with the recombinant catalytic domain of human EphB4 in
solution and ATP concentration of 20 μM. Each inhibitor was tested twice. To provide evidence
against non-specific effects (e.g., aggregation), compound 2 was also tested upon addition of the
detergent triton X-100 (0.1% v/v). Similar values of percentage inhibition (at 30 μM and 10 μM
of compound 2) were measured with and without detergent. b Enzymatic assay with the
recombinant catalytic domain of human EphB4 and [γ-33P]-ATP concentration of 1 μM
(performed at Reaction Biology Corp).
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The predicted binding mode of compound 1 (Figure 2) indicates that its amide group N1−H,
carbonyl group C2−O, and amide group N3−H are involved in HBs with the backbone polar
groups in the hinge region. Moreover, its carboxy group is involved in a HB with the entrance
pocket, and the dimethylphenyl ring is buried into the hydrophobic pocket. To validate the
predicted binding mode of compound 1, a set of 23 commercially available derivatives with
the same 2-formamido-4-phenylthiophene-3-carboxamide scaffold were purchased and tested
(Table 4). The SAR (structure-activity relationship) data are consistent with the binding mode. In
particular, the cyclopropyl group at R7 causes a major loss in activity (compound 12) in agreement
with the hinge region hydrogen bond of the amide group N1−H. Moreover, the similar inhibitory
activity of compounds 22 and 23 (about 50% @20 μM concentration), which differ only by a
methyl group at R2, is consistent with the orientation of the R2 substituent towards the solvent
(Figure 2).
The selectivity profile of compound 1 was tested using a panel of 85 protein kinases (National
Centre for Protein Kinase Profiling at University of Dundee, see Suppl. Mat. Table S-II). At
10 μM concentration, the activity of Aurora B remained 37% compared with a DMSO control,
while six other kinases retained 40 − 60% activity (Table 5). Note that three of these seven
kinases have Thr as gatekeeper residue. Importantly, the inhibitory activity of compound 1 on
the remaining 78 kinases is either zero or extremely modest. The binding mode obtained by
docking into EphB4 suggests that the phenyl ring of compound 1 interacts favorably with the
hydroxyl group of the gatekeeper Thr693 (Eprobe10 = −1.6 kcal·mol−1). These results indicate
that compound 1 is rather selective which is in part due to the use of the QM probe 10 at the
gatekeeper side chain (only about 20% of human kinases have Thr as gatekeeper). [59] Interestingly,
the known inhibitors PP2[61], ONC102,[62] and MIYA9f[63] have very favorable interaction energy
with QM probe 10 (Table 2) which is consistent with their good selectivity for protein kinases
with Thr as gatekeeper.
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Figure 2: Binding mode of compound 1 predicted by docking. (a) The intermolecular HBs to the
hinge loop and entrance loop are shown by yellow dashed lines. The pose was minimized in the
rigid EphB4 structure (PDB entry 2VWX). The atoms of the side chain of the gatekeeper residue
Thr693 are displayed by spheres. Non-polar hydrogen atoms are omitted for clarity. (b) The five
QM probes used as filters are emphasized by red labels. Integer labels on compund 1 emphasize
functional groups mentioned in the text. The side chain of Phe695 is not shown for clarity.
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Table 4: Structure and inhibitory activity of 23 commercially available derivatives of compound
1.
O
-O O
H
N
S
R2
R5
O
NH
R1
R3 R4
R7
R6
Compound R1 R2 R3 R4 R5 R6 R7
IC50(μM) or
% inhibitory activity @20μM a
4 −CH2−CH2− −CH3 H H F H H 49%@20μM
5 −CH3 H H H H H 50%@20μM
6 −CH2−CH2−CH2− −CH3 H H −C(CH3)3 H H 38%@20μM
7 −CH2−CH2− H H −CH3 −CH3 H H 46%@20μM
8 H −CH3 H H −CH3 H 50%@20μM
9 H Cl H Cl H H 9.7
10 −CH3 H H −CH3 H H 13.7
11 −CH3 Cl H Cl H H 7.8
12 −CH2−CH2−CH2− H H H −CH3 H 7%@20μM
13 −CH3 H H −CH3 H H 40%@20μM
14 H H −CH3 −CH3 H H 44%@20μM
15 −CH3 H −CH3 −CH3 H H 31%@20μM
16 H H −CH3 −CH3 H H 21%@20μM
17 −CH3 H −CH3 −CH3 H H 16%@20μM
18 −CH2−CH2−CH2− H H −CH3 −CH3 H H 55%@20μM
19 −CH2−CH2−CH2− −CH3 H H −CH2−CH3 H H 16.3
20 −CH3 H −CH3 −CH3 H H 27%@20μM
21 H H H −CH3 H H 15%@20μM
22 −CH2−CH2−CH2− −CH3 Cl H Cl H H 47%@20μM
23 −CH2−CH2−CH2− H Cl H Cl H H 54%@20μM
24 −CH3 H H −CH3 H H 5.2
25 −CH3 H −CH3 −CH3 H H 2%@20μM
26 H H H Cl H H 20%@20μM
a FRET-based enzymatic assay with the recombinant catalytic domain of human EphB4 in
solution and ATP concentration of 20 μM. Each inhibitor was tested twice and average values are
reported.
79
Table 5: Selectivity profile of compound 1 tested on a panel of 85 protein kinases.
Kinase % activity remaining at 10 μMconc. of compound 1 a
Gatekeeper
residue b
Aurora B 37 Leu
EPH A2 41 Thr
VEG-FR 42 Thr
P38B MAPK 51 Thr
FGF-R1 60 Val
LKB1 60 Met
CK1δ 60 Met
5 kinases 60 < %activity ≤ 70
13 kinases 70 < %activity ≤ 80
10 kinases 80 < %activity ≤ 90
Other 50 kinases > 90
The measurements of inhibitory activity were performed at the National Centre for Protein Kinase
Profiling at University of Dundee. a The activity is relative to a control with 100% of DMSO. The
78 unnominated kinases have the following residue as gatekeeper with occurrence in parentheses:
Met (35), Leu (16), Phe (12), Thr (10), Gln (2), Glu (1), Ile (1), and Tyr (1). The sequence
information and gatekeeper residue of the whole panel of 85 kinases is shown in the Suppl. Mat. (
Table S-III). The ATP concentration in the assay is also shown in the Suppl. Mat. (Table S-II).
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4 Conclusions
A new procedure for filtering millions of poses of small molecules based on QM calculations is
described by an application to the tyrosine kinase EphB4. Polar groups in the protein binding
site are substituted by small probes consisting of 2–10 atoms, e.g., water and methanol for the
carbonyl and hydroxyl group, respectively, and the interaction energy values between each pose
and individual QM probes are calculated using a semi-empirical Hamiltonian. The use of a
first-principle method is an advantage with respect to classical force fields with fixed partial
charges. As an example, the QM probes are able to detect favorable polar interactions like the
aromatic −CH···O−C interaction, which can be rather strong depending on the electronegativity
of eventual substituents in the aromatic ring.
The QM probe filtering is applied to about 100 millions poses of small molecules generated by
automatic docking into the ATP-binding site of the kinase catalytic domain of EphB4. Only 1% of
the poses pass the filters of favorable interaction energy with five QM probes: three in the hinge
region, one at the entrance pocket, and one at the gatekeeper side chain (Thr693 in EphB4). The
latter is a non-conserved residue in the kinome, and is therefore used to bias the virtual screening
towards selective inhibitors. Upon further filtering based on nonpolar interactions, ligand strain,
and visual inspection, 23 compounds are selected and tested in an enzymatic assay. It is important
to note that the QM probe filters as well as the additional filters used for post-processing require
rather arbitrary threshold values, which might seem in contradiction with the use of first-principle
methods. The QM probe method is an approximation of the real binding free energy because it
takes into account only part of the protein target. Moreover, entropic terms are neglected.
Of the 23 compounds tested, three molecules with a 2-formamido-4-phenylthiophene-3-
carboxamide scaffold are active in the low μM range in two different enzymatic assays. Additional
evidence for the binding mode of compound 1, and in particular its favorable interactions with the
protein functional groups approximated by the QM probes, is provided by the structure-activity
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relationship of 25 commercially available derivatives. Enzymatic assays on a panel of 85 protein
kinases indicate that compound 1 is not promiscuous as no inhibitory activity is observed for
most of these kinases and modest inhibitory activity for only seven of them (three of which have
Thr as gatekeeper residue). Thus, compound 1 has potential for further development into a lead
candidate, because of its low μM inhibitory activity for EphB4, low MW (373 g·mol−1), and good
selectivity profile.
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Assessment of QM probe method on protein kinase CDK2
Before applying the quantum mechanical (QM) probe method to EphB4, it was tested on the
cyclin-dependent kinase 2 (CDK2) for which a large number of ATP-binding site inhibitors have
been published.[1–8] The structure of CDK2 was downloaded from the PDB (PDB entry 1KE5),
and hydrogen atoms were added by CHARMM[9] according to the protonation states of side chains
and termini at pH 7. Then the structure was minimized with CHARMM using the CHARMm[10]
force field and MPEOE partial charges.
The catalytic domain in protein kinases is composed of two lobes connected by a segment
termed “hinge loop”. The majority of ATP-competitive inhibitors are involved in at least one
hydrogen bond with the hinge loop.[11] There are two hydrogen bond (HB) acceptors and one
donor in the backbone of the hinge loop so that two water probes and one hydrogen fluoride (HF),
respectively, were used (Figure S-I). About 1,000 compounds, randomly selected from the ZINC
library, were docked into the ATP-binding site of cyclin-dependent kinase 2 (CDK2) using version
4 of AutoDock[12]. A total of about 100,000 poses were generated by docking, then minimized
using the CHARMm force field, and filtered by van der Waals (vdW) interaction energy (IE) and
vdW efficiency as mentioned in ref 7. To study the effectiveness of the probe method, we selected
poses based on probe energies and visually inspected whether there is a particular interaction at
the expected position.
Figure S-II shows the QM probe energy is an effective detector of canonical HBs. The
structures of four putatively inactive compounds (compound 27–30 termed decoys hereafter)
and the cocrystallized ligand in PDB entry 1KE5, and their interactions with the protein are
schematically shown in Figure S-II. From the vdW point of view, the four decoys match the
binding pocket, since they all passed the filters of vdW and vdW efficiency.[7] However their
unfavorable polar interactions with the hinge region are not detected. A main reason of failure in
detecting the unfavorable polar contacts is that the Eele averages out the electrostatic interaction
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Figure S-I: The three QM probes at the hinge loop of the protein kinase CDK2. Positions 1, 2,
and 3 are the backbone –NH– of Leu83, –CO– of Glu81, and –CO– of Leu83, respectively.
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between the decoys and the protein, hence the resolution or sensitivity is not high enough. This
averaging effect is also present for the known inhibitor (Figure S-II) in the structure of PDB
entry 1KE5 which was optimized and evaluated using the same protocol, and it has Eele =
−5.02 kcal·mol−1, and Eele/MW = −0.0153 kcal·g−1, where MW is the molecular weight.
Electrostatic IE and electrostatic efficiency of this cocrystallized inhibitor are quite similar to
some inactive compounds (Figure S-II). Nevertheless, with QM probe method, an adverse contact
always shows a positive (unfavorable) probe energy, and can be easily distinguished. The three
probe energies of the cocrystallized inhibitor are −3.94 kcal·mol−1, −3.27 kcal·mol−1, and
−1.63 kcal·mol−1, while each of the compound 28–30 has one positive probe energy, which is
consistent with the unfavorable polar contact in the pose (Figure S-II). Note that compound 27
is not eliminated by the filters of the three probes at the hinge region, but was not selected for
experimental testing, since the hydrophobic pocket is not satisfied (see subsection 3.3).
The QM probe method is able to detect non-classical HBs. Most of the force fields use fix-
charge approximation to describe electrostatic interactions. QM gains an advantage in evaluation
of complex charge–charge interactions, e.g., anion–cation interaction,[13] metal–ligand interac-
tion,[14] and HB.[15] The non-classical HBs exist in protein–ligand complex extensively,[16] not
only in kinase cases, [17] but also in other targets. [18] The compound in Figure S-II(b) is involved
in a pair of C−H···O non-classical HBs with the protein (colored in black). [17] The probe energy
of Probe 3 is −3.22 kcal·mol−1, which expresses a distinct sign of a favorable interaction there.
Figure S-III shows another compound (compound 31) interacting with the hinge loop at Probe 2
by a non-classical HB, whose probe energy (−2.02 kcal·mol−1) is also comparable with that of
a classical HB. The partial charge of the hydrogen atom bonded to the C6 (red in Figure S-III)
is identical with that of the hydrogen atom in unsubstituted phenyl ring if the partial charges
are assigned using MPEOE approach. This is not accurate because the −NO2 group is strongly
electron-withdrawing, and the −−−CH−−− at the para position of the −NO2 is more positive (atomic
charges calculated by QM at MP2 6-31+G(d,p) level is shown in Figure S-VI) than the analogue
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Compound ZINC ID Eelea EvdW Eele/MW EvdW/MW Probe 1 Probe 2 Probe 3
27 476434 −1.6 −40.1 −0.005 −0.132 −2.38 −2.36 −3.65
28 43974 −4.0 −42.5 −0.012 −0.123 2.67 −3.43 −3.11
29 49031 −5.7 −35.5 −0.016 −0.103 −5.61 3.41 −7.22
30 55643 −0.9 −44.3 −0.003 −0.127 −4.63 −3.22 4.32
1KE5 Ligand −5.0 −41.5 −0.015 −0.126 −3.94 −3.27 −1.63
(f) Probe energy of compounds.b
a Electrostatic interaction energy. b All energy values are in kcal·mol−1. MW is in g·mol−1.
Figure S-II: Assessment of QM probe method on CDK2 using four putatively inactive compounds
(a)–(d), and a co-crystalized ligand (e). The distances between the critical atoms are noted with
the digits above the dashed lines. The unit of length is Å. The green color denotes favorable HB
interactions, the red indicates unfavorable interactions, and the black means favorable interactions
but forming non-classical HBs.
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Compound ZINC ID Eele EvdW Eele/MW EvdW/MW Probe 1 Probe 2 Probe 3
31 298885 −2.1 −39.5 −0.006 −0.113 −3.36 −2.02 −4.26
Figure S-III: Non-classical HB. All energy values are in kcal·mol−1. The colors of the dashed
lines and the digits have the same meanings as in the Figure S-II. The hydrogen atom in red is
discussed in the main text.
without a −NO2 group. Note that the experimental pKa of nitrobenzene is 3.98 (at 0 °C).[19]
Therefore, this hydrogen atom becomes a potential HB donor, and will form a HB when there is a
HB acceptor nearby gaining a favorable interaction.
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Figure S-IV: Distribution of energies of 5 probes (Probe 1–4, and 10) across 89,350,018 poses of
neutral molecules.
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Distance(Å) PM6 PM3 RM1 AM1
1.22 10.44 25.07 11.93 27.76
1.42 2.92 14.02 4.80 16.33
1.62 1.74 1.92 0.38 5.69
1.83 3.75 1.97 0.73 1.09
2.03 4.25 1.18 0.82 3.53
2.23 3.98 1.02 1.39 3.73
2.43 3.45 1.45 2.03 3.24
2.64 3.15 1.52 1.97 2.74
2.84 2.39 1.41 1.76 2.43
3.04 2.02 1.26 1.53 1.70
3.24 1.72 1.11 1.33 1.39
3.45 1.50 0.97 1.17 1.17
3.65 1.32 0.86 1.04 1.02
3.85 1.17 0.77 0.92 0.90
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4.46 0.85 0.56 0.67 0.66
4.66 0.77 0.51 0.61 0.60
4.87 0.69 0.46 0.55 0.55
5.07 0.63 0.42 0.50 0.50
(c)
Figure S-V: (a) The PM6 interaction energiesa between a water molecule and a N-
methylacetamide are plotted against the distances from atom H to O connected with the dashed
line in (b). The movement of the water molecule is along the vector defined by the atom H and
O in the fully PM6-optimized conformation, i.e., the conformation when the distance equals to
2.03 Å in the second column of (c). After moving the water molecule to a new position, the
conformation is partially optimized. The coordinates of atoms except for the H and the O atom
are optimized using four Hamiltonians (PM6, PM3, RM1, and AM1) in MOPAC. The unit of
all energy terms is kcal·mol−1. The energy terms do not contain basis set superposition error
correction.
a IE = Hcomplex −Hwater −HN-methylacetamide, where H is the formation enthalpy.
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(1) Compound 31
(2) Analogue of compound 31 without −NO2 group
Figure S-VI: The quantum mechanical atomic charges of compound 31 and its analogue without
−NO2 group. The structures were minimized by B3LYP 6-31+G(d,p) starting with the docking
structures. The digits in the parenthesis are the partial charges calculated by natural bond orbital
theory at MP2 6-31+G(d,p) level. The group charge of C6H changes from 0.059 electronic unit to
0.114 electronic unit, when a −NO2 group substitutes its para hydrogen.
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Table S-I: Probe energies of minor-different conformers of four known inhibitors of EphB4. The
conformer in the first row of each block is the minimized conformer of each inhibitors which is
identical to those listed in Table 2 of the main text. The other conformers are snapshots taken
every 10 fs from a short molecular dynamics run (100 fs at 50 K) without minimization.
Conformer Probe 1 Probe 2 Probe 3 Probe 4 Probe 10
RMSD of
Coordinates(Å)
ALTA −4.31 0.37 0.14 0.34 0.41 0.000
ALTA_1 −4.27 0.33 −0.04 0.33 0.34 0.025
ALTA_2 −4.32 0.34 0.20 0.35 0.34 0.026
ALTA_3 −4.16 0.39 0.05 0.30 0.43 0.030
ALTA_4 −4.18 0.34 0.25 0.36 0.38 0.031
ALTA_5 −4.24 0.34 0.08 0.30 0.40 0.035
ALTA_6 −4.39 0.40 0.05 0.37 0.43 0.031
ALTA_7 −4.18 0.38 −0.03 0.33 0.42 0.030
ALTA_8 −4.23 0.39 −0.03 0.35 0.41 0.031
ALTA_9 −4.16 0.39 0.31 0.35 0.46 0.034
ALTA_10 −4.12 0.35 −0.19 0.28 0.39 0.034
MIYA9f −3.04 −2.25 −1.16 −5.53 −3.47 0.000
MIYA9f_1 −3.05 −2.17 −1.27 −5.49 −3.43 0.020
MIYA9f_2 −3.03 −2.26 −1.18 −5.45 −3.31 0.026
MIYA9f_3 −3.02 −2.39 −1.14 −5.64 −3.62 0.028
MIYA9f_4 −3.03 −1.96 −1.21 −5.27 −3.21 0.029
MIYA9f_5 −2.97 −2.25 −1.16 −5.50 −3.50 0.029
MIYA9f_6 −3.01 −2.22 −1.14 −5.25 −3.40 0.027
MIYA9f_7 −2.97 −2.09 −1.16 −5.35 −3.41 0.030
MIYA9f_8 −3.12 −2.15 −1.23 −5.52 −3.51 0.028
MIYA9f_9 −3.03 −2.03 −1.07 −5.15 −3.42 0.030
MIYA9f_10 −3.02 −1.99 −1.34 −5.23 −3.38 0.036
ONC102 −2.46 −2.43 −1.38 −0.22 −2.32 0.000
ONC102_1 −2.36 −2.40 −1.43 −0.20 −2.25 0.023
ONC102_2 −2.54 −2.43 −1.36 −0.22 −2.24 0.025
ONC102_3 −2.55 −2.49 −1.41 −0.20 −2.36 0.026
ONC102_4 −2.57 −2.54 −1.54 −0.22 −2.47 0.032
ONC102_5 −2.56 −2.34 −1.35 −0.20 −2.27 0.036
ONC102_6 −2.61 −2.38 −1.43 −0.21 −2.31 0.038
ONC102_7 −2.50 −2.33 −1.49 −0.21 −2.28 0.040
ONC102_8 −2.60 −2.33 −1.53 −0.20 −2.32 0.036
ONC102_9 −2.54 −2.50 −1.47 −0.22 −2.44 0.031
ONC102_10 −2.59 −2.51 −1.57 −0.21 −2.36 0.036
PP2 −3.71 −3.18 −1.24 0.12 −2.98 0.000
PP2_1 −3.73 −3.13 −1.34 0.12 −2.88 0.021
PP2_2 −3.62 −3.15 −1.26 0.12 −3.00 0.026
PP2_3 −3.72 −3.34 −1.24 0.11 −2.92 0.028
PP2_4 −3.63 −3.08 −1.23 0.15 −2.97 0.029
PP2_5 −3.63 −3.25 −1.09 0.14 −3.10 0.028
PP2_6 −3.57 −3.20 −1.21 0.09 −2.91 0.033
PP2_7 −3.71 −3.15 −1.13 0.15 −3.12 0.032
PP2_8 −3.65 −3.19 −1.17 0.10 −2.94 0.029
PP2_9 −3.60 −3.41 −1.06 0.13 −3.13 0.033
PP2_10 −3.65 −3.34 −1.14 0.08 −2.97 0.036
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Figure S-VII: The distribution of shape Tanimoto of 15,979 poses. The blue vertical line at 0.9
emphasizes the threshold for filtering out the large-strain ligands.
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Table S-II: List of 85 kinases for selectivity profile. The ATP concentration in each assay is
denoted in the head row.
5μM 20μM 50μM
PH-PKB (S473D) Aurora B PH-PKBß (S474D)
CK2 CaMKKß AMPK
DYRK3 CDK2/cyclin A BRSK2
EF2K CHK1 BTK
EPH-B3 CHK2 CaMK1
ERK1 CK DYRK1a
ERK8 CSK DYRK2
GSK3ß FGF-R1 EPH-A2
HER4 GCK IKK
HIPK2 IR-HIS LCK
IGF1R IRAK4 MAPK2/ERK2
IKKß JNK11  MAPKAP-K1a/RSK1
IRR JNK2 MAPKAP-K1b/RSK2
MARK3 LKB1 MELK
MKK1 MAPKAP-K2 MINK1
p38 MAPK MLK1 MNK1
	
 MAPK  MLK3 MNK2
PAK4 MSK1 NEK2a
PIM2 MST2 NEK6
PKC MST4 p38 MAPK
PLK1 NUAK1 PhK1
PRK2 p38ß MAPK PKD1
PAK5 smMLCK
PAK6 Src
PDK1 SRPK-1
PIM1 TBK1
PIM3 
PKA 
PKC 
PRAK 
ROCKII 
S6K1 (T412E) 
SGK1 
SYK 
TTK
VEG-FR 
YES1 
* * *
∗ The ATP concentrations are at or below the calculated Km for ATP for that kinase.
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Table S-III: The sequence information and the gatekeeper residues of 85 kinases.
Protein Kinase Accession No. GI Gatekeeper Protein Kinase Accession No. GI Gatekeeper
AMPK[26-268] NM_006252 46877068 M MLK3 [96 - 386] NM_002419 4505195 M
Aurora B [1-344] NM_004217 83776600 L MNK1 [2-424] AB000409 2077825 F
BRSK2 [2-674] AF533878 33187742 L MNK2α [2-465] AF237775 11023170 F
BTK [2-659] NP_000052.1 4557377 T MSK1 [2-802] AF074393 3411157 L
CaMK1 [2-369] NM_003656 4502553 M MST2 [2-491] U60206 1477789 M
CaMKKβ [1-541] NM_153499 27437017 F MST4 [1-416] NM_016542 15011880 M
CDK2[4-286] NM_001798 16936528 F NEK2A [1-445] NM_002497 4505373 M
CHK1 [1-476] AF016582 2367669 L NEK6 [8-313] NM_014397 19923407 L
CHK2 [5-543] NM_007194 6005850 L NUAK1 [2-660] NM_014840 7662170 M
CK1δ [1-294] AB063114 14422451 M p38β MAPK [1-364] Y14440 2326554 T
CK2α [2-391] NM_001895 4503095 F p38α MAPK [1-360] L35264 603919 T
CSK [1-450] NM_004383 4758078 T p38γ MAPK [1-367] Y10487 1785656 T
DYRK1a [1-499] NM_130437.2 18765754 F p38δ MAPK [1-365] Y10488 2266640 M
DYRK2 [3-528] NM_003583 4503427 F PAK4 [2-591] O96013 12585288 M
DYRK3 [1-588] AY590695 46909167 F PAK5 [2-719] Q9P286 12585290 M
EF2K [2-725] AAH32665 21618568 E PAK6 [2-681] Q9NQU5 23396789 M
EPH-A2 [591-976] NM_004431 32967311 T PDK1 [52-556] NM_002613 4505695 L
EPH-B3 [561-998] NM_004443 17975768 T PhKγ1[2-297] X80590 1147567 F
ERK1 [2-379] BC013992 15559271 Q PIM1 [2-313] NM_002648 4505811 L
ERK2 [1-358] X58712 53002 Q PIM2 [2-334] U77735 1750276 L
ERK8 [2-544] AY065978 19263187 F PIM3 [2-326] Q86V86 215274221 L
FGF-R1 [400-820] M34641 182530 V PKA [2-351] NM_002730 4506055 M
GCK [2 - 812] BC047865 28839779 M PKBβ (S474D) [120-481] NM_001626 4502023 M
GSK3β [2-420] L33801 529237 L PKBα (S473D) [118-480] BC000479 12653417 M
HER4 [706 - 991] NM_005235 4885215 T PKCα [1-672] NM_002737 4506067 M
HIPK2 [165-564] AF326592 17225377 F PKCζ [2-592] NM_002744 52486327 I
IGF1R [954-1367] NM_000875 4557665 M PKD1 [2-912] NM_002742 115529463 M
IKKβ [1-736] XM_032491 20538863 M PLK1 [1-603] NM_005030 21359873 L
IKKε [1-716] NM_014002 7661946 M PRAK [1-471] AF032437 3133291 M
IR [1001-1382] NM_000208.2 119395736 M PRK2 [501-984] S75548 914100 M
IRAK4 [140-460] BC013316.1 15426432 Y ROCKII [2-543] U38481 1384133 M
IRR [944-1236] NM_014215 31657140 M RSK1 [1-735] M99169 206772 L
JNK1α1 [1-384] L26318 474901 M RSK2 [2-740] NM_004586 4759050 T
JNK2α2 [1-424] L31951 598183 M S6K1 (T412E) [1-421] NM_003161 4506737 L
LCK [2-509] X03533 244791455 T SGK1 (S422D) [60-431] NM_005627 25168263 L
LKB1 [1-433] NP_000446 4507271 M Src [2-533] NM_005417.3 4885609 T
MAPKAP-K2 [46-400] NM_032960 32481209 M SRPK1 [2-654] NM_003137 47419936 F
MARK3 [2-729] U64205 3089349 M SYK [1-635] AAH01645.1 12804475 M
MELK [2-651] NM_014791 7661974 L TBK1 [1-729] NM_013254 7019547 M
MINK1[1-320] NM_015716 7657335 M TTK [1 - 857] NM_003318 23308722 M
MKK1 [1-393] Z30163 456202 M VEGFR [784-1338] NM_002019.3 156104876 V
MLCK [475-838] NM_005965 16950601 L YES1 [1-543] NM_005433 4885661 T
MLK1 [132 - 413] NM_033141 52421790 M
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Table S-IV: Energy values in kcal·mol−1 of experimentally tested compoundsa.
ZINC ID Structure Probe1 Probe2 Probe3 Probe4 Probe5 Probe6 Probe7 Probe8 Probe9 Probe10 Probe11 Probe12 Probe13 hydrophobicmatching
% inihibition
at 50 M
842896 3.01 2.51 0.21 0.37 0.03 0.12 0.28 0.12 0.05 0.97 6.76 8.52 0.33 9.27 19, 8
2361207 4.49 2.08 0.25 0.09 0.03 0.04 0.40 0.11 0.22 2.90 5.82 3.78 0.61 7.96 ~0
1406465 3.84 1.25 2.25 1.38 0.15 0.07 0.29 0.06 0.05 0.46 3.96 2.98 0.14 5.02 0, 54
1213337 2.94 1.08 0.43 4.04 0.01 0.08 0.43 0.25 0.06 1.69 11.19 2.57 0.29 8.19 42, 70
1053478 3.90 2.34 2.03 1.05 0.10 0.08 0.35 0.18 0.23 1.17 7.04 0.61 0.23 5.65 -NA-
838240 3.16 1.46 0.27 1.90 0.37 0.14 0.24 0.13 0.07 2.05 7.22 2.08 0.33 5.43 -NA-
N
HN N
O O
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S
N
H
O
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Cl
H2N
O
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N
N
N
N
N
O
O
N
N
NH
N
N
a We do not have energy values of the 23 compounds mentioned in the main text because most of
them are derivatives of ZINC compounds, since the original compounds were not available. The
compounds 1 to 26 in the main text are derivatives of ZINC compound 1053478.
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High throughput docking (HTD) using high performance computing platforms is a multidisciplinary challenge.
To handle HTD data effectively and efficiently, we have developed a distributed virtual screening data
management system (DVSDMS) in which the data handling and the distribution of jobs are realized by the
open-source structured query language database software MySQL. The essential concept of DVSDMS is
the separation of the data management from the docking and ranking applications. DVSDMS can be used
to dock millions of molecules effectively, monitor the process in real time, analyze docking results promptly,
and process up to 108 poses by energy ranking techniques. In an HTD campaign to identify kinase inhibitors
a low cost Linux PC has allowed DVSDMS to efficiently assign the workload to more than 500 computing
clients. Notably, in a stress test of DVSDMS that emulated a large number of clients, about 60 molecules
per second were distributed to the clients for docking, which indicates that DVSDMS can run efficiently on
very large compute cluster (up to about 40000 cores).
INTRODUCTION
In silico screening of large libraries of compounds is a
commonly used tool in drug discovery because it efficiently
identifies candidate lead compounds.1-7 Its efficiency is due
to methodological progresses and the ever increasing per-
formance of ordinary low-cost computers. Despite these
progresses, handling large libraries of compounds is still a
challenge for data management in drug design and discovery.
The demand for an efficient data management increases even
further if multiple computing instances access and update
the data simultaneously.
Recently, several applications of large-scale virtual screen-
ing in parallel have been reported. For instance, para_glide,
a recently developed extension of Glide8,9 for parallel
execution, counts the number of ligands, divides them into
equal segments, and distributes them over several processors
or machines. At the end of all docking calculations it provides
a unified report of docking scores. Zhang and co-workers
have developed the free package DOVIS which runs Au-
toDock10 in parallel.11 With DOVIS users can submit
multiple jobs from a graphical user interface to both cluster
and standalone computers. The authors docked about 2
million compounds on a Linux cluster with 256 CPUs and
observed near-optimal performance. The essential concept
of para_glide and DOVIS is the splitting of the molecular
database into multiple partitions, which are then submitted
to different processors individually, and the results are
retrieved from all processors and combined after docking.
In this way, the number of partitions and the amount of
molecules are determined before splitting, the running time
of each partition cannot be estimated, and the balance of
each processor cannot be guaranteed either. Moustakas and
Kuntz developed the MPI version of DOCK,12 which used
a master-worker scheme for parallelization.13 To reduce
bookkeeping tasks associated with manual partition of jobs,
data were distributed to workers as molecules were read by
the master, such that the poor load balance due to the random
distribution of jobs was circumvented. Furthermore, Peters
and co-workers recently optimized and validated DOCK on
a massively parallel system with more than 16000 proces-
sors.14 They pointed out that as the number of processors
increased, the HTC (High Throughput Computing)15 version
of the DOCK program was more efficient than the MPI
version, since library docking could be run as a collection
of independent tasks while the MPI version suffered from
overloading of the master. In other words, the efficiency of
distribution of the master is the bottleneck of the master-
worker scheme, in particular when a considerable amount
of workers request jobs simultaneously. As an example, the
efficiency of the MPI version of DOCK is 88% at 8192
workers but decreases to 55% at 16384 workers.14 The
overloading has been overcome by employing multilevel
master-worker scheme (MLMW). However, both HTC and
MLMW require additional time-consuming programming,
in particular, HTC demands for the implementation of an
asynchronous task dispatch subsystem, while MLMW re-
quires the modification of the source code of the docking
software.
The efficiency of data management is crucial in parallel
applications. Furthermore, there is a strong demand of an
efficient and easy-to-implement procedure to handle the data
for a large number of computing clients. At present, most
docking software reads the input and stores the output in
plain files directly. Nonetheless, storing massive data in plain
files is not suitable for extensive data management, since it
usually requires more application programming effort to
create, modify, and access data efficiently and securely. A
database management system is a computer software de-
signed to handle massive data efficiently. Providing controls
of communication and synchronization, it allows multiple
tasks to access and update the data in parallel with marginal
* Corresponding author phone: (+41 44) 635 55 21; fax: (+41 44) 635
68 62; e-mail: caflisch@bioc.uzh.ch.
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additional effort in programming. It contains mature facilities
to keep data integrated and consistent and provides utilities
for database maintaining, such as backup, recovery, monitor-
ing, and tuning.
In this paper, we introduce the Distributed Virtual Screen-
ing Data Management System (DVSDMS) for docking and
ranking based on a master-worker scheme and the freely
available database software MySQL. By separating opera-
tions related to data management from the main application
and allocating the former to the database management
system, DVSDMS can manage HTD data effectively and
efficiently. The connection between the different programs
is handled via scripts written in Python. A MySQL database,
the master of the system, is used for organizing all the data.
The clients (workers) do not communicate among each other
but only with the database. In the application presented here,
AutoDock was used as the docking engine, while DAIM,16
Witnotp,17 CHARMM,18 and MOPAC19 were employed for
preparing the compound library, file type conversion, mini-
mizing poses, and quantum mechanical calculations, respec-
tively. Because of the flexibility of DVSDMS, other pro-
grams can be used for docking and ranking. Alternative
procedures range from simple molecular mechanics energy
terms and combinations thereof20 to a quantum mechanics
based ranking approach.21 Furthermore, it is straightforward
to use DVSDMS for consensus scoring.22-24 In fact energy
values calculated by different scoring functions can be stored
in tables for ranking.
DVSDMS was validated in this study by docking about
1.5 million compounds into the ATP-binding site of the
receptor tyrosine kinase EphB4 and ranking about 100
million poses using two Beowulf clusters (located on the
same grid but with a number of switches ranging between 1
and 4). In the productive phase of docking and ranking the
average load of the database management system was less
than 10% and 30% with more than 500 workers requesting
jobs, respectively. In a stress test, the database server built
on a low cost Linux PC was able to distribute about 60
molecules per second.
DOCKING AND RANKING BY DVSDMS
The following three subsections describe briefly the overall
process and programs used for docking and ranking in this
application of DVSDMS. Details of the DVSDMS architec-
ture are given in the next section.
Predocking. All structures and properties of the molecules
required for docking and ranking were calculated and stored
in the database. For each molecule in the ZINC library25
(version 7) CHARMm26 atom types were assigned with
Witnotp.17 Then DAIM16 was applied to calculate the atomic
and chemical properties of each molecule (listed in Table
1). Even though not all of these properties were used in
docking and ranking, they were prepared for different kinds
of filters one might want to apply before docking. Besides
these properties, the mol2 file of each molecule was also
Table 1. Structure of Table “ZINCMOL”a
column name data type explanation
zincmol.id int(11) unsigned not null auto_increment a unique identity for each molecule
zincmol.numatoms tinyint(3) unsigned not null number of atoms
zincmol.numc tinyint(3) unsigned not null number of carbon atoms
zincmol.numn tinyint(3) unsigned not null number of nitrogen atoms
zincmol.numo tinyint(3) unsigned not null number of oxygen atoms
zincmol.numhal tinyint(3) unsigned not null number of halogen atoms
zincmol.nums tinyint(3) unsigned not null number of sulfur atoms
zincmol.nump tinyint(3) unsigned not null number of phosphorus atoms
zincmol.numarombnd tinyint(3) unsigned not null number of aromatic bonds
zincmol.numdoubbnd tinyint(3) unsigned not null number of double bonds
zincmol.numtribnd tinyint(3) unsigned not null number of triple bonds
zincmol.numamibnd tinyint(3) unsigned not null number of amide bonds
zincmol.numacc tinyint(3) unsigned not null number of hydrogen bond acceptors
zincmol.numdon tinyint(3) unsigned not null number of hydrogen bond donors
zincmol.numring tinyint(3) unsigned not null number of rings
zincmol.totringsize tinyint(3) unsigned not null number of heavy atoms in rings
zincmol.longestchain tinyint(3) unsigned not null longest chain of atoms in the molecule
zincmol.wienerind4 float(16,14) not null Wiener index
zincmol.numbnd tinyint(3) unsigned not null number of bonds
zincmol.numfrg tinyint(3) unsigned not null number of fragments
zincmol.numrotbnd tinyint(3) unsigned not null number of rotatable bonds
zincmol.mw float(8,3) unsigned not null molecule weight
zincmol.clogp float(5,2) not null CLogP
zincmol.charge int(2) not null formal charge
zincmol.mol2file blob compressed mol2 file
zincmol.tag1 char(20) default null notes of calculation status for first target
zincmol.tag2 char(20) default null notes of calculation status for second target
... ... ...
zincmol.tagn char(20) default null notes of calculation status for nth target
a The data types are represented in MySQL syntax.33 The column “zincmol.id” is the primary key. The auto-incremental identifier can be
used to discriminate individual protonation states and/or tautomeric forms. The 23 following columns contain the atomic and chemical
properties of a molecule. The column “zincmol.mol2file” contains the compressed molecule file in mol2 format. The last columns
“zincmol.tagn” (tag columns) record the calculation status for each protein target (e.g., multiple structures of protein or multiple proteins).
Besides the primary key on column “zincmol.id”, indexes are built on tag columns to speed up checking of the status by the computing clients.
Other columns were not indexed because there was no query on them in the applications presented here.
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stored in the database. A table termed “ZINCMOL” (Table
1) was designed to store these data (Figure 1).
Docking. AutoDock10 (version 4) was applied for docking
small molecules from the library into the receptor (see the
Supporting Information). The poses of each molecule in the
PDB format, with their interaction energies with the receptor
and efficiencies (electrostatics and vdW), were stored in the
table “POSE” (Table 2) of the database. During the docking,
the computing clients acquired the 3D structure of the
molecules directly from the database and stored poses and
energies in the database after each docking process finished
(Figure 1).
Ranking. Different scoring approaches can be handled
efficiently by DVSDMS. In the present application to the
EphB4 kinase, we used an in-house developed approach
based on calculations of semiempirical quantum mechanics
to efficiently rank the poses (Zhou et al., manuscript in
preparation). Ranking a pose was usually faster than docking
a molecule; therefore, the former needed a more efficient
database I/O environment than the latter (see Results).
ARCHITECTURE OF DVSDMS
Database Structure. All the actions of the computing
clients were coordinated by the database server (Figure 2).
Three tables are necessary in the database for handling poses
and molecules: one for the data of the molecules (Table 1),
one for the poses from docking (Table 2), and one for the
results of the ranking process (Table 3). Besides the
properties of the molecules and mol2 files, the column
“zincmol.tag” was added to Table “ZINCMOL” to record
the status of docking. The format of the “zincmol.tag”
column is shown in Figure 3. In the case of multiple protein
targets, additional tag columns can be appended for each of
the targets to record the status of docking processes. If the
amount of targets is large and the appended tag columns
affect the efficiency of the database, the ZINCMOL table
can be vertically partitioned like the POSE table (not used
in this application, see Partitioning Large Tables). The main
columns, such as the properties and the coordinates of
molecules, do not need to be copied for each target. If the
molecule has not been handled for the specific target, the
related “zincmol.tag” column is set to “null”. Before the
docking starts the non-drug-like molecules (according to
user-defined filters) can be marked as “not passed” at
“zincmol.tag” columns (see Results). The database server
returns one of the molecules with a “null” tag when a docking
client requests a job. The molecules which were marked as
“not passed” will not be returned to computing clients. The
“pose.tag” column of Table “POSE” (Table 2) was parti-
tioned into another table (“POSETAG”, Table 4) to improve
the database performance (see Partitioning Large Tables).
Column “posetag.sign” in the Table “POSETAG” is the
status of ranking process of the related pose: “1”, “2”, “3”,
and “6” mean “in process”, “finished normally”, “finished
with errors”, and “unhandled”, respectively. When a ranking
client requests a job, the database returns a set of poses with
“unhandled” signs.
Interface between Software Packages. Python scripts
were developed for connecting all software packages in
DVSDMS. The whole process needed the cooperation of
several types of software (Table 5) developed by different
groups. Therefore, some jobs such as converting file type,
preparing input files, and parsing output files were needed
to connect each stage of the pipeline. The communication
to the database is essential in the DVSDMS. The Python
package SQLAlchemy27 is used to establish the crucial
connection of python scripts (connecting the different stages
of the docking pipeline) and the MySQL database (the data
and result storage facility). The package Elixir28 (object-
relational mapping features) facilitates the consequent treat-
ment of all data entries as objects, which results in clean
code such that raw SQL statements are used only in
performance critical parts.
Running on Standalone and Cluster Computers. DVS-
DMS runs as a single executable Python script on standalone
or cluster computers without a queuing system. In the
presence of a queuing system DVSDMS can be submitted
to the queue with a runtime limit in accordance with the
configuration of the queuing system. In this case, the
DVSDMS client estimates the execution time of the next
job before acquiring it from the database.
Monitoring Process and Identifying Errors. Users can
monitor progress of the computation and trace errors by
means of “sign” and “tag” columns of the corresponding
tables in DVSDMS. The docking status of a molecule,
machine name of the client, and the starting time of the job
Figure 1. Schematic representation of docking and ranking
processes. Red boxes indicate the public-domain databases, while
blue parallels mean the tables in DVSDMS.
Table 2. Structure of Table “POSE”a
column name data type explanation
pose.id int(11) not null
auto_increment
a unique identity for
each pose
pose.ele float electrostatic interaction
pose.elee float electrostatic efficiency
pose.vdw float vdW interaction energy
pose.vdwe float vdW efficiency
pose.pdbfile blob compressed pdb file
pose.mol_id int(11) unsigned
not null
related zincmol.id in
Table “ZINCMOL”
a The data types are represented in MySQL syntax.33 The
Column “pose.id” is the primary key. An index is built on Column
“pose.mol_id”, which is a pointer for connecting the record in Table
“POSE” to the one in Table “ZINCMOL”. The value of Column
“pose.mol_id” equals to the value of the primary key of Table
“ZINCMOL”.
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can be read from Column “zincmol.tag” in Table “ZINC-
MOL” (Figure 3). In Table “POSETAG”, Column “posetag.
sign” is further separated from Column “posetag.tag” (Table
4) because in the I/O intensive ranking stage, the database
only needs to scan “posetag.sign” to attain the status of the
pose when requested for an “unhandled” pose.
Distributed computing systems are more prone to error
than a standalone computer. It is very labor-consuming to
reroll the process and locate errors when millions of
compounds are handled in a high-throughput screening
campaign. DVSDMS records stage information of clients in
“sign” and “tag” columns and can check the status of jobs
with user-defined frequency. Practically if a job does not
finish during a given period of time, its status will be set to
“unhandled”, and its executing client will be reported. Then
the job returns to the waiting list and is ready to be assigned
to another free client.
PERFORMANCE TUNING
The optimization of DVSDMS focuses on the database
performance tuning because, as mentioned above, the data
management is separated from the main docking and ranking
applications in DVSDMS. In the following, details on the
process of optimization are given.
Figure 2. Hardware and data flow in DVSDMS. Note that in the application presented here the user’s machine, backup machine, and
database server were all on a single PC.
Table 3. Structure of Table for Ranking (PROBENER in Our
Application)a
column name data type explanation
probener.id int(11) not null
auto_increment
auto increment
“probener” id
probener.p1 float interaction energy with
the first probe
probener.p2 float interaction energy with
the second probe
... ... ...
probener.pn float interaction energy with
the nth probe
probener.pose_id int(11) related pose.id in
Table “POSE”
a The data types are represented in MySQL syntax.33 The
Column “probener.id” is the primary key. An index was built on
Column “probener.pose_id”, which is a pointer for connecting the
record in Table “PROBENER” to the one in Table “POSE”. The
value of Column “probener.pose_id” equals to the value of the
primary key of Table “POSE”.
Figure 3. Format of “zincmol.tagn” column in Table “ZINCMOL”.
Table 4. Structure of Table “POSETAG”a
column name data type explanation
posetag.id int(11) not null
auto_increment
auto increment
posetag ID
posetag.pose_id int(11) related pose.id
in Table POSE
posetag.sign int(2) unsigned
default ‘6’
sign of status
posetag.tag char(20) default null note for calculation
status
a The data types are represented in MySQL syntax.33 The
Column “posetag.id” is the primary key. The Column
“posetag.sign” was introduced for efficient retrieval of the ranking
status. The meanings of signs are mentioned in the main text. An
index was built on Column “posetag.pose_id”, which is a pointer
for connecting the record in Table “POSETAG” to the one in Table
“POSE”. The value of Column “posetag.pose_id” equals to the
value of the primary key of Table “POSE”.
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Using Database Index. An index was created on the
column which was of high querying frequency. Each table
has a primary key, a unique index to identify each row in a
table, used for attaining the specific record promptly. For
instance, with the primary key, any molecule record in the
Table “ZINCMOL” can be retrieved out of millions of others
by its ID stored in the Column “zincid.id” (Table 1) in one
millisecond after the index was cached in the memory (see
RESULTS section for hardware description). This is also
valuable when the application needs to find out which
molecule a given pose belongs to via Column “pose.mol_id”
in Table “POSE” (Table 2). Similarly, but in an inverse way,
the index of Column “pose.mol_id” (Table 2) is of use for
fast reverse query, e.g., attaining poses related to a molecule.
Only columns frequently queried are indexed. Other columns,
e.g., interaction energies of poses and ranking scores, are
not indexed because each additional index increases the size
of the database and reduces the writing speed of tables.
Partitioning Large Tables. The performance of the
database can be improved by partitioning large tables. During
the database scan operation initiated by a query, only
partitions containing the data are accessed, and during the
maintenance, only damaged partitions instead of the entire
table are repaired. Furthermore, the partitioned tables can
be distributed on different physical drives, and tables can
be scanned in parallel to improve both CPU and disk
performance (which was not necessary for the present
application). Two major forms of partitioning were applied
in our database:
Horizontal Partitioning: Tables “ZINCMOL” and “POSE”
were horizontally segmented into 50 partitions according to
the hash function of their primary keys. Partitioning by hash
is used primarily to ensure an even distribution of data among
a predetermined number of partitions.29 The value of a hash
function determines the membership of a partition, e.g., the
hash function returns an integer from 0 to 49 in the case
with 50 partitions. The horizontal partitioning feature is
supported by MySQL starting from version 5.1.
Vertical Partitioning: The most referenced columns “sign”
and “tag” in the original Table “POSE” were separated into
a new table “POSETAG” (Figure 4). Table “POSE” and
“POSETAG” referred to each other via the column “pose.id”
in “POSE” and the column “posetag.pose_id” in “POSETAG”.
This relation is analogous to foreign key constraints in the
context of relational databases, even though MyISAM30 (see
Storage Engine) still does not support it in the latest version
(MySQL 6.0). In this way, when handling the status of poses,
the database management system only scanned the smaller
table (“POSETAG”) with the fixed row format instead of
the large and dynamic table (“POSE”). In addition, different
storage engines could be applied on different tables (see
Storage Engine).
Storage Engine. Most tables in the database are con-
structed with MyISAM,30 which is the default storage engine
of MySQL due to its very low overhead, except for Table
“POSETAG” constructed with InnoDB.31 InnoDB uses more
memory as cache to achieve a high performance. In fact,
the database engine does not allow parallel accesses: a client
has to lock the object for an update to prevent conflicting
with other clients. InnoDB implements row-level locking,
so that InnoDB only locks the rows needed for update instead
of locking the entire table as MyISAM does. This feature is
advantageous to concurrent updating from multiconnections
with low lock wait ratio (LWR). The LWR is the percentage
of queries that are required to wait for object locks to be
released so that the query can itself acquire a lock on the
object, e.g., many clients can update statuses of poses by
modifying the Table “POSETAG” synchronously. The
parallel performance of DVSDMS can be estimated by the
LWR. A low LWR means that the performance loss due to
the multiple connections of database is marginal. By using
InnoDB instead of MyISAM as the storage engine of
“POSETAG”, the LWR of the database is reduced signifi-
cantly, specifically in the ranking process MyISAM often
induced a deadlock (LWR≈100%) while InnoDB reduced
LWR to less than 0.1%.
Table 5. Software and Its Function
software name function ref
DAIM calculate the properties
of molecules
16
AutoDockTools convert molecule file
into pdbqt type
34
AutoDock dock small molecules
into receptor
10
CHARMM add hydrogen atoms,
and minimize structure
18
Witnotp convert molecule file
types among mol2, pdb, and psf
17
MOPAC calculate QM energies
used for ranking
19
MySQL the database
management system
35
SQLAlchemy the database toolkit
for Python
27
Elixir a declarative layer on
top of SQLAlchemy
28
Figure 4. Vertical partitioning of Table “POSE”. The value of
Column “posetag.id” in “POSETAG” (Table 4) has no relation to
that of Column “pose_id”. The value of Column “sign” can be “1”,
“2”, “3”, and “6”, which mean “in process”, “normally finished”,
“finished with errors”, and “unhandled”, respectively.
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Local Cache and Bulk Update. The performance of the
database can be improved by using local cache and bulk
update, which were especially important for the short-term
process, such as ranking in our calculation. Otherwise, the
applications communicated with the database with high
frequency and cast a heavy burden on the database. In our
application, 2000 poses were retrieved from the database by
a single SQL command and stored in the local memory.
During the calculation, every result of single pose was stored
in memory temporarily, which works as local cache. After
all the ranking calculations of these poses had been finished,
the client sent the results to the database and updated multiple
rows (bulk update) by another SQL command. In this way,
the clients only need to communicate with the database twice
for handling 2000 poses. Note that if the amount of poses
retrieved by the client using a single SQL command is too
small, there will be no obvious increment of performance.
Conversely, a large amount of poses will increase the
individual query time and the memory use of the database
server.
Compressing Molecule Files. Compressing molecule files
is favorable for saving disk space and network bandwidth
and decreasing the I/O intensity. For a normal PDB or MOL2
file, compression reduced its size by about 75% using zlib.32
The compression and decompression work was performed
by the clients and would not influence the load of the
database server. After compression, the Table “POSE” used
93.1GB hard disk for about 100.8 million poses and their
energies (Table 2).
RESULTS
Benchmark. Since we could not access a large computer
cluster, we wrote an emulator of a docking client to test the
performance of DVSDMS under conditions typical of very
large clusters where the bottleneck is the master rather than
the clients. In fact, our emulator does not run the real docking
calculation but only requests jobs from the master and returns
the output data, such as randomized interaction energies and
efficiencies as well as binding poses (Figure 5). Note that
emulated docking does not require any CPU time, which is
essential to estimate the maximal rate of distribution of
molecules (maxRoD) to the computer clusters we could
access (e200 nodes). The benchmark database server was
built on a dedicated desktop computer, which had two Xeon
3.06 GHz CPUs, 2 GB of RAM, and a 250GB normal speed
hard disk drive (maximal reading speed 50MB/s). The
efficiency of a parallel docking program based on the master-
worker scheme can be measured by the maxRoD of the
master. A series of test cases was performed with the amount
of emulators ranging from 1 to 160 and running one emulator
per core. Two Beowulf clusters at the University of Zu¨rich
were used: The Etna and Matterhorn, which are separated
from the master by one and four switches, respectively. Both
clusters and the master are on a Gigabit network. The time
required for emulated docking of 128000 molecules, which
is a subset of ZINC library, is shown in Figure 6 for different
numbers of emulators. The minimal times for the simulated
docking are 1816 and 2292 s on the Etna and Matterhorn
cluster, respectively. The lower amount of switches to reach
Etna yields about 26.2% performance improvement in the
benchmark. Note that the system load of the master does
not hit 100% when the maxRoD reaches the plateau at about
12 cores (or emulators), which indicates that the network
delay rather than the capacity of the master limits the overall
performance. The maxRoD of DVSDMS running on Etna
and Matterhorn are 70 and 56, respectively. The MaxRoD
of the MPI version of DOCK14 is about 19 (see the
Supporting Information). Therefore the DVSDMS is about
two times faster than the MPI version of DOCK on the Blue
Gene/L platform. Even though the HTC version of DOCK
Figure 5. The flowchart of the docking emulator. In the benchmark the average amount of poses for each molecule is 37 ( 3 and the
average size of each pose is 1 ( 0.5KB, which are consistent to the average in the real application to identify kinase inhibitors.
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and the DVSDMS have similar capacities for distributing
molecules (up to at least 16384 processors) it is easier to
implement other docking engines in DVSDMS than to write
a specific HTC version for each docking engine.
Performance in Production. The database server, backup
machine, and the user’s machine (Figure 2) were all built
on the Linux desktop PC of the first author, which had dual-
core 3.4 GHz Pentium D, 3 GB of RAM, and 3×320GB
hard disks. The disk could read data at about 70 MB/s.
About 1.5 million compounds out of 3.8 millions in the
ZINC library passed the filters used for eliminating the non-
drug-like molecules (molecular weight <500 Da, number
of rotatable bonds e7, number of hydrogen bond donors g1,
and number of hydrogen bond acceptors g1). For the
compounds which did not pass the filters the column
“zincmol.tag” was set to “not passed”. About 15 to 20 min
were required for docking a single compound into the
receptor and CHARMM minimization of the poses (with a
rigid protein) on an Opteron Processor 252 (2.6 GHz). After
all the docking jobs had finished, about 100 million poses
were stored in Table “POSE”, 80% of which were selected
for ranking according to their interaction energies and
efficiency. The computational time required for ranking a
pose ranged from 1 s to 15 min depending on whether further
calculations were needed for the pose and/or the convergence
of quantum mechanical calculations.
The jobs were carried out by the Etna and Matterhorn
clusters and some standalone computers simultaneously. The
number of processors varied dynamically depending on the
availabilities. The load of the database was low during the
docking process using about 500 clients (<100 queries/s,
about 100KB/s traffic of network, and <10% overall system
load), because each docking client only communicated with
the database 3 to 5 times per hour. Therefore, if the master
of DVSDMS can distribute 60 molecules per second and a
client requests 5 molecules per hour, the database server can
support up to 43200 computing clients with nearly linear
scalability if the clients are well synchronized. In contrast,
during the ranking process, the load of the database was high
(about 300 queries/s, 500-1000 KB/s traffic of network, and
about 30% overall system load), because ranking 2000 poses
usually took less than 5 min, and each of the 500 clients
communicated with the database more than 12 times per
hour. Note that docking and ranking could be combined
sequentially to reduce the load of database.
CONCLUSIONS
DVSDMS uses freely available database software for
efficient and automatic virtual screening distributed on Linux
platforms. The essential concept of DVSDMS is the separa-
tion of data management from the main jobs in virtual
screening, i.e., docking and ranking. In this way, the user
has full flexibility on the choice of software for docking and
ranking as well as hardware. Organized by DVSDMS, jobs
are dispatched to each computing client to optimally exploit
the available resources even in the case of heterogeneous
hardware. Users not only can control and inspect the
computing process but also attain consistent and logically
organized data while computing is in progress or finished.
Because docking and ranking consist of many independent
jobs, they are typically suited for a coarse-grained parallel
architecture. In DVSDMS, computing clients do not com-
municate among each other but only with the database server.
When a job is requested by a client, the database server scans
the handling statuses and returns an unhandled job. In this
way, a priori job partitioning is not required, and the overall
computational load can be distributed equally to all comput-
ing clients. Moreover, the queue of jobs can be modified at
any time; new jobs can be added to the computational
pipeline by appending them to the database, while existing
jobs can be removed before they start to run.
Upon performance tuning, the evaluation of the number
of queries, the duration of queries, and the data flow indicate
that the overall performance of DVSDMS is good. In
particular, local cache and bulk updates reduce the query
number; database index, proper storage engine, and database
partitioning speed up queries; and data compression reduces
Figure 6. The duration of simulated docking of 128000 molecules
with different numbers of emulated docking clients. Note that each
core runs only one emulator. (Top) The emulators were submitted
to the Matterhorn cluster (80 compute nodes each with dual-
processor Opteron 2.4 GHz or 2.6 GHz), from which data needed
to pass 4 switches to reach the database server. With more than 12
emulators, the database server, i.e., the master of DVSDMS,
achieves a maximal rate of distribution of molecules (maxRoD) of
about 56 per second on average (128000/2292s). (Bottom) On the
Etna cluster (3 compute nodes each with dual Quad Core Xeon
2.33 GHz), the data only needed to pass 1 switch to reach the
database server, and the maxRoD increased to about 70 per second
on average (128000/1816s). Note that the delay due to the network
equipment is negligible when there is a small quantity of requests.
In both benchmarks however, the database server needs to respond
to thousands of requests per second, so that the network delay limits
the overall performance, and the plateau of the maxRoD is due to
the network.
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the data flow. Furthermore, since the database management
system works as the master of DVSDMS, most of its
sophisticated techniques (e.g., read write splitting and
database cluster) can be applied directly to improve the
performance of the master avoiding the overload without
modifying the code for docking and ranking. In a docking
benchmark, the master of DVSDMS built on a low cost
Linux PC could distribute about 60 molecules per second.
Furthermore nearly linear scalability of DVSDMS is expected
up to 50000 nodes.
In the application presented here, docking the ZINC library
into the receptor tyrosine kinase EphB4 with AutoDock and
ranking poses under the control of DVSDMS, a low cost
Linux PC was perfectly competent for the database server
connected to about 500 computing clients. Since, the database
management system MySQL and the program language
Python are both open-source projects, DVSDMS can be
applied in high-throughput virtual screening campaigns
without restrictions typical of proprietary software.
AVAILABILITY OF DVSDMS
All scripts are available at http://biocroma.uzh.ch/zhou/
dvsdms/.
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DOCKING DETAILS
Before docking, the atom-specific affinity map files were created by AutoGrid.1 The
numbers of points in the x, y, and z directions were 62, 52, and 42, respectively, and the
spacing between two adjacent grid points was 0.25 Å. The AutoDock2 program was used to
produce poses for further minimization and the custom ranking (Zhou et al., in preparation).
To speed up the calculation, the maximum number of energy evaluations was set to 25000.
The docking was followed by CHARMM3 minimization using the CHARMm force field.4 To
suggest enough poses for minimization and testing of the ranking protocol, the hybrid genetic
algorithm in AutoDock was run 400 times with different initial seeds. The poses were
minimized with the rigid protein after docking, and the duplicated poses were eliminated by
clustering using an all-atom RMSD cutoff of 0.01 Å.
THE ESTIMATION OF THE MAXIMUM AMOUNT OF MOLECULES DISTRIBUTED
PER SECONDS FOR THE MPI VERSION OF DOCK
The estimation is based on “High Throughput Computing Validation for Drug Discovery
Using the DOCK Program on A Massively Parallel System”5 where the authors used a subset
of 27005 drug-like ligands as a benchmark. Supposing that the efficiency of the “master” of
MPI-DOCK is 100%, which is the upper limit, it took about 50000 seconds to finish docking
on 256 Blue Gene/L processors. By increasing the number of processors to 16384, the
efficiency diminished to about 55% due to the overload of the master. Therefore, the
maximum amount of molecules distributed per seconds is about 19, which is calculated by
50000 25627005
55% 16384
 
  
.
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Abstract: We introduce the mixed product of three vectors spanning four molecular locations as
a descriptor of optical isomerism. This descriptor is very efficient as it does not require molecular
superposition, and is very robust in discriminating between a given isomer and its mirror image.
In particular, conformational isomers that are mirror images of each other, as well as optical
isomers have opposite sign of the descriptor value. For efficient database searches, the optical
isomerism descriptor can be used to complement an available ultrafast shape recognition (USR)
method based solely on distances, which is not able to distinguish enantiomers. By an extensive
comparison of the USR-based similarity score with an approach based on Gaussian molecular
volume overlap, the accuracy and completeness of the former are discussed.
1 Introduction
Shape complementarity is essential in macromolecular recognition and binding of small molecules
to proteins because of the sensitivity of the van der Waals energy at separations close to the optimal
distance. There is abundant experimental evidence that small molecules with shape similar to
known active compounds are likely to have similar biological activities.1 Therefore, screening
of databases of three-dimensional (3D) molecular structures can be performed by comparison of
molecular shapes.2–4 Several methods have been developed and applied in the past few decades
to identify compounds similar to a query molecule.5–10 They are useful whenever one or more
inhibitors of a target protein are known particularly when the 3D structure of the protein is not
available.
Recently, a method termed Ultrafast Shape Recognition (USR) has been developed for search-
ing very large databases of molecular structures.11 Despite its recent publication, USR has already
been used in several drug design projects3,12–15 because of its simplicity and efficiency. Im-
portantly, the molecules do not need to be superposed. Only, the distances between each atom
of the molecule and four molecular locations are calculated for USR: the molecular centroid
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(ctd), the closest atom to ctd (cst), the farthest atom to ctd (fct), and the farthest atom to fct
(ftf). The shape of a molecule is then encoded by 12 descriptors independent of the number of
atoms. The first descriptor is the mean of atomic distances from ctd μctd1 ≡ 1N ∑Nj=1 dctdj , where
d j is the distance of the jth atom from ctd, and N is the number of atoms in the molecule. The
second descriptor is the square root of the second central moment of the distribution of the same
atomic distances μctd2 ≡ [ 1N ∑Nj=1 (dctdj −μctd1 )2]1/2. The third descriptor is the cubic root of the
third central moment of the same distribution μctd3 ≡ [ 1N ∑Nj=1 (dctdj −μctd1 )3]1/3 which is a measure
of asymmetry. The remaining nine descriptors are calculated analogously using cst, fct, and
ftf. Since only intramolecular distances are used in the 12 descriptors, the USR is not able to
distinguish mirror images. Here, we supplement the original USR method11 with an optical
isomerism descriptor that is able to discriminate a molecule from its mirror image, and is therefore
particularly useful for clustering conformers and searching 3D databases. Our extension of USR
(called USR:OptIso) is first tested on three pairs of conformations of kinase inhibitors and 15
pairs of different types of isomers. Then similarity scores based on USR and USR:OptIso for
1.6×1010 pairs of conformers of 2.7 millions small molecules are compared with the ones based
on Gaussian molecular volume overlap16 calculated by ROCS (OpenEye Scientific Software).
2 Methods
Optical isomerism descriptor. Considerable efforts have been devoted to symmetry detection
in chemistry and chemoinformatics. In particular, several methods have been developed to analyze
chirality. These include two-dimensional descriptors17–19 for the prediction of the major product
of stereoselective reactions,20–22 and three-dimensional descriptors (chiral topological indices)
as complement to distance matrices in quantitative stereochemical structure-activity relationship
models.23–29
Here, the following vectors are introduced for the efficient evaluation of the optical isomerism
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descriptor: a ≡ cst− ctd, b ≡ fct− ctd, and c ≡ ftf− ctd, where ctd, cst, fct, and ftf are the
vectors connecting the origin of the coordinates to each of the four molecular locations (Figure
1). The optical isomerism descriptor is defined as the cubic root of the scalar triple product
(or mixed product) of a, b, and c, i.e., optical isomerism descriptor ≡ [c · (a×b)]1/3. The cubic
root is used to obtain a unit of length (Å) as for the other 12 descriptors. The ability of the
optical isomerism descriptor to discriminate isomers is presented in Figure 2. For a molecule
and its mirror image the 12 descriptors of the original USR method are identical because they
only depend on distance distributions. However their optical isomerism descriptors are opposite
because their four molecular locations are mirror images as well. In contrast, structural isomers,
diastereoisomers, and other types of conformers that are not mirror image of each other have
different distance distributions. Therefore, the first 12 descriptors are enough to discriminate them.
The computational cost for evaluating the optical isomerism descriptor is neglectable, since the
coordinates of the four molecular locations have to be calculated for the other 12 descriptors.
During the writing of this manuscript, Armstrong et al. reported a modification of USR that is
able to distinguish enantiomers.30 They use the cross product of two vectors spanning three of
the four USR molecular locations (ctd, fct, and ftf) to define a fourth location which is different
from cst. In contrast, the crucial component of our descriptor is the triple product of three vectors
spanning all of the four locations. Moreover, Armstrong and collaborators replace three of the 12
USR descriptors (those involving cst) whereas we supplement the USR with the optical isomerism
descriptor. Note that the atomic distances to ctd are different from that to cst as the separation
between ctd and cst is usually between 0.4 and 2.0 Å for small molecules (Suppl. Mat. Figure
S-1).
Similarity score. The inverse Manhattan distance is used as similarity score:11
Spq =
1length unit
1length unit+ 1n∑
n
i=1 |Mpi −Mqi |
,
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optical isomerism descriptor ≡ [c · (a×b)]1/3
Figure 1: Optical isomerism descriptor. The four molecular locations of a conformer of compound
1 are denoted with red circles, and the three vectors a, b, and c with blue arrows. The optical
isomerism descriptor is the cubic root of the volume of the parallelepiped with blue edges. The
sign of the optical isomerism descriptor is negative for this conformer because c and a×b form
an obtuse angle (violet angle α). The mirror image of this conformer has a positive value of the
optical isomerism descriptor, and is shown in Figure 3.
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Isomer1 Isomer2 Type of Isomerism OID1 OID2 ROCS
Structural isomerism: 
functional group 
isomerism
0.891 0.887 0.153 -0.032 0.999
Structural isomerism: 
position isomerism 0.802 0.789 0.396 -0.106 0.825
Structural isomerism: 
skeletal isomerism 0.826 0.833 0.838 0.911 0.892
Conformational 
isomerism 1.000 0.889 0.815 -0.815 0.667
Diastereoisomerism: 
cis/trans 0.979 0.972 0.456 0.334 0.685
Diastereoisomerism: E/Z 0.922 0.928 0.000 0.000 0.302
Chirality with one 
stereogenic centers: R/S 1.000 0.910 0.642 -0.642 0.997
Chirality without 
stereogenic centers: 
allenes
1.000 0.884 0.849 -0.849 0.997
Chirality without 
stereogenic centers: 
alkylidenecycloalkanes
1.000 0.860 1.054 -1.054 0.953
Chirality without 
stereogenic centers: 
spiranes
1.000 0.987 -0.087 0.087 0.963
Chirality without 
stereogenic centers: 
byphenyls - 
atroposomerism
1.000 0.964 -0.238 0.238 0.993
Chirality without 
stereogenic centers: 
helicenes
1.000 0.790 1.725 -1.725 0.703
Chirality without 
stereogenic centers - 
planar chirality: 
cyclophanes
1.000 0.759 2.053 -2.053 0.322
Chirality without 
stereogenic centers - 
planar chirality: 
annulenes
1.000 0.863 1.035 -1.035 0.947
Chirality without 
stereogenic centers - 
planar chirality: 
cyclalkenes
1.000 0.809 -1.514 1.514 0.957
Cl
Cl
OH
CH3
Br
Cl
OH
CH3
Cl
Br
CH3
OHF
Cl CH3
OHCl
F
O
O O
O
H3C
Br
CH3
Br
OH
CO2H
S12pq S
13
pq
0.4 0.5 0.6 0.7 0.8 0.9 1.0
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Spq
12
S
pq1
3
●
●
●
●●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●
●
●
●
●●
●
●
●
●●
●●
●●
●●
●●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
0.80 0.85 0.90 0.95 1.00
0.
80
0.
85
0.
90
0.
95
1.
00
Spq
12
S
pq1
3
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
● ●
●
Figure 2: Application of the optical isomerism descriptors to isomers. All pairs of isomers can be
distinguished by the USR:OptIso (13 descriptors) because the optical isomerism descriptors (OID1
and OID2) of mirror image isomers have opposite signs. The scatter plots show the pairwise USR
comparisons of these 30 compounds (top right, full data set; bottom right, zoom-in on values close
to 1). The original USR (S12pq) and USR:OptIso (S
13
pq) methods assign close similarities except
for 10 pairs (blue diamonds) out of 435. The five pairs of isomers that can be distinguished by
both S12pq and S
13
pq are denoted with red diamonds. The dashed line represents S
13
pq = S
12
pq. The last
column of the table is the ROCS shape Tanimoto.16
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where Mpi is the ith descriptor of the conformation p. Note that all the USR descriptors have a
unit of length, which is Å here, therefore the Spq is dimensionless. The addition of 1 length unit at
the denominator prevents a division by zero in the case of identical 3D structures, and yields a
similarity score of 1 for them. The similarity scores with the optical isomerism descriptor (S13pq)
and without (S12pq) are analyzed in the following.
First, it is interesting to compare the USR-based similarity scores with a metric based on
superimposed volume. The correlation coefficient between the similarity score based on Gaussian
molecular shape overlap and either S12pq or S
13
pq is 0.64 for the 30 compounds in Figure 2. This
relatively low correlation is due to the fact that the similarity score evaluations are based on two
different procedures. In the former, the similarity is calculated by volume-overlap percentage
after structural superposition, whereas in USR, the similarity is evaluated using distributions of
nuclei distances from the molecular centroids. Moreover, neither the iterative maximizing of the
overlapped molecular volume in ROCS nor the maximum/minimum function for determining
centroids in USR is continuous with respect to the Cartesian coordinates of the atomic nuclei,
which are used as input. These two methods are compared extensively on around 1.6× 1010
conformation pairs in the section Results and Discussion.
3 Results and Discussion
Mirror images, clustering, and database searches. A recently published inhibitor of the
receptor tyrosine kinase Ephrin type-B receptor 4 (EphB4)13 is used to illustrate the usefulness
of the optical isomerism descriptor (Figure 3). The similarity score S13pq is able to distinguish
the two mirror image conformers of compound 1 because of the opposite sign of their optical
isomerism descriptors. In contrast, the two conformers of 1 have identical 12 descriptors based on
the original USR method.11
The optical isomerism descriptor is useful for clustering as it can distinguish between different
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conformers/isomers that would be clustered together by the original USR. In our previous study,13
multiple conformers of 1 were generated by systematic bond-rotation and optimized to their
nearest local minima using density functional theory. Two local minima were then considered
identical if their similarity score Spq was higher than 0.999. Interestingly, the opposite sign of the
optical isomerism descriptor contributes significantly to the identification of mirror images (or
pairs of conformers very close to mirror images), in particular when S12pq is close to 1 (Figure 4).
Furthermore, the USR:OptIso was tested on two pairs of isomers of recently published kinase
inhibitors (2 and 3 in Figure 5 and Figure 6, respectively).31,32 The first 12 descriptors of USR
have identical values, while the optical isomerism descriptor reduces the similarity score from 1
to 0.705 for compound 2 and from 1 to 0.650 for compound 3.
The optical isomerism descriptor can be used for searching (multi-)conformational libraries.
As an example, using the similarity score S13pq yields only the conformer similar to the query
whereas the conformations that are similar to its mirror image might be retrieved erroneously if
one neglects the optical isomerism descriptor.
Finally, it is necessary to verify that similar conformers of a given molecule yield very similar
values of S12pq and S
13
pq. A set of 100 similar structures of the protein kinase inhibitor PP2
33
was used for assessing the robustness upon minor structural change of the original USR and
USR:OptIso. A scatter plot is presented in Suppl. Mat. Figure S-2. This test indicates that slight
changes in the coordinates yield minor changes in both S12pq and S
13
pq when they are close to 1. Note
that the high similarity range (i.e., values close to 1) is the most relevant case for virtual screening
as only a small fraction of hits can be tested in practice.
Potential limitations of the optical isomerism descriptor. The optical isomerism descriptor
is the cubic root of the (signed) volume of the parallelepiped defined by three vectors connecting
four molecular locations. It is therefore equal to zero whenever the four molecular locations are
coplanar. To estimate the frequency of the coplanarity of these four locations, we calculated the
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Mp = (3:93; 1:47;¡0:83; 3:93; 1:50;¡0:85;7:23; 3:21;¡2:39; 7:01; 3:10;¡1:39;¡2:64)
+
Spq =
1
1 + 1
n
Pn
i=1 jMpi ¡Mqi j
)
(
n = 12 S12pq = 1:000
n = 13 S13pq = 0:711
*
M q = (3:93; 1:47;¡0:83; 3:93; 1:50;¡0:85;7:23; 3:21;¡2:39; 7:01; 3:10;¡1:39; 2:64)
*Isomer q of compound 1
Isomer p of compound 1
N
N
N
NHN
O
O
O
N
N
N
NHN
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O
Figure 3: The two mirror images of 1 generated by systematic bond-rotation are distinguished by
the optical isomerism descriptor. The four molecular locations are connected with black lines on
the 3D structures which are shown with sticks and transparent CPK models. This example shows
the high discriminating power of the optical isomerism descriptor whose usage results in a low
similarity score S13pq = 0.711 for the two mirror images of 1 whereas they are not distinguished by
the original USR method (S12pq = 1.000).
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Figure 4: Scatter plot of the similarity scores with the optical isomerism descriptor (S13pq) and
without (S12pq) for the 10,585 pairs of 146 local minima
13 of 1. The color of each data point
illustrates the sign of the optical isomerism descriptor (same and opposite signs are in red and
blue, respectively). The dashed line represents S13pq = S
12
pq.
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Mp = (4:20; 1:27;¡0:67; 4:33; 1:47;¡1:15; 7:36; 3:19;¡2:63; 7:03; 2:75;¡2:09; 2:72)
Mq = (4:20; 1:27;¡0:67; 4:33; 1:47;¡1:15; 7:36; 3:19;¡2:63; 7:03; 2:75;¡2:09;¡2:72)
)
)
(
S12pq = 1:000
S13pq = 0:705
*Isomer q of compound 2
Isomer p of compound 2
Figure 5: The two conformers of an inhibitor of protein kinase C are distinguished by the optical
isomerism descriptor. The conformer of compound 2 observed in the X-ray structure31 is shown
in the top, while its mirror image is shown in the bottom. The similarity score decreases from 1 to
0.705 by taking into account the optical isomerism descriptor.
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*q 3
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Figure 6: The two atropisomers of a p38 MAP kinase inhibitor are distinguished by the optical
isomerism descriptor. The active conformer, which is >100-fold more potent than the other
atropisomer,32 is shown in the top, while its mirror image is shown in the bottom. The similarity
score decreases from 1 to 0.650 by taking into account the optical isomerism descriptor.
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optical isomerism descriptor of 100,812,356 poses of about 2.7 million molecules (downloaded
from the 2007 version of the ZINC library34) generated by high-throughput docking into EphB4.35
Strikingly, only 28 poses (of 24 molecules) have an optical isomerism descriptor smaller than
0.01 in absolute value, which indicates that the optical isomerism descriptor is able in the vast
majority of cases to clearly discriminate a given isomer from its mirror image. Note that a value
of the optical isomerism descriptor different from zero does not necessarily imply that a molecule
is chiral. For this reason, we prefer to use the term “optical isomerism” rather than “chirality”
descriptor.
Comparison between similarity scores calculated by USR and ROCS. To compare similar-
ity scores calculated by USR and USR:OptIso with ROCS shape Tanimoto scores (the maximum
ratio of the overlap of a pair of Gaussian molecular volumes) the aforementioned 100 million poses
of about 2.7 million molecules from ZINC were used to generate 1.6×1010 pairs of conformations.
Notably, these two methods have very different algorithms to evaluate molecular shape similarity.
Cartesian coordinates are the only input required to calculate USR scores, whereas ROCS also
needs atomic radii to evaluate the Gaussian molecular volume. To compare the conformation
pairs filtered by different similarity cutoffs, the “accuracy” was defined as the number of pairs
for which both scores exceeded the cutoff divided by the pairs for which only the USR similarity
score exceeded the cutoff (i.e., C/(A+C) in Figure 7). In the same way, the “completeness” was
defined as the ratio of the number of pairs for which both scores exceeded the cutoff to the pairs
for which only ROCS shape Tanimotos exceeded the cutoff (i.e, C/(B+C) in Figure 7).
Both accuracy and completeness increase monotonously with the similarity cutoff (Figure
7). The accuracy of USR:OptIso has improved compared with the original USR, because the
mirror images of the query conformation have been eliminated by the opposite optical isomerism
descriptors. For instance, 91.25% of the conformation pairs that have USR:OptIso scores ≥ 0.968
also have ROCS shape Tanimotos ≥ 0.968, whereas the percentage decreases to 57.17% for the
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Figure 7: Accuracy and completeness of USR similarity score in reproducing ROCS shape
Tanimoto. In the left figure, the green and the red squares are the sets of conformation pairs for
which USR similarity scores and ROCS shape Tanimoto satisfy a particular cutoff, respectively.
Their overlap (yellow part) represents the conformation pairs for which both similarity scores
satisfy the cutoff. In the right figure, the cutoff varies from 0.9 to 1.0, which covers the range
interesting for virtual screening applications. The solid and dashed lines represent accuracy and
completeness, respectively, while the red and black color denote the USR and USR:OptIso results,
respectively.
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original USR. If the similarity score cutoff is set to 0.98, the accuracy of the USR:OptIso increases
to 99.02% compared to 86.30% for the original one. Figure 8 (a) shows “the most inaccurate”
example whose USR score is higher than the ROCS shape Tanimoto.
The completeness of USR methods is low. One of the main reasons is that USR overestimates
the difference of conformation pairs that are different at the extremity of the molecule where
fct and/or ftf are defined. Figure 8 (b) shows an example of a conformation pair whose ROCS
shape Tanimoto is higher than the USR similarity score. In this example, USR overestimates the
conformational difference because of a change of the ftf location. The low completeness is not
surprising as ROCS shape Tanimoto distinguishes atomic elements by different van der Waals
radii whereas both USR and USR:OptIso treat all atoms equally. Moreover, the optimal volume
overlap has to be calculated in ROCS shape Tanimoto for every pair of conformations while the
USR methods are significantly more efficient as they use only interatomic distances.
4 Conclusions
The optical isomerism descriptor (defined as the mixed product of the three vectors from the
molecular centroid to the three molecular locations cst, fct, ftf) is an efficient and robust tool for
shape comparison. It can be used as a supplement of the original 12 USR descriptors, which
are based solely on distance distributions, while the optical isomerism descriptor is able to
distinguish mirror images. It is therefore helpful for analyzing molecules with stereogenic centers,
atropisomerism, and in the clustering of conformers generated by systematic bond-rotation.
Moreover, it can be used for the efficient search of molecular conformations that are superposable
on the query structure. Finally, a comparison of the USR similarity score with the ROCS shape
Tanimoto shows that both accuracy and completeness increase monotonously with the similarity
score cutoff. The accuracy of the USR:OptIso similarity score is always higher than the one based
on the original USR, and the completeness of USR:OptIso is close to the one of USR in high
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Figure 8: Examples of large discrepancies between USR and ROCS shape Tanimoto. (a) High
USR similarity score but low ROCS shape Tanimoto. The overlaid conformations were optimized
by ROCS. The USR and USR:OptIso similarity scores are 0.9807 and 0.9810. The ROCS shape
Tanimoto is 0.676. This is the only case out of 1.6×1010 conformation pairs whose USR is larger
than 0.98 and ROCS shape Tanimoto smaller than 0.7. (b) Low USR similarity score but high
ROCS shape Tanimoto. The USR and USR:OptIso similarity scores are 0.6988 and 0.6981. The
ROCS shape Tanimoto is 0.999. These two molecules are different in only one substituent. The
additional methyl group in the green conformation changes the location of ftf from the phenyl
hydrogen (of the cyan conformation) to the methyl hydrogen.
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similarity ranges, which are relevant for virtual screening.
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Figure S-1: The distribution of ctd–cst distances of 100 million poses of 2.7 million of molecules.
These molecules are from a subset of the ZINC library with molecular weight less than 500Da.
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Conclusions and Outlook
Several quantum mechanical(QM) methods already play an important role in many phases of
computer-aided drug discovery (CADD), and will have a stronger impact in the future because
of the ever growing computing power and development of efficient algorithms. The work
in this thesis focuses on the use of QM to improve methods for calculating the binding free
energy, and the implementation of the QM method in high-throughout virtual screening. The
compromise between accuracy and efficiency is a perpetual issue in the CADD applications
especially for QM methods. One of the main conclusions of this thesis is that it is important
to select the most appropriate technique at each phase of drug development, and QM methods
should be selected only if there is a real advantage with respect to the classical approaches.
The initial phase of CADD, e.g., high-throughput docking, which is useful to identify hit
compounds, requires full sampling of conformations of the small molecules within the protein
binding site. Such extensive sampling calls for approximated energy functions and predicted
properties thereof, which are usually calculated by classical force field methods or fast semi-
empirical QM methods, e.g., QM probe methods. In the subsequent phase, hits have to be
optimized to leads which does not require extensive sampling but high accuracy because of
the small differences in the binding free energy. Therefore QM methods should be applied on
the hits to shed light on the energetics of binding. The QM methods are particularly important
to capture charge transfer and polarization effects, which are usually pronounced in systems
containing metal atoms or charged groups, and/or dispersion forces which play a significant
role in the interactions of conjugated π systems. Importantly, before starting CADD it is
necessary to evaluate the status of the project, which in turn dictates the number and diversity
of molecules to be evaluated and the demand of accuracy, and to select the most appropriate
approach accordingly.
However, the CADD methods with static descriptions of molecules (like those described in
this thesis) seem to reach a plateau-like region instead of the globally optimum after years
of efforts. The limited computing power and an insufficient description of dynamics of both
the target and ligands hinder the analysis of dynamic intra/intermolecular interactions under
realistic high-throughput circumstances. Consequently, the molecular fluctuations, which
contribute to the entropic part of binding free energy, and the induced-fit, which contributes
to the enthalpic part, cannot be evaluated adequately. In fact, based on rigorous classical
statistical mechanics, molecular dynamics (MD) or Monte Carlo (MC) was extended for
calculating free energy differences in the late 1970s either by free energy perturbation or by
thermodynamic integration. The problem of integration of insufficient sampling of MD/MC
can be partially resolved by limiting the scale of virtual screening and using more computing
power in calculation, However, inaccuracy and inadequacy of the force field, particularly
for small molecules and metal ions, quickly emerge when these calculations are performed
nowadays. The weakness of parameterization of the force field can be naturally overcome
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with QM methods, but QM methods still have difficulties in yielding accurate weak London
dispersion forces with acceptable amount of calculation for dynamics of macromolecules.
The CADD is an interdisciplinary research of chemistry, biology, mathematics and computer
science. This intrinsic character calls for importation of concepts from other fields of science,
not only the newfangled technology but also the classical methodology. In the other part of
this thesis, a professional database management system developed by computer scientists is
applied in high-throughput virtual screening. The open-source programs MySQL is used for
handling large amount of data of molecular properties and calculated energy terms efficiently
with small amount of extra programming. Well-organized data is required for the further
systematic research to reveal the relationship among targets and ligands by taking advantage
of chemogenomic and bioinformatic network analysis, which, as a return, will benefit the
computer-aided screening and design of compounds with a desired activity and property
profile.
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